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                                                       ABSTRACT 
                Breast cancer is the most common malignancy in women in the Western 
world, accounting for 18% of all female cancers. Two-thirds of breast cancers express 
Estrogen receptor-! (ER!) and ER! is a predictive and positive prognostic marker. 
Estrogens stimulate breast cancer growth, primarily through activation of ER! and 
hormonal therapies used in breast cancer treatment either inhibit estrogen synthesis to 
prevent ER! activation or bind to ER! to inhibit its activation. Unfortunately resistance 
to these drugs is a common clinical problem. 
                Altered phosphorylation of ER! has been proposed as one of the mechanisms 
of resistance to endocrine therapy. Phosphorylation of ER! can result in its activation, 
both in the presence and absence of ligand. The key phosphorylation sites have been 
mapped to transcription activation function AF1. In particular, phosphorylation of 
serine residues at amino acid positions 104, 106 and 118 in AF1 results in stimulation 
of ER! activity. A wealth of evidence demonstrates an important role for the ERK1/2 
MAPK signal transduction pathway in non-responsiveness to endocrine therapies. 
However, it remains unclear as to how phosphorylation potentiates the activity of AF1. 
It is likely that phosphorylation of AF1 stimulates the recruitment of transcriptional 
coactivators that mediate the transcriptional activity of AF1. Identification and 
characterisation of such coactivators would further our understanding of the role of 
phosphorylation in the molecular mechanism of transcriptional regulation by ER !  
               Two approaches were used to identify coactivators that may mediate the 
effects of ER! phosphorylation on its activity. In the first approach, bacterial two-
hybrid system was used to screen a breast cDNA expression library. In the second, p68 
and p72 RNA helicases, two known transcriptional coregulators, previously reported to 
interact with AF1 of ER!, were characterised as coactivators of ER!. Both proteins 
stimulated activity of ER! and show synergism with the well-characterised nuclear 
receptor coactivator, SRC-1. Surprisingly, reporter gene assays showed that 
phosphorylation of ER! is not essential for the coactivator function of p68. 
Importantly, RNA interference studies revealed complex effects of p68 and p72 on ER! 
activity and consequently on estrogen-regulated gene expression. p72 knockdown 
reduced the expression of the estrogen-regulated genes, pS2, Cathepsin D and GREB1, 
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and inhibited the growth of the ER!-dependent MCF-7 breast cancer cell line. 
Surprisingly, p68 knockdown did not affect ER signalling. Data are also presented to 
suggest that the balance and interplay between p68 and p72 may be responsible for the 
previously described regulation of ER! activity by p68. Collectively, the data presented 
show that p72 may be more important than p68 in modulating transcriptional responses 
of ER! in breast cancer cells. 
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1. INTRODUCTION 
 
1.1. Estrogens in health and disease 
 
 
                  Estrogens including other steroid hormones such as androgens, 
mineralocorticoids, and glucocorticoids are derived from cholesterol. In females, 17"-
estradiol (E2), the most abundant circulating form of estrogens is produced in the 
granulosa cells of ovary before menopause, and in adult men, in the adrenals, testes and 
adipose tissue. A small proportion of estrogen is also produced in skeletal muscle, skin, 
adipose tissue, brain, and bone (Simpson and Davis, 2001). The estrogen synthesis in 
the ovary is under the control of pituitary gonadotrophins, follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH) (Russo and Russo, 1998) which influence the 
reproductive cycles. They exert their effects on target tissues by binding to their 
cognate receptors, the estrogen receptors ! and "  (ER! and ER"), which function as 
transcription factors in the nucleus.  
                 Estrogens play a crucial role in the development and function of both female 
and male reproductive system and in the development of the mammary gland where 
they stimulate the growth and differentiation of the ductal epithelium and connective 
tissue. In the central nervous system, they have neuroprotective actions and are 
involved in memory. Estrogens reduce vascular tone and cause vasodilatation by 
increasing the formation and release of nitric oxide. They are considered to be 
vasoprotective and have beneficial effect on lipids and protect against atherosclerosis. 
Estrogens inhibit the osteoclastic activity and are antiresorptive. Estrogen therapy 
reduces bone loss and reduces risk of fracture in women with osteoporosis (Auchus and 
Fuqua, 1994; Mendelsohn and Karas, 1999; Hall et al., 2001; Gruber et al., 2002).  
                While they play an important role in the physiological functions noted above, 
they have also been implicated in the pathogenesis of diseases like osteoporosis 
(Horowitz, 1993), breast, endometrial and ovarian cancers, (Henderson et al., 1988; 
Deroo and Korach, 2006), arteriosclerosis (Rackley, 2004), cardiovascular disease 
(Mendelsohn and Karas, 1999), and Alzheimer’s disease (Honjo et al., 2001) (Figure 
1.1). 
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Figure1.1 Estrogens in health and disease 
The physiological role of estrogens in different organ systems is highlighted in blue and 
the diseases linked to estrogens are highlighted in red (adapted from Gruber et al., 
2002). 
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1.2 ER!  and its role in breast cancer 
 
                  Breast cancer is the most common malignancy in women in the western 
world, accounting for 23% of all cancers with an estimated 1.15 million new cases in 
2002, with the highest rates in the developed world and the lowest rates in Africa and 
Asia (Parkin et al., 2005). In 2004, in the UK, there were 44,659 new cases of breast 
cancer diagnosed and the estimated figure for USA in 2006 was 212,920 (Office for 
National Statistics, UK, 2004; Jemal et al., 2006). The incidence of breast cancer is 
increasing, partly due to the screening programs and the lifetime risk of developing 
breast cancer is 1 in 9. However, the mortality from breast cancer has fallen over the 
last one or two decades due to   early diagnosis and the use of   adjuvant therapy (Jatoi 
and Miller, 2003). 
                 Two-thirds of breast cancers express estrogen receptor ! (ER!) and ER! is a 
predictive marker of response to endocrine therapies in breast cancer as well as a 
positive prognostic marker (Fisher et al., 1998). The estrogen dependent nature of 
breast cancer was first demonstrated when in 1896, Beatson reported regression of the 
breast cancer after surgical oophorectomy (Beatson, 1896). Clinical studies have 
identified prolonged estrogen exposure through early menarche, late menopause, 
nulliparity, late age at first pregnancy and use of oral contraceptive hormones, as risk 
factors for breast cancer. Drugs to block the effects of estrogens have been used 
successfully to inhibit the growth of breast cancer as well as prevent the development 
of breast cancer, further supporting the role of estrogens and estrogen receptor in 
development and progression of breast cancer (Clemons and Goss, 2001; Jordan, 2003). 
 
1.3 Endocrine therapy of breast cancer 
 
                 The key principle of hormonal treatment of estrogen-responsive breast 
cancer is based on targeting the ER signalling and thus preventing the hormonal 
stimulation of malignant cells by estrogen. This is accomplished by a) decreasing the 
production of estrogens by the ovary, by surgical or chemical means b) competing with 
the binding of the hormone to its receptor with anti-estrogens such as tamoxifen or the 
newer generation receptor modulators such as fulvestrant or raloxifene, or c) by 
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interfering with the production of estrogens from the steroid precursors, such as 
androgens, in post-menopausal women via inhibition of the converting enzyme, the 
aromatase. The endocrine therapies can be classified according to the mechanism of 
action (Osborne and Schiff, 2005) (Table 1.1). 
 
1.3.1 Ovarian ablation or oophorectomy  
 
               Ovarian ablation or oophorectomy can be achieved through pharmacological, 
radiation or surgical means. Luteinizing hormone-releasing hormone agonists such as 
goserelin suppress ovarian function by reducing the estrogen levels to menopausal 
levels through suppression of pituitary secretion of FH and LSH. Goserelin has been 
shown to produce equivalent results to oophorectomy in terms of response rates and 
survival times (Nicholson et al., 1985; Taylor et al., 1998). However, laparoscopic 
oophorectomy remains an option for women who like to avoid monthly/injections. 
Some centres also practice radiation induced ovarian ablation although this is much less 
common now. 
 
1.3.2 Selective estrogen receptor modulators (SERMs) 
              Tamoxifen, a nonsteroidal anti-estrogen is the prototype drug   from the class 
of SERMs which also include toremifene, and raloxifene. They are so named because 
they can either stimulate or inhibit ER activity depending on the target organ. 
Tamoxifen, for example, has antagonist action in breast, while in the endometrium, 
bone and liver it has agonist activity mimicking the estrogen effects (MacGregor and 
Jordan 1998). Tamoxifen competes with endogenous estrogens for receptor binding and 
inhibit the activation of a ligand-dependent activation function of ER!, AF-2, thereby 
inhibiting activation of estrogen regulated genes in the breast epithelium, where most 
activity of ER! is dependent on AF-2.  However, these compounds do not inhibit 
activation of a second, non-ligand dependent, activation function, AF-1, which 
accounts for the agonist activity in other tissues, such as the uterus (Berry et al., 1990; 
Osborne, 1998). Tamoxifen is currently the most widely used drug for the treatment of 
all stages of endocrine-responsive breast cancer and has also been investigated for its  
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Table1.1Classification of endocrine therapies 
(Taken from Osborne and Schiff, 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Selective estrogen receptor modulators (possess both estrogen antagonist and 
agonist activities) 
      Tamoxifen, toremifene, raloxifene 
 
Estrogen deprivation therapy 
      Ovarian ablation, LHRH agonists 
      Aromatase inhibitors (steroidal and nonsteroidal) 
 
ER down regulators/complete antagonists 
      Fulvestrant 
 
Pharmacologic hormone therapy 
      High dose estrogens, androgens, progestins 
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utility prophylactically in the treatment of women at high risk of developing breast 
cancer (Fisher et al., 1998). In the adjuvant setting, tamoxifen therapy for 5 years, 
results in a 40-50% reduction in the annual odds of recurrence and leads to prolonged 
disease-free and overall survival.  Additionally, adjuvant tamoxifen therapy reduces the 
risk of death by 26% and nearly halves the 10-year recurrence risk (EBCTCG, 1998). A 
recent Oxford meta-analysis has shown similar data confirming the benefits of adjuvant 
tamoxifen (EBCTCG, 2005). In patients with advanced disease tamoxifen therapy 
resulted in response rates of 16- 56 % with overall mean time to disease progression of 
about 6 months and duration of response between 12 and 18 months. In some patients 
the responses may persist for a number of years (Osborne, 1998). Tamoxifen is 
generally well tolerated but adverse effects such as thromboembolism, cerebrovascular 
accident, cataract and endometrial cancer have been associated with its usage (Osborne, 
1998). 
                  Tormifene has shown similar efficacy as Tamoxifen and has been approved 
for treatment of advanced disease. Raloxifene has been used for osteoporosis and has 
been evaluated for the primary prevention of breast cancer (Powles, 2006). The main 
clinical problem apart from the adverse effects associated with tamoxifen therapy is the 
development of resistance. Newer agents have been developed to circumvent these 
problems. Fulvestrant is a pure anti-estrogen which on binding the receptor, inhibits 
dimerization of ER and promotes rapid degradation of the receptor and unlike 
tamoxifen, it has no agonist activity (Howell, 2002). In clinical trials it has shown 
equivalent results to AIs in tamoxifen-resistant disease. In the first line treatment of 
advanced breast cancer, fulvestrant showed no superiority in terms of response rates 
and time to progression, compared to tamoxifen. Currently it is used in sequencing 
treatment in patients who have failed prior endocrine therapy (Perey et al., 2004; Perey 
et al., 2007; Robertson et al., 2003). 
 
1.3.3 Aromatase Inhibitors 
                 The Aromatase inhibitors (AIs) act by inhibiting the cytochrome P450 
aromatase enzyme that converts androgens to estrogens (Brueggemeier et al., 2005). 
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The steroidal AIs such as exemestane, bind irreversibly to the enzyme while the non-
steroidal compounds such as anastrozole and letrozole, bind reversibly. The newer third 
generation AIs (exemestane, anastrozole and letrozole) are more potent and highly 
selective compared to the first-generation (testolactone, aminoglutethimide) and 
second-generation AIs (formestane, fadrozole). In clinical trials the third generation AIs 
showed superior results compared to the first and second generation agents in the 
treatment of advanced hormone responsive breast cancer (Smith and Dowsett, 2003; 
Mauri et al., 2006).  
In first-line therapy of postmenopausal women with advanced breast cancer, 
anastrozole, letrozole and exemestane, have all shown superior efficacy over tamoxifen 
in terms of response rates and time to progression. Following on the success and 
superior efficacy of AIs in the advanced breast cancer in postmenopausal women, a 
number of randomized control trials were initiated comparing the adjuvant therapy with 
tamoxifen to AI. Three modes of comparisons have been performed against 5 years of 
tamoxifen which had been the standard treatment: 5 years of AIs (upfront strategy), 2–3 
years of tamoxifen followed by 2–3 years of AIs (switch/sequencing strategy) and 5 
years of AIs after 5 years of tamoxifen (extended strategy). 
Upfront strategy: Two major international trials established the superiority of AIs over 
tamoxifen in the post menopausal women in the adjuvant setting. The ATAC study 
randomized women to tamoxifen or anastrozole either alone or in combination. The 
combination arm was closed after initial analysis showed no benefit. The results after a 
median follow up of 68 months showed superiority of anastrozole over tamoxifen with 
improved disease free survival( DFS) (hazard ratio(HR) 0.87,  p=0.01), time-to-
recurrence (HR 0.79, p=0.0005), and distant metastases DFS(HR 0.86, p=0.04) .The 
contra lateral breast cancers were reduced in the anastrozole arm compared to 
tamoxifen (42% reduction,  p=0.01).The overall survival, however was equivalent 
between the two arms( HR 0.97, p=0.7) (Howell et al., 2005). Updated results after a 
median follow up of 100 months have been published recently and these again showed 
improved DFS, distant DFS, time to recurrence  and incidence of contra lateral breast 
cancer in the anastrozole arm(The ATAC Trialists’ Group, 2008).  
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BIG 1-98(Breast International Study Group), another large randomized control study 
randomised post-menopausal ER positive breast cancer  patients  to one of four 
treatment arms: (1) 5 years of letrozole, (2) 5 years of tamoxifen, (3) 2 years of 
letrozole followed by 3 years of tamoxifen, or (4) 2 years of tamoxifen followed by 3 
years of letrozole. The results were comparable to ATAC study with superior efficacy 
of letrozole compared to tamoxifen. At a median follow-up of 51 months, letrozole 
showed significantly improved DFS (HR 0.82; P=0.007) and time to distant metastases 
(HR 0.81; P -0.03) compared to tamoxifen. The overall survival was again equivalent 
(Coates et al., 2007).  
Switch/Sequencing strategy: The largest sequencing trial, Intergroup Exemestane 
Study (IES) randomised postmenopausal women with ER positive (or unknown) breast 
cancers, who were disease-free after 2–3 years of tamoxifen therapy, to switch to 
exemestane or remain on tamoxifen for a total period of 5 years. Analysis of data after 
a median follow–up of 55.7 months showed benefit in switching from tamoxifen to 
exemestane at 2-3 years versus 5 years of tamoxifen, in terms of DFS (HR 0.76 
P=0.0001), breast cancer specific survival and distant recurrence. An updated sub group 
analysis showed OS advantage for the exemestane group after exclusion of patients 
with estrogen-receptor-negative disease (HR 0.83 p=0.04) (Coombes et al., 2007). 
The ITA trial, a smaller study, randomized women with ER positive breast cancer, who 
were on adjuvant tamoxifen for 2- 3 years, to receive anastrozole or continue tamoxifen 
for a total of five years. At a median follow up of 64 months, switch to anastrozole was 
associated with a significantly longer DFS (HR 0.57; P= 0.005) and distant metastases-
free survival. There was no overall survival advantage (Boccardo et al., 2006). 
Austrian Breast and Colorectal Cancer Study Group (ABCSG)-8 trial and  Breast 
Cancer Group’s Arimadex/Nolvadex (ARNO)-95, trial were designed similar to ITA 
trial. There were differences in the tamoxifen dose in these two trials, with ABCSG 
using 20 mg while the ARNO-95 used 20-30 mg of tamoxifen. The ARNO-95 study 
randomised patients who were disease free after 2 years of tamoxifen to either continue 
or switch to anastrozole where as the ABCSG 8 study randomized women prior to 
starting adjuvant tamoxifen. In a combined analysis of the Arimidex-Nolvadex 
(ARNO) 95 and Austrian Breast Cancer Study Group (ABSG) 8 studies, 3224 women 
receiving tamoxifen for 2 years, were randomized to switch to anastrozole for a further 
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3 years or to continue on 5 years of tamoxifen. A switch was associated with improved 
event-free survival (EFS) (HR 0.60 p=0.0009) and distant recurrence-free survival (HR 
0.61 p=0.0067) but no difference in overall survival (Jakesz et al., 2005). A meta-
analysis of the ABCSG-8, ARNO-95, and ITA trials showed improved DFS (HR 0.59, 
p <0.0001), distant DFS (HR 0.61, p=0.002) and OS (HR 0.71, p = 0.04) with the 
switching strategy (Jonat et al., 2006). 
In all the major trials comparing tamoxifen and AIs, the AIs were associated with lower 
incidence of thromboembolism and endometrial cancer compared to tamoxifen. 
However, the AIs were associated with increased skeletal events with changes in bone 
mineral density, osteoporosis and fractures. Further, there is concern about changes in 
lipid profile and cardiovascular events with AIs.  
The data from these studies show modest but statistically significant benefit for AIs 
over tamoxifen with a suggestion that a switch strategy may be superior to upfront AI.  
Although the above studies appear similar, there were many differences that might 
affect the outcome. ARNO, ITA and IES trials randomised patients after 2-3 years of 
tamoxifen to switch or no switch, therefore excluding those with early relapse. ITA 
patients were mostly node positive while the ARNO 95/ABCSG 8 patients were mostly 
node negative. ARNO and ABCSG 8, excluded patients who had prior chemotherapy 
or radiotherapy and in the other studies, the proportion of patients who received 
chemotherapy was not uniform. Therefore, it could be argued that a group of patients 
with favourable prognosis are selected who would have done better with any endocrine 
therapy. 
Extended strategy: In the extended strategy, studies were done to determine the 
benefit of continuing the endocrine therapy beyond 5 years. Two international trials, 
ATLAS (Peto et al.,2007) and aTTom (Gray et al., 2008), randomized women to 5 and 
10 years of adjuvant tamoxifen treatment. The emerging data show benefit in favour of 
extended therapy but further follow up is needed. The MA.17 trial randomized patients 
to 5 years of letrozole versus placebo after completion of 5 years of tamoxifen. The trial 
was unblinded after nearly 2 .5 years of follow up as the data showed improved DFS 
(HR 0.58, p>0.001) and overall survival (HR 0.61, p=0.040) in favour of letrozole. 
When this trial was unblinded, patients receiving placebo were offered letrozole. In a 
cohort analysis, patients who continued letrozole demonstrated superior DFS (HR, 
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0.37; p< 0.0001) and distant DFS (HR, 0.39; p=0.004) compared to those who opted to 
remain off letrozole (Goss, 2007). 
                   High dose estrogens, progestins and androgens are rarely used now as third 
line or fourth line treatment in view of the toxicities associated with these agents 
(Osborne and Schiff, 2005). 
1.4 Resistance to endocrine therapy in breast cancer  
 
      Despite considerable improvements in the developments of endocrine 
therapy for breast cancer, resistance to endocrine agents is a key clinical problem. In 
the case of tamoxifen, half of all patients do not respond, and of those that do, a large 
proportion eventually develop resistance, leading to tumour re-growth. The patterns of 
resistance can be illustrated from the analysis of the data from a clinical trial that 
compared letrozole with tamoxifen in advanced breast cancer in post-menopausal 
women. The trial showed superiority of letrozole over tamoxifen (Mouridsen et al., 
2003). Analysis of the time to disease progression curves reveal three groups of patients 
based on the response to treatment (Figure1.2). Arrow 1 indicates the subgroup of 
patients who did not respond to treatment either with tamoxifen or letrozole with rapid 
disease progression within 3 months. This pattern of resistance is pan-endocrine 
resistance or de novo resistance. Between 3 and 6 months, the two curves separate, 
indicating a group who show intrinsic resistance to tamoxifen but are sensitive to 
Letrozole (arrow 2). After 6 months, the two curves continue to separate during the 5 
year follow- up period and on further follow-up, tumours progress despite continued 
endocrine therapy in both groups. This is secondary or acquired resistance (arrow 3) 
(Ellis, 2004). Acquired resistance to tamoxifen is not due to loss or alteration of ER 
expression as these resistant tumours often respond to second line endocrine therapy, 
such as the potent anti-estrogen, Fulvestrant or other aromatase inhibitors (Ali and 
Coombes, 2002). Several mechanisms have been put forward for explaining Tamoxifen 
resistance, resulting from increased ER! activation, rather than inhibition of ER! when 
bound by tamoxifen. These include mutations in the ER! gene, loss of expression of  
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Figure 1.2 Patterns of endocrine resistance. Time to disease progression curves from 
a  phase III study of letrozole versus tamoxifen as first-line therapy for postmenopausal 
women with advanced breast cancer showing pan endocrine resistance (arrow 1), agent-
selective resistance (arrow 2), and secondary resistance (arrow 3)(Taken from Ellis, 
2004) 
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ER!, aberrant growth factor signalling, phosphorylation of ER, alteration in the 
coregulatory proteins and altered expression of ER ". 
1.4.1Mutations in the ER!  gene  
                 Dysfunctional forms of ER with mutations have been described in vitro and 
in breast cancer cell lines that would make these constitutively active. However there is 
little clinical evidence for such mutations in breast cancer patients and therefore this 
does not support as the main mechanism of resistance. In fact,  studies have shown that 
only 1% of primary breast cancers showed  ER mutation in the coding regions, most of 
which did not result in alteration in the  protein ( Ali and Coombes, 2002). Some 
mutations have been identified in small series of breast cancer samples which could 
contribute to resistance. One such mutation with substitution of tyrosine-537 in the 
ligand-binding domain for asparagine was found in metatstatic breast cancer. This 
mutation conferred constitutive estradiol-independent transcriptional activity, 
uninhibited by tamoxifen (Zhang et al., 1997). Another mutation, lysine to arginine at 
amino acid 303, was found in hyper plastic breast lesions. This mutation produced a 
hypersensitive receptor, with enhanced binding of co-activators in the presence of low 
estrogen levels (Ring and Dowsett, 2004; Herynk and Fuqua, 2004). 
1.4.2 Loss of ER! expression/function  
                  One of the mechanisms of de novo resistance is the lack of ER expression as 
these tumours do not respond to treatment. Therefore, loss of expression could lead to 
acquired resistance. However clinical studies suggest that ER continue to be functional 
and drive the tumour growth and loss of expression has been demonstrated only in 17-
28 % of patients resistant to tamoxifen. Furthermore, nearly 20% of patients with 
tamoxifen resistance respond to AIs implying that ER is continued to be expressed in 
majority of patients resistant to tamoxifen (Osborne., 1998; Howell et al., 1995; Ring 
and Dowsett, 2004). 
 
1.4.3 Alterations in co-regulatory proteins  
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                  Coactivator and corepressor proteins have important roles in mediating 
transcriptional activation or repression by the ER. The agonist or antagonist effects of 
SERMs like tamoxifen may be determined by the balance of coactivator and 
corepressor proteins in a cell. Changes in the levels of coactivator and corepressors can 
lead to resistance by modifying the agonist and antagonist properties of SERMs such as 
tamoxifen. High levels of coactivator expression may enhance the agonist activity of 
tamoxifen, thus contributing to endocrine resistance. The SRC family member, 
AIB1(Amplified in Breast Cancer 1), is over expressed in 50% of the breast tumours, 
and the AIB1 gene is amplified in 5-10% of breast tumours (Anzick et al., 1997; 
Bautista et al., 1998). Over expression of the coactivator, SRC-1 enhances the ER 
agonist response to tamoxifen and over expression of AIB1 together with HER-2 in 
breast tumours is associated with tamoxifen resistance (Schiff et al., 2003; Nicholson et 
al., 2004; Osborne et al., 2003; Shou et al., 2004). Corepressors are recruited to ER 
when bound by an antagonist such as tamoxifen. Recruitment of corepressors in the 
multiunit repressor complex to ER leads to repression of transcription as the co-
repressors which include the HDACs facilitate chromatin compaction and inhibition of 
transcription. In a mouse model of tamoxifen resistance, nuclear-receptor corepressor 1 
(NCOR1) levels were decreased and expression of dominant negative NCOR in MCF7 
cells resulted in enhanced transcriptional activity of tamoxifen bound ER. Furthermore, 
in a study, patients who had low levels of NCOR1, treated with tamoxifen had 
significantly shorter relapse free survival (Clarke et al., 2003; Ring and Dowsett, 2004). 
Alteration of cofactor dynamics has been found in estrogen resistant MCF-7 cell line 
with loss of coactivator recruitment and   loss of requirement of these factors for cell 
growth (Naughton et al., 2007). 
 
 1.4.4 Cross talk between ER and growth factor signalling 
 
                 In addition to the classical mode of ER signalling or genomic pathway, ER is 
also involved in signalling through a small proportion of ERs in the cytoplasm and 
plasma membrane. Some of the rapid effects seen in response to estrogens are mediated 
by these receptors without direct involvement of ER in transcription. This is referred to 
as non-genomic or membrane initiated signalling. ER can interact with the insulin-like 
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growth factor (IGFR), epidermal growth factor (EGF), c-Src, shc and p85 subunit of 
phosphatidylinositol- 3-OH kinase (PI3K) and the net result is activation of secondary 
signalling messengers and downstream kinase pathways such as p21 ras/p42/44 
mitogen-activated protein kinase (MAPK) and AKT, leading to activation of various 
cellular processes such as proliferation, growth and survival. The kinase pathways can 
in turn activate the nuclear activity of ER, establishing a link between the genomic and 
non-genomic pathway. The non genomic signalling can be activated both by estrogen 
and SERMS such as tamoxifen. There is growing evidence, both from preclinical and 
clinical studies linking the cross talk between ER and growth factor pathways in 
resistance to endocrine therapy (Schiff et al., 2005; Osborne et al., 2005; Massarweh 
and Schiff, 2006). Over expression of EGFR and its member HER2 potentiates the non 
genomic activity in response to estrogen and tamoxifen. While the membranous ER 
activates HER2 signalling, the kinase cascade downstream can phosphorylate ER and 
its coregulatory proteins. ER itself is the substrate for a number of kinases in the growth 
factor pathway, including ERK 1/2 and p38 MAPKs, cyclin-dependent kinase 2, cyclin-
dependent kinase 7, c-Src, protein kinase A, pp90rsk1, and AKT. These kinases 
phosphorylate ER at specific sites increasing the transcriptional activity of ER even 
when bound by tamoxifen and therefore, it may play a role in resistance to endocrine 
therapy. Phosphorylation of coactivators such as AIB1 (SRC3) increases ER-dependent 
transcription .In MCF-7 cells, over expression of HER2 converts tamoxifen to agonist, 
promoting the growth of cells. Inhibition of cross talk between HER 2 and ER by TK 
inhibitor geftinib could restore the antagonist activity of tamoxifen (Shou et al., 2004). 
Furthermore, tumours over expressing HER2 and ER coactivator AIB1, treated with 
adjuvant tamoxifen have been shown to be associated with poor disease free survival. It 
is known that kinases downstream of HER2 pathway phosphorylate AIB1 and these 
signalling molecules reduce the antagonist activity of tamoxifen, contributing to 
resistance (Nicholson et al., 2004; Osborne et al., 2003; Schiff et al., 2003; Shou et al., 
2004). 
                  Another signalling pathway that might have an important role in ER activity 
is the PI3K signalling pathway in response to growth factor stimulation including IGF-
1R, EGFR and HER2. The serine/threonine protein kinase AKT (or PKB) is one of the 
downstream targets of PI3K. Its activation promotes cellular proliferation and anti-
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apoptotic responses. ER! can bind in a ligand-dependent manner with the p85a 
regulatory subunit of PI3K, leading to the activation of AKT. PI3K activates AKT 
which phosphorylates the ER at serine-167 resulting in ligand-independent activation. 
The expression and activity of all three AKT family members is increased in breast 
cancers, as well as other cancers, and often involves gene amplification. Moreover, the 
tumour suppressor PTEN, a negative regulator of AKT, is frequently inactivated in 
breast cancer. So, altered activity of the PI3K–AKT pathway could contribute to 
resistance to endocrine therapy (Campbell et al., 2001; Jordan et al., 2004).  
Collectively these studies support the role of cross talk between ER and growth factor 
signalling in endocrine resistance. This knowledge has been utilised in combining 
hormonal therapy with the signal transduction inhibitors to overcome resistance 
(Nicholson et al., 2004). 
                  Over expression of HER2 has also been shown to be involved in de novo 
resistance. Breast cancer patients with higher levels of HER2 have low levels of ER 
than those with lower levels of HER2. Since absolute levels of ER correlate with 
response to endocrine therapy, reduced expression of ER may be a mechanism of 
resistance in those with co expression of HER2 and ER.!Preclinical data suggest that 
increased growth factor signalling in response to ligands like EGF, IGF-1, TGF-B and 
heregulin can down regulate ER expression leading to estrogen- independent 
phenotype. Transfection of constitutively active GF receptors or signalling molecules 
such as HER2, EGFR, MEK1 and Raf-1 led to down regulation of ER expression and 
genomic signalling. It is debated whether ER negative and HER 2 positive tumours are 
as a result of down regulation of ER by the increased signalling from HER2. If this is 
indeed true, then HER2 therapy can restore the expression of ER and can reverse 
resistance to endocrine therapy with combination therapy (Moy and Goss, 2006; 
Masserweh and Schiff, 2006; Nicholson et al., 2004). 
                 In the case of acquired resistance to AIs, certain adaptive changes occur as a 
result of sustained low estrogen environment conferring a supersensitive phenotype. 
This may be due to an increase in ER protein or to relocation of ER to the plasma 
membrane in association with Shc and insulin-like growth factor-1 receptor. Increased 
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activation of Src and RAS/RAF/MEK/MAPK signalling may also result in enhanced 
sensitivity to estrogen. Although xenograft tumour models exposed to AIs display some 
initial up-regulation of the ER, it seems that increased growth factor pathway 
signalling, particularly the mitogen-activated protein kinase cascade, is critical to the 
process of adaptation and tumour resistance. This suggests that tumour cells adapt to 
estrogen deprivation during treatment with AIs by the activation of alternate signalling 
pathways. Abrogation of alternative growth factor signalling, therefore, may restore 
sensitivity to endocrine therapy (Nicholson et al., 2004; Ring and Dowsett, 2004, Schiff 
et al, 2005). In cell culture models, MCF-7 cells grown in the absence or low estrogen 
levels, show increased expression of ER and increased transcription of estrogen 
regulated genes such as pS2 and PgR .In cell lines resistant to fulvestrant there was also 
reduced phosphoryaltion of ER ! (Kuske et al., 2006). 
 
1.4.5 Phosphorylation of ER!  
 
               Phosphorylation has been shown to modulate the activity of many nuclear 
receptors. Being a phosphoprotein ER activity is also regulated by phosphorylation. 
The role of phosphorylation in resistance to endocrine therapy is discussed later under 
‘phosphorylation of ER!. 
1.4.6 Altered expression of ER" 
                  ER" has been shown to be expressed in the normal and malignant breast but 
its role in breast cancer and/or resistance to endocrine therapies is unclear. ER" 
expression is decreased in premalignant lesions compared to normal or benign lesions 
suggesting that it might have a protective role (Harris, 2007; Bardin et al., 2004). 
 
 
 
1.5 Nuclear receptor superfamily 
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                   Nuclear hormone receptors are ligand-activated transcription factors which 
form a superfamily of evolutionally conserved proteins that regulate gene expression in 
response to lipophilic molecules. They are essential for a variety of processes involved 
in development, growth, procreation, cell differentiation, proliferation, and apoptosis, 
and the maintenance of homeostasis. Abnormal function of nuclear receptor signalling 
has been implicated in proliferative, reproductive and metabolic diseases such as 
cancer, infertility, obesity and diabetes (Gronemeyer et al., 2004; Germain et al., 2006). 
Agonists/antagonists for a number of these receptors have been used in the treatment of 
these disorders. Examples of these include tamoxifen in breast cancer targeting ER, 
androgen antagonists in prostate cancer targeting Androgen receptor, thiazolidinediones 
in type II diabetes targeting peroxisome proliferator-activated receptor - # (PPAR #) and 
dexamethasone in inflammatory diseases targeting the glucocorticoid receptor 
(Gronemeyer et al., 2004). Forty eight nuclear receptors have been identified in humans 
and based on sequence alignment and phylogeny they are classified into six groups. 
The first group contains the TRs, RARs, VDR, and PPARs, as well as orphan receptors 
such as RORs, Rev-erbs, CAR (NR1I3), PXR (NR1I2), LXRs, and others. The second 
group consists of RXRs, COUP-TF, and HNF-4. The third subfamily includes the 
steroid receptors with ERs, GRs, PRs, and ARs as well as the ERRs. The fourth family 
contains the nerve growth factor-induced clone B group of orphan receptors [NGFI-B, 
NURR1, and NOR1. The fifth is small family that includes the steroidogenic factor 1 
(NR5A1) and the receptors related to the Drosophila FTZ-F1. The sixth subfamily 
contains only the GCNF1 receptor (NR6A1), which does not fit well into any other 
subfamilies (Germain et al., 2006). The orphan receptors refer to a family of nuclear 
receptors which share the homology with the other nuclear receptors for which no 
ligand has been identified yet (Robinson-Rechavi et al., 2003). The nuclear family can 
also be divided into four classes based on the dimerisation and the DNA binding 
properties.  Class I receptors include the steroid hormone receptors which bind as 
homodimers and bind to DNA half-sites organized as inverted repeats. Class II 
receptors heterodimerize with RXR and characteristically bind to direct repeats. This 
group contains all known ligand dependent receptors excluding the steroid receptors. 
Class Ill receptors bind primarily to direct repeats as homodimers. Class IV receptors 
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typically bind to extended core sites as monomers. Most of the orphan receptors fall 
into class Ill and IV categories (Mangelsdorf et al., 1995). 
 
1.5.1 The estrogen receptors 
 
                 The effects of estrogen are mediated by two receptors, ER! and ER", 
products of two separate genes located on two different chromosomes. The ER! gene 
is located on chromosome 6(6q25.1) and consists of 8 exons spanning more than 140 
kb on chromosome 6, encoding a 595 amino acid protein (~66.2 kDa) (Walter et al., 
1985; Green et al., 1986). The human ER" gene (ESR2) is located on chromosome 14 
spanning ~61.2 kb and encodes 530 amino acids (Enmark et al., 1997; Ogawa et al., 
1998). 
                 Both receptors share the modular structure, characteristic of the NR 
superfamily which includes six functional domains. DBD of both receptors shows 97% 
similarity in the sequences while the LBD and AB regions show 55 % and less than  
20 % similarity, respectively (Figure 1.3). When bound to estradiol, ER! and ERß can 
form homo and heterodimers. Although ER! and ER" have similar binding affinities 
for estrogen, they show some differences in the regulation of gene expression. For 
example, at AP-1 sites when bound by estrogen, ER!  inhibits transcription while ER! 
activates it (Peach et al., 1997; Webb et al., 1999). ER! and ER" also exhibit different 
transcriptional effects in regulation of the cyclin D1 promoter (Liu et al., 2002a). 
ER! mediates the stimulatory effect of estrogen on cyclin D1 expression whereas ER" 
has a repressive effect. However, both ER! and ER" induce the expression of cyclin 
D1 in response to anti-estrogens.  
                  ER! and ERß are widely distributed throughout the body showing distinct 
but overlapping tissue distribution. ER! is expressed predominantly in the uterus, liver, 
kidney, and heart, whereas ER" is expressed primarily in the ovary, prostate, lung, 
gastrointestinal tract, bladder, and the hematopoietic and central nervous systems. 
However, they are co-expressed in a number of tissues including the mammary gland, 
epididymis, thyroid, adrenal, bone, and certain regions of the brain (Pettersson & 
Gustafsson, 2001; Couse & Korach, 1999). Loss of ER" expression has been shown in 
breast, ovarian and prostate cancer suggesting a protective function of ER" (Pasquali et 
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al., 2001; Roger et al., 2001; Konstantinopoulos et al., 2003; Lazennec, 2006).The 
relative importance of each receptor in various tissues and the consequences of lack of 
functional receptor has been studied by development of ER!, ER" and double knock 
out models in mice (Couse & Korach, 1999; Curtis et al., 2000). The phenotypes 
exhibited by mice lacking ER!, ER" and both receptors and their effects in different 
organs systems is summarised in the Table 1.2. 
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ERKO, Estrogen receptor knockout; FSH, follicle-stimulating hormone; LH- Luteinising hormone 
Table 1.2 Phenotype of ER! , ER"  and double knock out in mice (adapted from 
Couse & Korach, 1999; Curtis et al., 2000 and Hewitt et al., 2005).  
 
 
 
 
1.5.2 Structure and function of estrogen receptors 
                  ERs are characterised by six regions of differing amino acid sequence 
homology, designated A to F (Figure 1.3) based on the sequence alignment of human 
and chicken ER! (Kumar et al., 1987). 
AB region  
              The N-terminal A/B region is the least conserved domain between ER! from 
different species and is poorly conserved between ER! and ERß. The A/B region 
encodes transcriptional activation function AF1, which, when linked to a heterologous 
DNA-binding domain, can activate transcription in a constitutive manner. The AF-1 
region contains phosphorylation sites for a number of kinases including MAPK, AKT 
and cyclin A/cdk2 (Kato et al., 1995; Rogatsky et al., 1999; Campbell et al., 2001),  
resulting in ER activation in the absence of ligand or when the receptor is bound by 
tamoxifen. 
The DNA binding domain (C-domain) 
                The C domain is the most conserved among nuclear receptors and is 97% 
identical between human ER! and ERß. This domain contains the DNA-binding 
domain (DBD), which is comprised of two zinc-binding Cys2-Cys2 sequence motifs, 
known as zinc fingers. ER! and ERß bind to palindromic DNA sequences, known as 
estrogen response elements (ERE), in the promoters of the estrogen responsive genes 
(Schwabe et al., 1993) as homodimers, or as heterodimers (Cowley et al., 1997; Pace et 
al., 1997). The consensus ERE sequence is a 13bp palindromic inverted repeat: 5’ -
AGGTCAnnnTGACCT- 3’, where n = any nucleotide. However, EREs within most 
estrogen-regulated genes are imperfect palindromes (Driscoll et al., 1998).   
The hinge region (D-domain)  
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                The hinge region joins the DBD and the ligand binding domain, allowing the 
receptor to change its conformation upon ligand binding. It harbours the nuclear 
localization signals and is involved in nuclear localization, dimerisation and in the 
interaction of unliganded ER! with the hsp90 complex that maintains ER! in an 
inactive state (Klinge, 2000). 
The ligand binding domain (E-domain)  
                This region contains not only the ligand-binding site but also the ligand-
dependent transactivation function (AF-2), and possesses interaction surfaces for 
multiple partners, including the homo-/heterodimeric partner, corepressors and 
coactivators. Crystallographic studies of LBD of ER bound by different ligands have 
revealed mechanism of agonist and antagonist nature of ligands. The LBD is composed 
of 12 ! helices with the amino acids in helix 3, 4, 5, and 12 forming the AF2 interaction 
surface. Binding of ligand leads to conformational change that alters the position of the 
H12 and the positioning of the helix 12 is important in discriminating the agonist or  
antagonist nature of the ligands. When bound by agonist such as estrogen, the helix 
12 is positioned over the ligand-binding pocket and forms the surface for recruitment 
and interaction of coactivators. In contrast, when bound by antagonist such as 
tamoxifen, helix 12 is displaced from its agonist position over the ligand-binding cavity 
and occupies the hydrophobic groove formed by helix 3, 4, and 5 preventing the 
recruitment of coactivators (Brzozowski et al., 1997; Shiau et al., 1998; Wurtz et al., 
1996). 
 
The F-domain 
                The role of the C-terminal region F is unclear, but it may facilitate coactivator 
recruitment to the E domain and in determining the specificity of the LBD coactivator 
interface as well as modulating the response to ER! antagonists (Peters and Khan., 
1999; Sladek et al., 1999; Montano et al., 1995). 
 
                 Transcriptional activation by ER! is mediated by AF-1 and AF-2, which can 
activate transcription independently of each other, and/or in a synergistic manner.  The 
relative activities of the two AFs are dependent on promoter and cell type (Tora et al., 
1989; Laszio et al, 1989). AF-2 activity requires agonist binding whereas the activity of 
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AF-1 is mediated via phosphorylation of specific residues by growth factors acting 
through the MAPK pathway (Bunone et al., 1996; Kato et al., 1995; Katzenellenbogen, 
1996; Kato et al., 2000).  The activity of ER! AF-2 is dependent on a hydrophobic 
interaction surface generated by conserved amino acids in helix 3, helices 4/5 and helix 
12 (Danielian et al., 1992; Henttu et al., 1997; Mak et al., 1999). On binding estrogen, 
ER! dissociates from HSP90 (Sabbah et al., 1996), HSP70 and other proteins, inducing 
a conformational change and homodimerization of the receptor (Cowley et al., 1997; 
Pace et al., 1997; Ogawa et al., 1998).  Dimeric ER! binds to EREs in the promoters of  
 
 
 
 
 
 
 
 
Figure 1.3 Schematic representation of the two human estrogen receptors, ER! 
and ER", showing functional domains. The numbers correspond to the number of 
amino acids in each domain. The numbers shown between the schematics of the two 
ER subtypes, indicate the percentage amino acid sequence homology between the two 
receptors in the different functional domains. 
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estrogen-regulated target genes. Direct binding of the ER! homodimer to EREs result 
in bending of the DNA towards the major groove. This is thought to facilitate 
interaction with the basal transcription complex and enhance transcription from the 
near by promoter (MacGregor and Jordan, 1998; Kerppola and Curran, 1997). Estrogen 
binding to the LBD results in a receptor conformation that facilitates co activator 
recruitment. Key to transcriptional activation by ER! is the recruitment of coactivator 
complexes that remodel and modify core histones in the chromatin at gene promoters 
and protein complexes that facilitate RNApolymerase recruitment to the transcription 
initiation site (Figure 1.4) (Rosenfeld and Glass, 2001; Metivier et al., 2003). In 
contrast when bound by  ER antagonist, tamoxifen, ER recruits corepressors that 
mediate repression by recruiting histone deacetylase complexes  leading to chromatin 
compaction and repression of transcription (Figure 1.4). 
 
 
 
 
 
 
 
 
 
 
 
 40 
 
 
 
 
 
 
 
 
 
 
 
          
 
Figure 1.4 Mechanisms of transcriptional activation and repression by the nuclear 
receptors. When bound by activating ligand nuclear receptors recruit various 
coactivator complexes each of which have distinct activities that contribute to 
decompaction of chromatin, enabling initiation of transcription. These complexes are 
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assembled and disassembled in an ordered and cyclical manner at the promoters of 
target genes. In the absence of ligand, or when bound by antagonist, nuclear receptors 
recruit corepressors that mediate repression by recruiting histone deacetylase 
complexes that contribute to chromatin compaction and repression of transcription 
(Taken from Rosenfeld and Glass, 2001). 
 
 
 
 
1.6 Transcriptional regulation in eukaryotes  
 
                 Expression of genes in eukaryotes is a tightly regulated process that enables 
an organism to respond to environmental stimuli and for its development. The 
regulation of switching on and off, of specific genes is critical for the proper 
functioning and survival of an organism and it ensures that only those genes in a given 
context are expressed .Transcription is a multistep process which starts with the 
initiation of transcription by RNA polymerase II at specific DNA sites called 
promoters. This is followed by transcription elongation and termination, and by 
processing of RNA which eventually leads to the production of a messenger RNA .The 
messenger RNA is then transported out of the nucleus for translation. While all these 
steps can be specifically regulated the majority of regulatory events occur at the 
initiation of gene transcription (Mitchell and Tjian, 1989). The regulatory factors of this 
process are cis- acting factors (DNA and chromatin), trans-acting factors 
(transcriptional activators and associated complexes), and the basal transcription 
machinery (including RNA polymerase II (Pol II) and TATA-binding protein (TBP). 
The cis-acting elements are DNA sequences that can influence transcription of a gene 
and these are subdivided into promoter and enhancer elements. Initiation of 
transcription requires the assembly of a pre-initiation complex (PIC) composed of RNA 
polymerase II and general transcription factors. This multi-protein complex binds to a 
short DNA sequence called the minimal promoter, which often contains a conserved 
DNA sequence motif called the TATA box, situated 20–30 nucleotides upstream of the 
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transcription start site. Not all promoters contain TATA box sequences.  In Drosophila, 
roughly half of all core promoters contain a TATA box, 25-30 nucleotides upstream of 
the transcription start site combined with an initiator element (Inr) overlapping the start 
site.  The other half contain an Inr element combined with a downstream promoter 
element (DPE) which is located around 30 nucleotides downstream of the start site.  All 
three of these elements act as recognition sites for subunits of TFIID, which contains 
the TBP and several TBP-associated factors. Many promoters seem to lack all three of 
these core elements and these have a GC-rich sequence in the promoter, 20-50 
nucleotides 5' of the initiation site. Enhancers are cis-acting elements that can be 
located within several hundred or thousand base pairs of DNA, situated 5’ or 3’ of the 
initiation site. Enhancers act to stimulate the activity of certain promoters. In common 
with upstream promoter elements they can be active in all tissues or can display tissue-
specificity.  Many enhancers seem to contain multiple binding sites for transcription 
factors and often these are sites which are also found in promoter sequences.  
Enhancers are thought to act by binding transcription factors, bringing factor binding 
sites together, and its essential role may be to increase the efficiency of recruitment of 
transcription factors to the promoter (Levine and Tjian, 2003). 
 
1.6.1 General transcription factors  
 
                 The PIC is formed by step wise association of several transcription factors 
with the RNA polymerase II on the minimal promoter. The general transcription factors 
are designated as TFIIA, TFIIB, TFIIC, TFIID, TFIIE, TFIIF, TFIIG, and TFIIH!"Lee 
and Young, 2000). The initial step in the initiation involves binding of TFIID to TATA 
box. The TFIID itself is composed of TBP and a group of eleven subunits called TBP 
associated factors. TFIIA binds subsequently to stabilise the TFIID-DNA complex 
followed by binding of TFIIB. The TFIIB makes contacts with the DNA, both upstream 
and down stream of TATA box and form a platform for the assembly of Pol II enzyme 
complex. This is followed by the recruitment of TFIIF, TFIIE and TFIIH to form the 
transcription initiation complex which catalyses the synthesis of mRNA from DNA. 
TFIIH plays a crucial role in transcriptional initiation by phosphorylating the C-
terminal domain of RNA Pol II at serine 5. Phosphorylation of CTD results in 
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recruitment of elongation factors, which facilitate the Pol II to transcribe along the gene 
(Orphanides and Reinberg, 2002). TFIIH is a multisubunit complex consisting of 9 
subunits with helicase, ATPase and kinase activities. Some of these subunits are also 
essential for the mechanisms of DNA repair coupled with transcription  
 
1.6.2 Trans- acting factors 
 
                 Trans-acting elements are proteins (activators and repressors) that bind 
specific cis-acting elements to activate or repress transcription by interaction with 
regulatory DNA sequences and other proteins. Eukaryotic transcriptional activators are 
modular proteins that are typically composed of a sequence-specific DNA binding 
domain and an activating domain. Activation domains could work by recruiting or 
accelerating the assembly of the general transcription factors on the promoter, but their 
mode of action remains unclear.  The majority of transcription factors bind DNA as 
homo- or heterodimers, and thus have a dimerization domain. Some transcription 
factors also have ligand binding domains, such as hormone binding domains, which are 
essential for controlling this activity. Comparisons of DNA binding domains of many 
transcription factors show distinct motifs that define a protein structure capable of 
binding DNA. The four well-described motifs are the basic helix-loop-helix (HLH) 
motif, the basic leucine zipper (LZ) motif, the zinc finger (ZF) motif, and helix-turn-
helix (HTH) domains (Tupler et al., 2001). The exact way regulatory transcription 
factors affect the level of transcription has not been clearly demonstrated but they 
probably work by the recruitment and/or stabilization of general transcription factors, 
induction of a conformational change or the stimulation of an enzymatic activity of the 
basal transcription machinery. Moreover, some trans-acting factors may be implicated 
in chromatin remodelling to permit enhanced accessibility to general transcription 
factors for specific activators. These different roles can be promoted directly via 
protein–protein interactions with the basal transcription machinery, or via interactions 
with other trans-acting factors. In addition, some regulatory transcription factors do not 
contact the basal machinery directly, but instead bind co-activators that in turn contact 
the basal apparatus (Pabo and Sauer 1992). Coactivators may be regarded as 
transcription factors whose specificity is conferred by the ability to bind to DNA-
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binding transcription factors instead of directly to DNA. The formation and dissociation 
of trans-acting factor complexes are an integral part of the regulation of many cellular 
processes. The combinatorial action of trans-activators confers specificity and 
synergistic activation of gene expression (Ptashne, 2003). 
 
 
1.6.3 Role of chromatin in gene expression 
 
                 The entire length of the DNA is tightly packaged within the nucleus as 
chromatin. The basic structural unit of chromatin is the nucleosome (Figure 1.5A).  
Nucleosomes comprise of around 147 base pairs of DNA wrapped in a left-handed 
superhelix, 1.7 times around a core histone octamer, composed of four highly 
conserved histones, H2A, H2b, H3 and H4 (Luger et al., 1997). These proteins carry a 
net positive charge which neutralises the net negative charge on the DNA, allowing 
folding to occur (Khorasanizadeh, 2004). The degree of compaction or condensation of 
chromatin has been characterised as heterochromatin and euchromatin. 
Heterochromatin represents highly condensed state with low gene density or genes that 
are repressed while the euchromatin represents more open structure containing genes 
that are active or potentially active. The result of this organisation is not only that it 
provides genomic structure but it also help to regulate gene expression by restricting 
access to the transcription factors. Changes in local chromatin structure, including post-
translational modification of histones (discussed below), would cause an opening up of 
the promoter DNA to allow transcription complexes access to the template, to activate 
gene expression or block access, to cause gene repression, depending on the type of  
modification (Figure 1.5B). 
                Chromatin remodelling is an ATP dependent process which involves the 
disruption and re-formation of histone–DNA contacts to activate or silence gene 
expression. Chromatin remodelling factors comprise an ATPase subunit along with 
other polypeptides that are responsible for the regulation, efficiency, and functional 
specificity of each complex. The ATPase subunit belongs to the Snf2 (Sucrose 
Nonfermenting in Yeast) super family of proteins, which includes the SWI2/Snf2 group 
and the imitation SWI (ISWI) group. The SWI2/Snf2 group includes yeast SWI/Snf 
(ySWI/Snf), yeast RSC, the Drosophila Brm (Brahma) complex, and the hBrm (human 
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Brm) and BRG1 (Brm/SWI2 Related Gene-1, hBRG1 in humans) complexes. There are 
many other proteins that are closely related to the ATPase subunits of chromatin 
remodelling complexes. In order to remodel chromatin, remodelling complexes 
recognize and bind to their substrate. The SWI/Snf, NURF, and RSC complexes act as 
ATP-dependent motors that track along the DNA strands and pull them away from the 
histone octamer cores. During this shift of histone-DNA contact points, the DNA 
presumably becomes accessible to the transcriptional machinery. These complexes 
serve to maintain chromatin in a repressive configuration by dissociating other  
 
             
Figure 1.5 (A) Chromatin structure: organisation of DNA in the nucleus into 
nucleosomes, chromatin and chromosomes (taken from Horn and Peterson, 2002). (B)  
A model for gene activation and repression by post translational modification of 
histones. Acetylation of histones by Histone acetyltransferases (HATs) generate 
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patterns of acetylation (Ac), recognised by other transcriptional regulators, such as the 
bromodomain-containing (Bromo) factors TAFII250, PCAF and GCN5, leading to 
‘open’ chromatin and gene activation. Conversely, the histone methyltransferase 
(HMT), SUV39H1 methylates (Me) histone H3, which is then bound by the 
heterochromatin-associated chromodomain (Chromo) protein HP1/Swi6, leading to a 
silent chromatin and gene repression (taken from Grant, 2001). 
 
 
chromatin-associated proteins from the DNA, such as the TATA-binding protein 
(Studitsky et al., 1995; Vignali et al., 2000; Narlikar et al., 2002).  
                The amino termini of histones that protrude from the nucleosome (termed as 
histone tails) are subjected to post translational modifications which allow access to the 
transcription factors. These modifications include acetylation, phosphorylation, 
ubiquitination, ADP-ribosylation, and methylation (Strahl and Allis, 2000; Kouzarides, 
2007). These modifications are mediated by histone acetyl transferases (HATs), the 
histone deacetylases (HDACs), the histone methyl transferases (HMTs) and the histone 
kinases. The outcome of these modifications is either gene silencing or activation. 
Specific modifications on the histone tails act as a marker for other proteins and 
produce distinct biological effects. This has been referred to as ‘histone code’ 
(Jenuwein & Allis, 2001). Acetylation, which adds an acetyl group to an amino acid on 
the histone tail, has been linked to both gene activation and silencing, depending on 
which amino acid is modified. Methylation (addition of a methyl group to the histone 
tail) has also been linked to gene activation and repression (Paterson and Laniel, 2004). 
                Acetylation was the first and most extensively studied modification in 
transcriptional regulation. Increased acetylation of lysines in histones tails has been 
correlated with transcriptional activity. Acetylation neutralizes the positively charged 
lysine residues of the histone NH2 termini, decreasing their affinity for DNA, which 
causes nucleosome to unfold and can increase access of transcription factor to the 
promoter. It is also probable that the acetylation of specific lysine residues in the core 
histones provides a platform   to promote the association of other regulators in the 
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transcription process (Havas et al, 2001). HAT proteins form a part of large complexes 
and a number of coactivator proteins are associated with HAT activity. Since the first  
identification of GNAT (Gcn5-related N-acetyltransferases) superfamily, there are 
several reported families of acetyl transferases, consisting of over twenty enzymes. The 
GNAT family includes Gcn5 and PCAF, Elp3) and Hat1. The p300/CBP HAT family 
consist of the highly related p300 and CBP proteins, which function as coactivators for 
several transcription factors. The MYST family of HATs include MOZ and its yeast 
homologue, Sas3, Sas2 and Tip60. Other acetyltransferases are grouped as basal 
transcription factors, such as the TAFII250component of the TFIID complex, or as 
nuclear hormone-receptor cofactors, such as SRC1 and SRC3 (Struhl, 1998; Sterner 
and Berger, 2000; Grant, 2001). While the histone acetylation is associated with gene 
activation, the opposite, deacetylation, catalysed by HDACs results in repression and 
silencing of genes. HDACs remove acetyl groups from lysine residues of core histones 
H3 and H4, increasing ionic interactions between positively charged lysines of histones 
and negatively charged DNA, resulting in a more compact nucleosome structure that 
limits gene transcription. In humans at least  eighteen different HDACs have been 
reported and are sub-divided into class I (HDAC 1, 2, 3, 8), class II (HDAC 4, 5, 6, 7, 
and 9), and class III (SIRT 1 to 7) (Thiagalingam  et al., 2003; de Ruijter et al., 2003). 
                Methylation plays an important role in maintaining the state of chromatin. 
Histones can be methylated at arginine and lysine residues. Histone arginine 
methylation is generally associated with transcriptionally active chromatin, whereas 
histone lysine methylation is found in both silenced and active regions of chromatin. In 
general, methylation of histone H3 at Lys-4, 36, and 79 is correlated with euchromatin 
and transcriptional activation, whereas methylation of histone H3 at Lys-9 and 27 and 
histone H4 at Lys-20 is associated with heterochromatin and transcriptional repression 
(Rice and Allis, 2001; Zhang and Reinberg, 2001). Unlike many other histone 
modifications, methylation does not alter the overall charge of the lysine or arginine 
residues and therefore is not thought to directly alter interactions between histone 
molecules and DNA. Several enzymes that mediate the arginine or lysine methylation 
have been identified. Protein arginine methyltransferases (PRMT1ases) and Cofactor 
associated arginine methyltransferase 1(CARM1), have been demonstrated to have 
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histone methyltransferase activity and both have been shown to act as co-activators  in 
transient transfection assays, and their co-activator potential is dependent on an intact 
methyltransferase domain (Chen et al., 1999a ; Koh et al., 2001; Wang et al., 2001). 
                 Phosphorylation of serine 10 in histone H3 has been shown be associated 
with gene activation. Phosphorylation of serine 10 in H2A has been correlated with 
chromosome condensation during mitosis .However the mechanism by which 
phosphorylation contributes to transcriptional activation is not clear. Addition of 
negatively charged phosphate groups to histones neutralises the charge reducing the 
affinity to DNA. Further phosphorylation of serine 10 seems to enhance the HAT 
activity of several acetyl transferases. Thus phosphorylation may contribute to gene 
activation through stimulation of HAT activity. Phosphoacetylation of histone H3 on c-
fos- and c-jun-associated nucleosomes has been demonstrated upon gene activation. 
Phosphorylation of serine 139 in histone H3 is also known to occur after activation of 
DNA-damage signalling pathways and is important in DNA repair (Grant, 2001). 
The consequence of chromatin remodelling leading to either activation of transcription 
or repression is dependent on the context of nucleosomes at a given promoter. In 
addition to catalyzing nucleosome mobility, chromatin-remodelling factors can enhance 
the access of DNA-binding factors and nucleases to DNA packaged into chromatin 
(Vignali et al., 2000). 
 
1.7 Mechanism of estrogen receptor signalling 
 
                 Genome wide transcriptome analyses have identified a large number of 
possible E2 target genes in a variety of cell types (Inoue et al., 2002; Frasor et al., 
2003; Bourdeau et al., 2004). Nearly half of these are induced and the others are 
repressed in response to estrogen. There are three different mechanisms by which the 
ERs modulate the expression of these genes (Figure 1.6). In the classical or genomic 
action, the ERs control the expression of genes either directly, by binding to EREs or 
indirectly, through interaction with other transcription factors without binding to DNA.  
In the non-genomic signalling estrogenic effects are mediated by membrane bound ERs 
without affecting the transcription (Hall et al., 2001). 
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1.7.1 Classical or Genomic action 
 
                 In the absence of hormone, ER is associated with a multiprotein inhibitory 
complex within the nucleus. Binding of hormone induces conformational change within 
the ER and promotes dimerisation and high affinity binding to EREs in promoters of 
estrogen responsive genes. Key to transcriptional activation by ER! is the recruitment 
of coactivator complexes that remodel and modify core histones in the chromatin at 
gene promoters and protein complexes that facilitate RNA polymerase recruitment to 
the transcription initiation site  (Rosenfeld and Glass, 2001; Metivier et al., 2003). A 
large number of proteins that modulate transcription by nuclear receptors have now 
been identified, the most important of which are the SWI/SNF chromatin remodelling 
complexes, the SRC/CBP/PCAF histone acetyl transferase (HAT) complex, which also 
includes PRMT1 and CARM1, histone arginine methylases (HMT) and the 
TRAP/DRIP/Mediator complex that interacts directly with RNA polymerase II and 
associated factors (Rosenfeld and Glass, 2001). The conformational change induced by 
ligand binding to the LBD enables interaction of transcriptional co-activators with the 
LBD through simple !-helical motifs in coactivators, having the sequence LXXLL 
(where L is leucine and X is any amino acid). Chromatin immunoprecipitation 
experiments show that transcription factors, coregulators and the RNA Polymerase II 
cycle on the promoter in an ordered and sequential manner (Metivier et al., 2003). The 
sequential recruitment of these complexes has been studied in detail, in particular for 
the pS2 gene. In the absence of ligand, a transcriptionally unproductive cycle is 
followed by recruitment of the ATP-dependent remodeling factor SWI/SNF, on 
addition of E2, which is then followed by the recruitment of HATs and HMTs. The 
action of these complexes in chromatin remodeling is followed by the recruitment RNA 
polymerase II and the TRAP/DRIP/Mediator complex. After transcription initiation, 
ER! and chromatin remodeling complexes are removed from the promoter, with 
proteosomal degradation of the DNA-bound ER!. New cycles of ER! and coactivator 
recruitment is preceded by histone deacetylation and demethylation (Figure 1.4 and 
Figure 1.5) (Metivier et al., 2003; Reid et al., 2003). 
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1.7.2 Indirect modulation of transactivation through protein-protein interactions 
 
                 ER! can also modulate gene transcription indirectly without binding to EREs 
through protein/protein interactions with DNA bound transcription factors such as AP1, 
Sp1 and NF-kB. The estrogen bound ER can activate the expression of collaginase and 
IGF-1 through the interaction with Fos and jun at AP1 binding sites. The estrogen 
induction of Cyclin D is through the interaction with Sp1. Similarly genes such as 
TNF ! and other cytokines are modulated through interaction with NF- kB 
transcription factor (Hall et al., 2001; Kushner et al., 2003). 
 
1.7.3 Non-genomic activity of ER! 
 
 
                 Certain effects of estrogen are apparent within seconds or minutes. The 
examples include rapid rise in the calcium observed in cultured endometrial cells, 
maturing oocytes and granulosa cells and vasodilator effects of estrogen on coronary 
arteries and aorta. These effects cannot be blocked by transcriptional or translational 
inhibitors, implying that these are independent of transcription. This rapid signalling is 
referred to as non-genomic activity, also called membrane-initiated steroid signalling 
(MISS). These effects are thought to be due to a small pool of ERs localised in the 
cytoplasm or plasma membrane.  ER, in response to estrogen, interact with several 
growth factor tyrosine kinase receptors such as HER2 and IGFR and activate their 
signalling pathways. ER also directly associates with the key signal transduction 
adaptors and kinases such as Shc, the p85 regulatory subunit of phosphatidylinositol-3-
OH kinase and c-Src. These interactions also trigger activation of crucial secondary 
downstream kinases such as p21Ras/ p42/44 MAPK and PDK1/Akt. ER predominantly 
residing at the membrane caveolar domains can act as a G-protein-coupled receptor. 
GPR30, a member of the G-protein coupled receptors is seven-transmembrane-
spanning (7TM) receptor shown to mediate the MISS. Binding of GPR30 to estrogen 
results in intracellular calcium mobilization and synthesis of phosphatidylinositol 3, 4, 
5-trisphosphate in the nucleus (Revankar et al., 2005). .The GPR30 is linked to the 
estrogen induced activation of adenylyl cyclase, release of epidermal growth factor 
(EGF) related ligands and the activation of growth factor -MAPK pathway and these 
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effects of GPR 30 are independent of, ER! and ER". In MCF-7 cells that express 
GPR30, estrogen stimulates adenylyl cyclase and MAPK activation  but this is not seen 
in  MDA-MB 231 cells that express ER" but not GPR30 (Filardo et al., 2002). The 
antiestrogens bind GPR 30 and mimic estrogen actions in breast cancer cell lines and 
this may a have role in resistance to endocrine resistance (Thomas et al., 2005). Kinase 
cascade signalling induced by non-genomic ER activity can impinge on the ER 
genomic pathway, by phosphorylating and activating the various components of the ER 
pathway as well as other components of the transcriptional machinery, resulting in 
potentiation of nuclear ER transcriptional activity (Levin, 2003; Losel and Wehling, 
2003; Bjornstrom and Sjoberg, 2005).The non-genomic effects of ER, as with genomic 
pathway are also modulated by coregulatory proteins. Several ER coregulatory proteins 
for non-genomic ER activity have been recently identified. The ER-interacting protein, 
modulator of non-genomic activity of estrogen receptor (MNAR)/PELP1 stimulates 
both genomic ER activity on gene transcription and non-genomic ER activity via the c-
Src/p42/44 MAPK pathway by facilitating ER interaction with c-Src. The nuclear 
MTA1 factor is a member of the metastasis-associated gene (MTA) family of ER 
coregulators. It acts as corepressor of genomic ER activity but increases non-genomic 
ER activity. Non-genomic activity is dependent on ligand for its activation but unlike 
genomic activity is not inhibited by SERMs such as tamoxifen. On the other hand, the 
non-genomic activity can even be stimulated by the SERMs, implying a role of this 
pathway in endocrine resistance (Losel and Wehling, 2003; Bjornstrom and Sjoberg, 
2005).  
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Figure 1.6 Mechanisms of ER signaling; Genomic and non genomic signaling 
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(A) ER, in response to estrogen (E) or tamoxifen (T) binds to estrogen response 
elements (EREs) in the promoter region of target genes and recruits coactivator 
complexes or corepressor complexes, activating or repressing the transcription (B) ER 
also modulates genomic activity, indirectly by via protein–protein interaction (e.g., with 
the Fos/Jun family members) at promoters responsive to other transcription factors such 
as AP-1. Both these activities are termed genomic signalling (C) In nongenomic or 
membrane-initiated steroid signalling (MISS), a small subset of the cellular pool of ER, 
localized near the plasma membrane, can associate in response to estrogen (E) with 
several growth factor tyrosine kinase receptors such as HER2 and IGFR and with 
signalling intermediate molecules (SIM). This activates protein kinase cascades 
involving MAPKs and AKT. ER also directly associates with the key signal 
transduction adaptors and kinases such as Shc, the p85 regulatory subunit of 
phosphatidylinositol-3-OH kinase and c-Src which activates metalloproteinases 
(MMPs), which then cleave and liberate heparin-binding EGF (HB-EGF). These 
interactions also trigger activation of crucial secondary downstream kinases such as 
p21Ras/ p42/44 MAPK and PDK1/Akt. MISS is also mediated by G-protein-coupled 
receptor, GPR30 which in turn is linked to the activation of growth factor-MAPK 
pathway. Kinase cascade signalling induced by nongenomic ER activity can impinge 
on the ER genomic pathway, by phosphorylating and activating the various components 
of the ER pathway as well as other components of the transcriptional machinery, 
resulting in enhancement of genomic activity. 
 
 
 
 
 
 
 
 
 
 
1.8 Phosphorylation of ER!  
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                 Phosphorylation has been shown to modulate the activity of many nuclear 
receptors. All aspects of receptor function can be regulated, including DNA binding 
and dimerisation, transcriptional activity, interaction with cofactors and ligand-binding 
affinity (Smith, 1998; Shao and Lazar, 1999). ER! is phosphorylated in the absence of 
ligand as well as on binding to estrogen and anti-estrogens (Ali et al., 1993). Several 
phosphorylation sites have been mapped and these include serine 104, 106, 118, 167, 
236, 305, thronine 311 and tyrosine 537 (Figure 1.7) ( Ali et al., 1993; Arnold et al., 
1994; Arnold et al., 1995a; Castoria et al., 1993; Joel et al., 1995; Le Goff et al., 1994; 
Lee and Bai, 2002, Wang et al 2002; Michalides et al ., 2004). The major ER! 
phosphorylation sites on serine residues at 104, 106 and 118 have been mapped to AF1, 
and serine 118 is the major site phosphorylated in response to estrogen as well as 
partial antagonist tamoxifen. Mutation of this residue to alanine reduces the ER 
transactivation while substitution of this residue by glutamic acid enhances its activity 
in reporter gene assays mimicking phosphorylation (Legoff et al., 1994, Joel et al., 
1995 Ali et al., 1993). These residues are the target for different kinases. Cyclin-A-
cyclin dependent kinase 2 (Cdk2) complexes phosphorylates Ser-104 and Ser-106 but 
not Ser-118 (Rogatsky et al., 1999) while Serine 118 is the major site of 
phosphorylation by the mitogen-activated protein kinases (MAPKs) ERK1 and ERK2, 
in response to growth factor induced activation of MAPK pathway (Joel et al., 1998; 
Kato et al., 1995). Ras/Raf/MEK/MAPK signal transduction pathway results in ER! 
activation through phosphorylation of S104, S106, and S118 (Thomas et al., 2008). The 
kinase responsible for ligand induced phosphorylation remains unclear and one of the 
kinase phosphorylating serine 118 in response to estrogen binding is CDK7, the cyclin-
dependent kinase that is associated with the basal transcription factor TFIIH cyclin 
dependant kinase (Chen et al., 2000). 
Serine 167 is another important phosphorylation site which is phosphorylated by p90 
ribosomal S6 kinase, a kinase downstream of MAPK pathway (Joel et al., 1998). It is 
also phosphorylated by AKT (protein kinase B) and protein kinase A (Campbell et al., 
2001; Martin et al., 2000).  
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Protein kinase A (PKA) has been shown to phosphorylate serine-305 in the hinge 
region of ER and converts tamoxifen from an antagonist to agonist of ER.  Protein 
kinase A also phosphorylates Ser-236, which is located in the DNA binding domain, 
involved in dimerisation and ER binding to EREs (Chen et al., 1999b). 
Tyrosine 537 is also phosphorylated and this residue is thought to be important in the 
interaction of ER with the kinases containing SH2 domains. This residue is important 
for AF2 function and some mutations of tyrosine 537 make the receptor constitutively 
active with the recruitment of coactivators seen even in the absence of ligand 
(Lannigan, 2003). 
 
1.8.1 Role of phosphorylation in resistance to endocrine therapy 
""""""""""""""""As discussed above, phosphorylation can increase the activity of ER both in 
the presence and absence of ligand. Growth factor induced signalling activate a number 
of kinase cascades which phosphorylate ER! and this “cross talk” of ER! with the 
growth factor signalling pathways,has been implicated in endocrine resistance. In 
particular serines 104,106 and 118 are phosphorylated by the p42/p44 mitogen-
activated protein kinases (MAPK). This is particularly interesting, as a proportion of 
breast cancers show increased expression of MAPK activity (Sivaraman et al., 1997) 
and its over-expression in breast tumours correlates with poor response to tamoxifen 
(Gee et al., 2001). Serine 167 is phosphorylated by ribosomal S6 kinase, which in turn 
is activated by MAPKs, ERK1 and ERK2 (Joel et al., 1998). Serine 167 is also 
phosphorylated by AKT (Campbell et al., 2001). There is evidence for increased 
activity of the AKTs in breast cancer (Faridi et al., 2003). PTEN, a tumour suppressor 
gene is a negative regulator of AKT, and has been shown to be frequently mutated in 
breast cancer (Testa and Bellacosa, 2001). Phosphorylation of serine-305 in the hinge 
region of ER by protein kinase A (PKA) converted tamoxifen from an antagonist to 
agonist of ER. In breast tumours PKA-RI alpha, a negative regulator of PKA has been 
shown to be down regulated, contributing to tamoxifen resistance (Michalides et al., 
2004). Thus, phosphorylation of ER! could be one of the key mechanisms of resistance 
to endocrine therapy. 
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Figure 1.7 Phosphorylation of ER! 
Schematic diagram showing the different sites of phosphorylation in ER!. The kinases 
and the kinase pathways that phosphorylate these sites are also shown. 
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                  Though the in-vitro data support the role of phosphorylation in endocrine 
resistance, there is little clinical evidence to corroborate this. Reports from the clinical 
studies, in fact suggests that the phosphorylation status is associated with good 
prognosis and   response to endocrine therapy (Murphy et al., 2004; Sarwar et al., 
2006). 
 
1.9 Coregulatory proteins 
 
                   Coregulatory proteins are a class of proteins which modulate the activity of 
receptors without directly binding to the DNA. The indication for the existence of these 
came from the phenomenon of squelching seen in transient transfection assays, in 
which the activated nuclear receptor inhibited transcriptional activation by another 
receptor. This was thought to be due to competition by the receptors for a limiting pool 
of cellular factors (Meyer et al., 1989). Subsequent biochemical and expression cloning 
approaches identified a large number of factors that were capable of interacting with 
steroid/nuclear receptors in a ligand-dependent manner.  As explained above the 
classical mode of action of estrogen receptor involves ligand and DNA binding and 
sequential recruitment of coregulator proteins for transcriptional initiation. The 
coregulatory proteins which enhance the transactivation are termed as coactivators 
while those that inhibit it are referred to as corepressors. These coregulatory proteins 
possess enzymatic activities such as acetylation, deacetylation, methylation, 
ubiquitination, and kinase activity that are important in modulating the transactivation 
by nuclear receptors. The well characterised coactivators and the corepressors with 
relevance to ER! are discussed in the following section and a brief description of others 
is given in the Table 1.3. 
1.9.1 The p160/ steroid receptor coactivator (SRC) family of Coactivators  
 
                 The p160/SRC family is a group of structurally and functionally related 
proteins that act as coactivators for several nuclear receptors to increase ligand -
dependant transactivation. Members of this family include (i) SRC-1 (or NcoA-1) (ii) 
SRC-2 (also known as TIF-2 or GRIP1, NcoA-2) and (iii) SRC-3 (also known as 
RAC3, ACTR, AIB1, P/CIP and TRAM) (McKenna and O’Malley BW, 2002; Glass 
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and Rosenfeld, 2000). They have characteristic conserved LXXLL signature motifs 
(where L is leucine, X is any amino acid), termed the nuclear receptor (NR) box which 
is necessary and sufficient to mediate binding of the coactivators to liganded nuclear 
receptors. Three such motifs are conserved in SRC family members, and an additional 
NR box is present in the extreme C terminus of SRC-1 (Voegel et al. 1996, Heery et al. 
1997). Core helix 12 in AF2 undergoes conformational change forming a charged 
clamp that accommodates the p160 coactivators within the hydrophobic cleft of the 
receptor LBD, through direct contacts with the LXXLL motifs (Nolte et al., 1998; 
Darimont et al., 1998). The SRC family possess two intrinsic transcriptional activation 
domains (AD1 and AD2). The AD1 is involved in the interaction with coactivators, 
CBP/p300 with HAT activity while AD2 is involved in the interaction with histone 
methyltransferases, CARM1 and PRMT1. The SRC proteins are thought to function in 
part by recruiting the general coactivators, CBP and p300, which possess histone 
acetyltransferase activity and interact with other components of the transcriptional 
machinery. Weak intrinsic HAT activity has been reported with the p160 family, 
suggesting that they may also have a role in chromatin remodelling, enabling the 
transcription factors to access the transcriptional machinery (Chen et al., 1997; Spencer 
et al., 1997; Klinge, 2000). 
 
1.9.2 The TRAP/DRIP complex  
 
                  TRAPS and DRIPS are homologous multi-protein complexes which interact 
with the ligand bound nuclear receptors. TRAP were purified from HeLa cells cultured 
in the presence of thyroid hormone and the DRIPs were similarly identified with 
vitamin D receptor in the presence of the ligand (Fondell et al., 1996; Rachez et al., 
1998).These complexes enhance the transactivation of nuclear receptors in response to 
the ligand and contain a distinct set of 14-16 proteins that range in size from 70 to 
230 kDa excluding the p610 family and the other coactivators. These complexes are 
recruited at the LBD/AF2 on ligand binding through a component of this complex, 
PBP/TRAP220/DRIP205 which has the nuclear receptor interacting signature motif, 
LXXLL. Several DRIP/TRAP components are similar to the components of other 
coactivator complexes including CRSP (coactivator required for Sp1 activation), NAT 
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(Negative regulator of activated transcription) and SMCC (SRB and MED containing 
cofactor complexes (Hampsey and Reinberg, 1999).These components associate with 
the RNA polymerase II and the DRIP/TRAP complex may function to enhance RNA 
polymerase recruitment to the target promoter (Rosenfeld and Glass, 2001).  
1.9.3 The SW1/SNF family 
                The SWI/SNF is a family of ATP-dependent chromatin-remodelling proteins. 
SWI/SNF is a 2 Mda, multisubunit, DNA-dependent ATPase that facilitates the access 
of the transcription factors to the nucleosomal DNA through chromatin remodelling. 
These proteins are conserved from yeast to humans and are involved in the regulation 
of transcription via remodelling of chromatin structure. Mammalian SWI/SNF 
complexes consist of about 15 subunits composed of hBrm or BRG1 and several 
BRG1-associated factors (BAFs) (Mohrmann and Verrijzer, 2005). These complexes 
along with BRG1 have been shown to be recruited to endogenous ER! promoters in a 
ligand-dependant manner (Chiba et al., 1994; Ichinose et al., 1997). 
 
1.9.4 Cointegrators- CBP/p300 
 
                  CREB-binding protein (CBP) and p300 are structurally and functionally 
related proteins that serve as coactivators for different types of transcription factors. 
CBP was initially   identified as a coactivator for the cAMP-response element-binding 
protein (Kwok et al., 1994). Subsequent studies have shown that it acts as coactivator 
for a number of transcription factors including nuclear receptors, p53, NF-$B (Shikama 
et al., 1997). In addition, it also interacts with the SRC family of coactivators and 
enhances the transcriptional activation by ER and PR (Smith et al., 1996). Being 
involved as coactivators for a number of transcription factors, they serve to integrate 
multiple signalling events at the transcriptional level (Kwok et al., 1994). They possess 
intrinsic HAT activity and are involved in chromatin remodelling of nucleosomes 
(Bannister and Kouzarides, 1996). They serve to link the transcription factors to the 
basal transcriptional machinery by interaction with TBP and TFIIH. In addition, it co-
purifies with RNA polymerase and exists in complex with RNA polymerase suggesting 
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its role in recruitment of RNA polymerase to the promoters (Cho et al., 1998; Nakajima 
et al., 1997). 
 
1.9.5 Corepressors 
 
 
                 Nuclear receptors such TR and RAR repress transcription in the absence of 
hormone. The repression domains were mapped to the LBD of TR and RAR. Over 
expression of the repression domains was able to inhibit the repression suggesting the 
existence of a limited pool of repressors that mediate the repression. Yeast two hybrid 
screens led to the identification and cloning of two repressors proteins. Nuclear 
receptor corepressor (NCoR) and Silencing mediator for retinoid and thyroid hormone 
receptor (SMRT) (Horlein et al ., 1995; Chen and Evans 1995).These are structurally 
related molecules which bind to NRs in the absence of ligand and harbour autonomous, 
transferable repression domains. NCoR and SMRT are large proteins, whose NR 
binding and repression functions are mediated by the carboxyl and amino terminal 
halves of the molecules, respectively. Similar to the coactivator binding, the 
corepressors bind to surface formed by the helices 3, 4 and 5, through a motif in the 
corepressor, CoRNR box, similar to the NR box in the coactivators (Hu and Lazar, 
1999; Nagy et al., 1999; Xu et al., 2002). Loss of the CoRNR box led to loss of 
repression by unliganded TR suggesting that this motif is essential for interaction with 
nuclear receptor for repression (Horlein et al., 1995). The aminoterminus contains 
several interaction domains that mediate the formation of complex containing WD-40 
proteins TBL1/TBLR-1, GPS2 and histone deacetylase 3. SMRT and N-CoR both exist 
in repression complexes with HDAC enzyme activity, and HDAC3 is largely 
responsible for this activity (Guenther et al., 2000; Li et al., 2000; Zhang et al., 2002). 
The deacetylation of lysine residues in the N-terminal tails of histone proteins by the 
HDACs leads to closed nucleosomal structure and repression. 
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1.9.6 AF 1 interacting proteins 
 
                While the mechanisms of AF2 mediated transcriptional activity in response to 
ligand binding is well characterised (McKenna and O’Malley, 2002; Gronemeyer et al., 
2004), the mechanisms of AFI mediated transcriptional activity remains less well 
defined. It also remains unclear, how the phosphorylation potentiates the AF1 activity. 
This is important given that the key phosphorylation sites are mapped to AF1 domain 
and the phosphoryaltion of key residues is important in modulating the response. 
Moreover, the phosphorylation plays an important role in the cross talk between ER ! 
and growth factor mediated kinase signalling. Attempts to investigate the AF1 
transcriptional activity through recruitment of coregulatory proteins has led to 
identification of co-regulatory proteins for AF1. These include SRC1, CBP, SRC1-
associated Steroid receptor RNA activator (SRA), p68 RNA helicase, stromelysin-1 
platelet-derived growth factor responsive element-binding protein (SPBP) and 
spliceosome component splicing factor (SF) 3a p120.  Among these SRC1, CBP and 
SRA have been shown to interact with AF1 and stimulate ER! activity in reporter gene 
assays but are not phosphorylation dependant (Lanz et al., 1999; Watanabe et al., 2001; 
Smith et al., 1996). The other three co-regulator proteins, p68RNA helicase, SPBP and 
SF3a p120 have been shown to be recruited preferentially by ER! phosphorylated at 
serine 118. The first, p68 RNA helicase has been shown to preferentially interact with 
AF1 phosphorylated at serine 118 but the stimulation of ER! activity by p68 is 
relatively weak and cell specific and it is not strictly S118 dependent (discussed below). 
The second, stromelysin-1 platelet growth factor responsive element-binding protein 
(SPBP), acts not as a coactivator, but as a corepressor for ER!. It inhibited triple 
glutamic acid mutant but not that of triple alanine mutant in the presence of OHT in 
HepG2 cells. It also repressed AF1 activity in response to EGF stimulation and 
inhibited both basal and E2 induced proliferation of MCF-7 cells when cotransfected 
with SPBP (Gburcik et al., 2005). Finally, another protein that interacts preferentially 
with ER! phosphorylated at S118 is the component splicing factor (SF) 3a p120. SF3a 
p120 was identified by far western  blotting  analysis of nuclear extracts from MCF-7, 
HeLa and COS-1 cells, using in-vitro phosphorylated ER AF1 as a probe. It interacted 
with AF1 on GST pull down assays and enhanced ER! transactivation in reporter gene 
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assays. Transactivation and binding was stimulated in response to Growth factor 
mediated phosphoryaltion of ER at serine 118 and inhibited by mutation of serine 118 
to alanine. Furthermore, it was shown that the SF3a p120 potentiated the ER mediated 
RNA splicing which was dependant on Ser-118 phosphorylation. Thus the coactivator 
function of SF3ap120 is mediated through its effect on enhancement of ER! mediated 
RNA splicing on phosphorylation of ER (Masuhiro et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
 
 
Table 1.3 List of a selection of nuclear receptor coregulatory proteins 
Adapted from McKenna et al., 1999 and Klinge, 2000. 
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1.10 RNA helicases  
                  Helicases are highly conserved enzymes that utilize the energy derived from 
nucleotide triphosphate hydrolysis to unwind DNA and/or RNA duplexes.  Based on 
the sequence homology helicases are grouped into helicase super families 1-4, which 
include both DNA and RNA helicases (Gorbalenya and Koonin, 1993). They share a 
highly conserved helicase domain consisting of several motifs which are involved in 
ATP binding, hydrolysis, and nucleic acid binding and unwinding (Tanner and Linder, 
2001). Most RNA helicases belong to helicase super family 2(SF2) and they are also 
referred to as ‘DExD/H family’ based on  the presence the characteristic ‘DExD/H’ 
sequence (where x can be any amino acid)  in the central domain. The amino acid 
sequence of RNA helicases is characterized by the presence of eight conserved motifs 
(Figure 1.8) (Tanner and Linder, 2001; Fuller-Pace, 2006).  They have a high degree of 
homology in the central conserved helicase domain but show divergence in the N-
terminal and C-terminal sequences flanking the conserved domain which is thought to 
confer specific function to these proteins .The RNA helicases are found in almost all 
organisms, from bacteria to human and are involved in diverse biological processes that 
involve RNA, including transcription, splicing, transport, translation, decay and 
ribosome biogenesis (de la Cruz et al., 1999; Tanner and Linder, 2001; Jankowsky et 
al., 2001). They have been implicated in growth regulation and have been shown to be 
involved in both pre-mRNA and pre-rRNA processing. They modulate the 
rearrangement of RNA-protein interactions and regulate gene expression by their role 
in splicing. They are required for pre-mRNA splicing and alternative splicing, and are 
components of spliceosome (Liu, 2002b; Lin et al. 2005; Guil et al. 2003). They are 
also involved in the processing of rRNA and miRNAs (Fukuda et al. 2007). Though the 
principal function of RNA helicases is to unwind double-stranded RNA, not all RNA 
helicases show unwinding activity on duplex RNA molecules in vitro. 
                While the function of these proteins in various aspects of RNA metabolism 
has been well characterised, a number of these proteins recently have been shown to 
play important roles in transcriptional regulation (Fuller-Pace, 2006). The RNA 
helicases involved in transcriptional regulation and their functions are summarised in 
table 1.4. 
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Figure 1.8 Schematic diagram showing the conserved motifs in the DEAD box 
proteins and their functions (Adapted from Rocak and Linder, 2004). 
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1.10.1 p68 and p72 RNA helicases 
 
                  p68 RNA helicase is the prototype member of the DEAD box family which 
was initially discovered by a cross-reaction with an antibody against simian virus (SV) 
40 large T proteins (Lane and Hoeffler, 1980). p72 RNA helicase is another member of 
DEAD box family of proteins, closely related to p68 with 90 % homology in the central 
helicase domain and a 60% and 30%   similarity in the N- and C-terminal domain, 
respectively. Both are nuclear proteins with ATPase, RNA binding and helicase 
activities. p68 and p72 can interact with each other, as well as self-associate, and form 
heterodimers in cells (Lamm et al, 1996; Rossler et al., 2001; Lee, 2002; Ogilivie et al., 
2003). The high homology in the central domain could explain their functional 
redundancy while the divergence in the N and C terminal might account for the 
differences in their functions.  
                  p68 and to some extent p72 have been shown to  be involved in 
transcriptional regulation  by  acting as cofactors for  a number of transcription factors 
such as p53, ER!, MyoD, Runx2 (Fuller-Pace and Ali, 2008) and  AR (Clark et al., 
2008). They also interact with other coactivators such as SRC-1, CBP and SRA and 
associate with RNA polymerase II (Watanabe et al, 2001; Rossow and Janknecht, 
2003; Caretti et al., 2006). 
                  p68 and p72 are coactivators of p53 which is a tumour suppressor activated 
in response to several cellular stresses including DNA damage.  p68 depletion by RNA 
interference leads to inhibition of p53 target gene expression in response to DNA 
damage, as well as p53-dependent apoptosis. p53 and p68 interact in vivo and p68 is 
recruited to the promoters of the p53 regulated genes (Bates et al, 2005). Thus, p68 in 
conjunction with p53 acts a tumour cosuppressor. 
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Table 1.4 A brief summary of RNA helicases involved in transcriptional regulation.  
Adapted from Fuller-Pace, 2006. 
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                 p68/p72 also coactivates ER ! by interacting with AF1 domain of ER!   and 
acts in synergy with SRC1 and SRA to enhance ER! activity (Endoh et al., 1999; 
Watanabe et al., 2001). It was reported that the interaction of p68 with ER was 
enhanced by phosphorylation of serine 118 in AF1 of ER. It was reported to be specific 
coactivator of ER with no interaction with other nuclear receptors. However, a recent 
report suggests that p68 also acts as a coactivator of androgen receptor (Clark et al, 
2008). 
                p68/p72 and SRA have been shown to be coactivators of MyoD, which is a 
transcription factor that regulates myogenesis. Depletion of p68/72 through RNAi leads 
to inhibition of activation of genes involved in myogenesis and   skeletal cell 
differentiation.  Furthermore,  p68/72 depletion  impaired  the recruitment of the TATA 
binding protein, TBP, RNA polymerase II and the catalytic subunit of the ATPase 
SWI/SNF complex, Brg-1, suggesting that these proteins play an important role in 
formation of the transcription initiation complex and chromatin remodelling (Caretti et 
al., 2006). 
                More recently p68 has been reported as a coactivator of Runx2, a 
transcription factor essential for osteoblast development. Interestingly, Runx2 itself 
regulates the expression of p68 and their complex interaction seem to control the 
osteoblast maturation and differentiation (Jensen et al., 2008). 
                p68 has been shown to be phosphorylated at multiple amino-acid residues, 
including serine/threonine and tyrosine (Yang et al., 2005). In response to platelet 
derived growth factor (PDGF) stimulation, p68 is phosphorylated at Tyrosine 593. 
Phosphorylated p68 is involved in transcriptional regulation of cyclin D1 and c-Myc 
genes and is recruited to the promoters of cyclin D1 and c-Myc. Phospho p68, through 
the activation of cyclin D1 and c-Myc genes mediates the stimulatory effects of PDGF 
on cell proliferation. Interestingly, the helicase activity was required for this function 
(Yang et al., 2007). Furthermore, phosphorylation of p68 promotes epithelial-
mesenchymal transition via promoting " catenin nuclear translocation (Yang et al., 
2006).  
                  While the above reports highlight their role in transcriptional activation, 
they have also reported to act as repressors. p68/p72 can also act as corepressors 
depending on the context of the promoter and the transcriptional complex in which they 
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exist (Wilson et al, 2004). Both proteins interact with histone deacetylase 1 (HDAC1) 
which is a transcriptional repressor. Furthermore, Yeast homologue of the p68 has been 
shown to be involved in clearing of the nascent transcripts from the promoter leading to 
transcriptional deactivation (Buszczak and Spradling. 2006). 
                 From the above data, the role of p68/p72 in transcriptional regulation seems 
to be complex. At least with some transcription factors such as ER! and MyoD, a 
model of p68/72 in transactivation is emerging, where they serve as linking or bridging 
molecules between transcription factors and coactivators. Interestingly, the helicase 
activity does not appear to be required for the coregulatory function. The interactions of 
these proteins with corepressors argue for a complex role, in which these proteins act to 
enhance or repress transcription depending upon the promoter and cellular context.   
                p68 and p72 share some but not all functions. Both p68 and p72 have been 
shown to be coactivators of ER!, p53 and MyoD and associates with SRC1 and SRA 
(Bates et al., 2005; Watanabe et al., 2001; Caretti et al., 2006).  Like p68, p72 forms 
complexes with the coactivators p300 and CBP in vitro and in vivo (Rossow and 
Janknecht, 2003; Shin and Janknecht, 2007). Both are involved in pre-mRNA 
processing and alternative splicing (Liu et al., 2002b; Honig et al., 2002). There are, 
however, some subtle differences in their function which could be due to the 
divergence in their sequences in the N and C- terminal domains. The expression of 
these proteins is growth and developmentally regulated with differences in their 
expression patterns. p68 is up regulated, correlating with organ maturation and 
differentiation, where as p72 appeared to be down-regulated during development 
(Fuller-Pace, 2006). Further more, p68/p72 mice knock out studies show that the p68 
disrupted embryos do not survive beyond 11.5 days, while the p72 knock out mice 
survived only for 2 days after birth. Embryos with double knock out led to earlier death 
than the p68 knock out alone. These studies imply that both proteins are essential for 
growth and development (Fukuda et al., 2007). In some contexts their function could be 
redundant or complimentary while in others one protein may be more important than 
the other. For example, with regards to coactivation of p53, both p68 and p72 augment 
p53 activity in reporter gene assays. However, knockdown of p68 but not p72, affected 
the p53 regulated genes in response to DNA damage, implying that p68 might be more 
important for p53 function than p72 (Bates et al., 2005). 
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1.10.2 p68/p72 RNA helicases as coactivators of ER ! 
 
                 p68 RNA Helicase was isolated from MCF-7 nuclear extracts by GST pull-
down assays using ER! AF1-GST fusion protein as a probe. Endoh et al showed that 
the interaction between ER! AF1 and p68 was enhanced by in-vitro phosphorylated ER 
! AF1 at serine 118 by MAPK. Substitution of Serine 118 by alanine inhibited this 
interaction. In mammalian two-hybrid assays p68 stimulated reporter gene activity of 
ER! AF1 and full length ER! in the presence of estrogen but not of ER!- AF2/LBD. It 
stimulated the tamoxifen bound ER but not ICI 164,384 confirming the specificity of 
p68 to AF1. p68 did not show interaction with the other nuclear receptors (Endoh et al., 
1999). p68 is recruited to the promoter of the ER target gene, pS2, confirming a direct 
role for p68 in ER! transactivation (Metivier et al, 2003). p68 RNA helicase also 
interacts with the other ER ! coactivators such as SRC1, CBP and SRA. It is therefore 
thought that the p68 might mediate the interaction between AF1 and AF2 of ER! and 
act as bridging factor between transcription factors and coactivators (Watanabe et al., 
2001). Interestingly the RNA helicase activity was dispensable for the ER! AF-1 
coactivator activity in these experiments. In the original report, p68 was shown to be 
ER ! specific coactivator.  However, according to a recent report, p68 also coactivates 
androgen receptor. It regulates the androgen   dependant gene expression by its role in 
RNA processing in AR-regulated genes, coupling the process of transcription and 
splicing (Clark et al., 2008). p72 RNA helicase which shows striking similarity to p68 
also functions as a coactivator of ER! and like p68, shows interaction with the other 
coactivators such as SRC1, SRA and CBP.  
 
1.10.3 Role of RNA helicases in cancer 
 
                 RNA helicases play an important role in transcription, translation and 
splicing. A number of RNA helicases are dysregulated in cancer and have been 
implicated in cancers such as lung, colorectal, hepatocellular, gastric, murine sarcoma, 
melanoma, neuroblastoma and retinoblastoma (Abdelhaleem, 2004). 
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                  p68/p72 has been found to be over expressed in colon cancer cell lines and 
the expression of these proteins was found to be progressively increased in the in 
specimens of colonic polyp, adenoma and carcinoma, which is the sequence of events 
in colon carcinogenesis. Down regulation of p68/p72 lead to inhibition of the colon 
cancer cell proliferation and inability of these to form tumours in vivo (Shin et al., 
2007). p68 has been shown to be poly-ubiquitylated, suggestive of defect in protesomal 
degradation of p68, leading to over expression in tumour cells (Causevic et al., 2001). 
p68 was also found to be phosphorylated in different cancer cell lines including breast 
cancer cell line but not in the corresponding normal tissues. Phosphorylated p68 is 
involved in the regulation of cyclin D1 and c-Myc genes, promoting abnormal cell 
proliferation. Phosphorylation of p68 therefore, might be involved in carcinogenesis 
(Yang et al., 2005; Yang et al., 2007). Collectively, these studies suggest that altered 
expression or posttranslational modification of p68/p72 might be involved in cancer 
development or progression. 
 
1.11 Hypothesis and aims  
                 As described in the introduction, the estrogen-dependent growth of breast 
tumours is underpinned by ER!. The last decade has seen considerable advances in 
understanding the molecular mechanisms of transcriptional regulation by the nuclear 
receptors, mainly through the identification and characterization of a number of 
transcriptional regulatory proteins. While the mechanism by which LBD/AF2 activates 
transcription by recruitment of transcriptional regulatory proteins upon ligand binding, 
has become much clearer, the mechanism(s) by which AF1 activates gene expression 
remains unclear. This is an important question, given that the agonist activity of 
tamoxifen in some tissues derives from its ability to inhibit AF2, but allow activation of 
AF1. Further, as described above, phosphorylation within AF1 can result in ER! 
activation in a ligand-independent manner, with potential for tumour growth in the 
absence of ligand or in the presence of anti-estrogens. Moreover, EGFR and HER2 
expression in breast tumours correlates with poor response to endocrine therapies and 
ERK1/2 MAPK is often over expressed in breast cancer, it’s over expression 
correlating with reduced likelihood of response to tamoxifen. As EGF signalling 
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through MAPK phosphorylates ER! at S104, S106 and S118 in AF1, resulting in 
ligand independent ER! activation, phosphorylation is likely to be involved, at least in 
part for the emergence of endocrine resistance in breast cancer (Sivaraman et al., 1997; 
Gee et al., 2001; Ali and Coombes, 2002).  
                  I hypothesised that stimulation of AF1 activity by phosphorylation is likely 
to be due to the preferential recruitment of transcriptional coactivators by ER!.  
Further, it is possible that such coactivators may be important in breast cancer 
progression. In order to test this possibility I proposed a screen to identify coactivators 
that preferentially interact with ERa phosphorylated within AF1. As p68 RNA helicase 
has previously been identified on the basis of its preferential interaction with ERa 
phosphorylated within AF1 at S118, I also wanted to investigate the importance of p68 
RNA helicase, as well as the highly related p72 RNA helicase in regulating ERa 
activity and in determining their importance in breast cancer progression. 
                  In order to identify phosphorylation-specific coactivators, I established a 
bacterial two-hybrid system to screen a human breast cDNA expression library, using 
the AF1 region of ER! in which serine residues at positions 104, 106 and 118 had been 
substituted by glutamic acid, as a bait. The aim of the screening was to identify novel 
ER! coactivators. A number of potential interactants were found which on further 
analysis turned out to be false positives. 
                 The second aim of the project was to understand the mechanisms by which 
p68 RNA helicase acts as a coactivator for ER!. Over-expression, interaction assays 
and RNA interference studies were carried out to map the interaction domains between 
p68 and ER and to determine the importance of p68 RNA helicase in transcription 
activation by ER!. p72 RNA helicase, another DEAD box RNA helicase is closely 
related to p68 and shares some of the functions of p68 including coactivation of ER!. 
Studies were done in parallel with p68 to study the interaction of p72 with ER!. While 
the p68 and p72 RNA helicases show similarity in some functions, the data presented 
here show important differences in the transcriptional regulation by ER! and estrogen 
dependant growth of breast cancer in vivo. Collectively, these studies show complex  
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role for these proteins in ER function and more studies are needed to understand the 
relevance of these to the development and progression of breast cancer. 
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2. MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 General chemicals and reagents 
 
                  All chemicals were obtained from Sigma-Aldrich (UK) or BDH/Merck 
(UK) with the exception of the His Dropout Supplement (BD/Clontech, UK).  
Molecular biology reagents such as restriction endonucleases, Taq polymerase and 
DNA ladders were obtained from Mbi Fermentas/Helena Biosciences (Sunderland, 
UK) and Roche Diagnostics (UK). AnalaR or molecular biology grade reagents were 
used, unless otherwise stated. Kits for large-scale DNA preparation or RNA preparation 
were obtained from Qiagen (West Sussex, UK). Small-scale DNA preparation kits were 
obtained from Promega (Hants, UK).  
 
2.1.2 General Stock Solutions 
                  Stock solutions were made by dissolving appropriate amounts of the 
chemicals in distilled, de-ionised water (ddH2O). Solutions were autoclaved and stored 
at room temperature, unless otherwise stated. 
 
Table 2.1 General stock solutions 
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Table 2.2 SDS- PAGE and western blotting solutions 
  
Table 2.3 SDS- PAGE gels 
 
 
 
2.1.3 Bacterial media and plates 
                   Bacterial medium was prepared using ddH2O.  Medium was autoclaved and 
stored at 4ºC. Selective antibiotic(s) was added fresh prior to inoculation with bacteria. 
L-Broth and L-Broth agar were obtained from BIO 101 systems as capsules. 
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Table 2.4 Bacterial media and plates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
 
Table 2.5 Special media used for the BacterioMatch II Two-Hybrid Assays
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2.1.4 Antibiotics 
All antibiotics were obtained as solids from the Sigma Aldrich, (Dorset, UK).  
  
Table 2.6 Antibiotics 
 
 
2.1.5   Bacterial strains 
                  BacterioMatch II Electro competent Reporter Cells: (! (mcrA) 183 ! 
(mcrCB-hsdSMR-mrr) 173 endA1 hisB supE44 thi-1 recA1 gyrA96 relA1 lac [F´ laqIq 
HIS3 aadA Kanr) and XL1-Blue MRF´ Kan (! (mcrA) 183 ! (mcrCB-hsdSMR-mrr) 
173endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F´ proAB lacIqZ !M15 Tn5 (Kanr) 
were obtained from Stratagene. 
The Escherichia coli bacterial strain DH5": (supE44 #lacU169 (Ø80 lacZ#M15) 
hsdR17 recA1 endA1 gyrA96 thi-1 relA1). This strain was used for transformation and 
preparing plasmid DNA. 
The Escherichia coli bacterial strain BL21 (DE3) pLysS: (F- ompT hsdSB (rb- mB-) gal 
dcm (DE3) pLysS (CmR)) (Studier et al., 1990). This strain was used for the preparation 
of GST proteins.   
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2.1.6 Cell Culture Reagents 
                  Cells were cultured at 37°C in a humidified 5% (v/v) CO2:air atmosphere.  
Cell manipulations were carried out in a NuAIRE class II, ducted, laminar flow safety 
cabinet (NuAIRE DH Auto flow, Oxon, UK). Dulbecco’s Modified Eagle’s Medium 
(DMEM), 0.02% Na-EDTA solution, 10X trypsin solution and 5mg 
penicillin/streptomycin/L-glutamine solution was supplied by Sigma-Aldrich (Dorset, 
UK). DMEM lacking phenol red and foetal calf serum (FCS) were supplied by Gibco-
BRL Life Technologies (Paisley, UK). Dextran-coated charcoal-treated FCS (DSS) was 
supplied by Globepharm (Surrey, UK). 17"-estradiol (E2) and 4 hydroxytamoxifen 
(OHT) were purchased from Sigma-Aldrich (Dorset, UK). ICI 182, 780 (ICI) was 
purchased from Tocris Bioscience (Bristol, UK). 
 
2.1.7 Cell Lines 
                  COS-1: African Green Monkey Kidney fibroblast-like CV-1 cell line was 
transformed with SV40 to give the COS-1 cell line (ATCC cat no.: CRL-1650). This 
cell line does not express ER!. 
MCF-7: Human cell line obtained from a pleural effusion derived from a breast 
carcinoma (ATCC cat. No.: HTB-22). This cell line is estrogen-dependent for its 
growth and expresses ER! (Soule et al., 1973).  
MELN: MCF-7 derived cell line established by transfecting MCF-7 cells with the ERE-
"-globin-luc-SV-Neo plasmid that express luciferase in an estrogen-dependent manner 
(Pons et al., 1990).  
MVLN: MCF7 cell line transfected with a reporter gene whereby the vitellogenin 
promoter regulates the expression of luciferase in an estrogen-dependent manner 
(Demirpence et al. 1993). Both MELN and MVLN cell lines are a kind gift from Dr 
Patrick Balaguer (Montpellier, France). 
 
2.1.8 DNA size Markers 
                   DNA fragments in the range 2- 25 Kb were sized against a Hind III digest 
of % bacteriophage DNA (%Hind III marker; MBI - Fermentas Enzymes, distributed by 
Helena Biosciences, Sunderland, and Tyne & Wear). The fragment sizes in this digest 
are (base pairs): 23 130, 9416, 6557, 2322, 2027, 562, 125. DNA fragments in the 
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range 1 Kb - 10 kb was achieved by using a “1kb ladder” (MBI - Fermentas Enzymes). 
Fragment sizes (base pairs): 10 000, 8000, 6000, 5000, 4000, 3500, 3000, 2500, 2000, 
1500, 1000, 500.  
 
2.1.9   Protein size markers 
The molecular weights of the protein bands were identified by comparison with the Full 
Range Rainbow markers (MW 250000, 160000, 105000, 75000, 50000, 35000, 30000, 
25000, 15000, 10000Da) (Amersham Life Science, Bucks, UK). 
 
2.1.10 General Equipment 
                 Centrifugation of volumes greater than 1.5 mls was carried out in disposable 
30ml centrifuge tubes (Sarstedt, Leicester, UK), using a Sorval SS34 rotor on a Sorval 
RC-5B refrigerated centrifuge (Du Pont Instruments (UK) Ltd, Stevenage, UK). 
Centrifugation of sample volumes < 1.5 mls was carried out using a bench top micro 
centrifuge (Heraeus' Biofuge Pico, DJB lab care, UK) at 13,000 rpm.  
    Samples were incubated at constant temperatures in water baths (Techne, 
Cambridge, UK) and incubator ovens (LEEC, Nottingham, UK; Fisons Scientific 
Instruments, Loughborough, UK), which were also used for growth of bacteria on agar 
plates. Liquid bacterial cultures were grown in a shaking incubator (New Brunswick 
Scientific Company Incorporated, Edison, NJ, USA). Samples were mixed using an 
autovortex (Stuart Scientific, London, UK). 
                Polymerase Chain Reactions (PCR) were carried out using GeneAmp PCR 
System 9700 (Perkin Elmer Applied Biosystems, Cheshire, UK). For Real-Time PCR 
the ABI-Prism 7900 sequence detection system (Applied Bio systems) was used. 
     Spectrophotometric measurements were carried out on a Shimadzu UV-1201 
spectrophotometer (Shimadzu Corporation, Tokyo, Japan). 
     For nucleotide separation mini horizontal agarose gel electrophoresis tanks 
from Cambridge Electrophoresis (Cherry Hinton, Cambridge, UK) were employed.  
Western blotting was carried out using vertical gel electrophoresis tanks and transfer 
apparatus from (Amersham Pharmacia Biotech, St Albans, UK) and Bio-Rad (Hemel 
Hempstead, UK). Power packs used were purchased from Bio-Rad, UK.  
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2.1.11 Sundries 
                 Polypropylene microfuge tubes were obtained from Sarsted (Leics, UK).  
Thin-walled PCR tubes were obtained from Advanced Biotechnologies Ltd (Surrey, 
UK). Parafilm, laboratory film was obtained from American National Can (CT, USA). 
Whatman filter paper was obtained from Whatman International Ltd (Kent, UK). 
Tissue culture plastics were obtained from Triple Red (Oxon, UK). 
 
2.1.12 Plasmids 
               The mammalian expression vector pSG5 (Green et al., 1988) encoding human 
ER! (HEGO), HE15 (encoding amino acids 1-281 of human ER! and lacking the 
LBD), HE19 (encoding amino acids 180-595 and lacking lacking AF1) have been 
described previously (Tora et al., 1989a), as have HEG0 in which serine 118 has been 
substituted by alanine (HEG0-118A, HE15-118A), or glutamic acid (HEG0-118E, 
HE15-118E) (Ali et al., 1993). HEG0 in which serine 104, 106 and 118 have been 
substituted by alanine or by glutamic acid (HEG0-104A/106A/118A, HEG0-
104E/106E/118E) were kindly provided by Dr Ross Thomas. HEG0 containing 
mutations in the LBD were kindly provided by Dr. Sylvie Mader (University of 
Montreal, Canada). The ERE-3-firefly luciferase reporter gene (pXP-ERE3) contains 
three copies of the ERE and the adenovirus major late promoter TATA box cloned in 
the polylinker of the luciferase gene containing vector pXP2 has previously been 
described (Nordeen, 1988). 5Gal-TK-Luc, a luciferase reporter gene which has 5 Gal4 
binding sites upstream of the Thymidine kinase promoter, was a kind gift from 
Dr.Charlotte Bevan (Department of Oncology, Imperial College, London).  pRLTK, 
encoding the Renilla luciferase gene under the control of a constitutive thymidine 
kinase promoter, was obtained from Promega, UK. pBluscript (BSM), used as a carrier 
DNA for transient transfection of mammalian cell lines, was purchased from Stratagene 
Ltd (Europe). GST tagged ER! deletion and substitution mutants were generated in our 
laboratory by Dr. Ross Thomas. p68 and p72 cloned into a myc-tagged derivative of 
pSG5, pcDNA encoding Gal4-p68 deletion constructs and pGEX-p68 deletion 
constructs were kindly provided by Dr F. Fuller-Pace (University of Dundee). 
                Recombinant plasmids used in the bacterial two-hybrid system: DNA 
sequences encoding the human ER! coding sequence or ER! functional domains were 
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cloned into the Bacteriomatch II pBT vector (Stratagene, UK), whilst human SRC1, 
TIF2 and p68 RNA helicase were cloned into the pTRG vector (Stratagene, UK) 
following PCR amplification from the mammalian expression plasmid pSG5 encoding 
the human ER! (HEG0), SRC1, TIF2 or p68 RNA helicase. HEG0 and TIF2 were 
kindly provided by Prof. P. Chambon, pSG5-SRC1 by Prof. M. Parker. ER! 
substitution mutants were similarly cloned into pBT following PCR amplification of 
HEG0 encoding these substitutions. The recombinant plasmids used in the bacterial 
two-hybrid system and the substitution mutants in HEG0 were generated by Dr Ross 
Thomas and Mr Paul Pace. Positive control plasmids pBT-LGF2 and pTRG-Gal11P 
were from Stratagene. 
 
2.1.13 Antibodies  
                 The antibodies used for immunoprecipitaion and western blotting are listed 
in Table 2.7. 
 
2.1.14 Oligonucleotides 
 
                 The oligonucleotides are listed in Table 2.8. The p68 and p72 siRNAs were 
from Dharmacon (USA) and primers and probes used for Real-Time PCR were 
obtained from Applied Bio systems. All other oligos were obtained from MWG 
Biotech AG, Edersberg, Germany. 
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Table 2.7 Antibodies 
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Table 2.8 Oligonucleotides 
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2.2 METHODS 
2.2.1 Preparation of plasmid DNA 
2.2.1.1 Miniprep plasmid DNA preparation 
 
                 Small-scale (5-10 µg) plasmid preparations were prepared from 1.5 ml 
cultures using the Wizard Plus SV spin column kit (Promega, Hants, UK), following 
the manufacturer’s instructions. A disposable plastic bacterial loop was used to 
inoculate 5ml aliquots of LB bacterial medium containing the appropriate antibiotic, 
with a single bacterial colony transformed with the desired plasmid and cultures were 
incubated overnight at 37°C in a shaking incubator. 1.5ml of each culture was 
transferred to microfuge tubes and centrifuged at 13000g for 5 minutes and the 
supernatant was discarded. The pellets were resuspended in 250µl of Cell resuspension 
solution (50mM Tris-HCl pH 7.5, 10mM Na-EDTA pH 8.0, 100µg/ml RNase A). Cells 
were lysed with 250µl of Cell Lysis Solution (0.2M NaOH, 1%SDS); tubes were 
inverted four times to mix and incubated at room temperature for 5 minutes. Ten µl of 
Alkaline protease solution was then added and mixed and incubated at room 
temperature for a further 5 minutes. 350µl of Neutralization solution (4.09M guanidine 
hydrochloride, 0.759M potassium acetate, 2.12M glacial acetic acid pH 4.2) was added 
to neutralise the reaction, tubes were inverted four times to mix thoroughly and samples 
were incubated at room temperature for 10 minutes. The samples were centrifuged for 
10 minutes at 13,000rpm in a micro centrifuge and the supernatants were transferred to 
a Wizard plus SV Miniprep Spin Column by decanting and centrifuged at 13,000rpm 
for 1minute at room temperature. Flow throughs were discarded from the collection 
tube and the spin column was reinserted. Columns were washed by adding 750µl of 
Wash solution (60mM potassium acetate, 10mM Tris-HCL pH 7.5, 60% ethanol) and 
centrifuged at 13,000rpm for 1 minute at room temperature and flow through was 
discarded. A second wash was performed with 250µl of Wash solution by 
centrifugation at 13,000 for 2 minutes to ensure complete removal of the solution. The 
columns were transferred to new sterile microfuge tubes and DNA was eluted by 
adding 100µl of Nuclease-Free water and centrifugation at 13,000 rpm for 1 minute at 
room temperature. The DNA concentration of the plasmid DNA was estimated against 
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a known amount of control, plasmid DNA following agarose gel electrophoresis. 
Typically, yields of 5-10#g of plasmid DNA were obtained. 
 
2.2.1.2 Large scale plasmid preparation (maxi prep) 
 
                 Large scale plasmid DNA preparation was carried out using the Qiagen-
tip500 maxi-prep kit as per the manufacturers’ protocol (Qiagen Ltd, West Sussex, and 
UK). A single bacterial colony transformed with the appropriate plasmid was picked 
using the disposable plastic bacterial loop and inoculated into 5ml of LB supplemented 
with the appropriate antibiotic. The culture was incubated at 37°C for 8 hours in a 
shaking incubator. This starter culture was diluted 1/500 into selective LB medium and 
incubated overnight at 37°C with shaking. The bacterial cells were harvested by 
centrifugation at 6000 x g for 15 min at 4°C. The pellet was resuspended in 10 ml 
Buffer P1 (50mM Tris-HCl, pH 8.0, 10mM Na EDTA pH 8.0, 100µg/ml RNase A). 10 
ml of lysis Buffer, P2 (0.2M NaOH, 1% SDS) was added and mixed thoroughly by 
inverting the sealed tube 6 times, and incubated at room temperature for 5 min. 10 ml 
of neutralisation Buffer, P3 (3.0M K acetate, pH 5.5) was then added and mixed by 
inverting the tube 6 times, and the tube was placed on ice for 20 min. The resulting 
precipitate was centrifuged at 20,000 x g for 30 min at 4°C. The supernatant containing 
plasmid DNA was transferred to a new 30ml centrifuge tube and the supernatant was 
centrifuged again at 20,000 x g for 15 min at 4°C. QIAGEN-tip 500 columns were 
equilibrated by applying 10 ml of Buffer QBT (0.75M NaCl; 50mM MOPS pH 7.0; 
15% isopropanol). The supernatant was applied to the QIAGEN-tip and allowed to 
enter the resin by gravity flow. The QIAGEN-tip was washed twice with 30 ml of 
Buffer QC (1M NaCl, 50mM MOPS pH 7.0, 15% isopropanol) and the DNA was 
eluted with 15 ml Buffer QF (1.25M NaCl, 50mM MOPS pH 7.0, 15% isopropanol). 
Eluted DNA was precipitated by adding 10.5 ml (0.7 volumes) of isopropanol and 
centrifuged at 15,000 x g for 30 min at 4°C. The DNA pellet was washed with 5 ml of 
70% ethanol, and centrifuged at 15,000 x g for 10 min. The supernatant was discarded 
and the pellet was air-dried for 10 min., resuspended in 1X TE buffer (pH 8.0) and 
transferred to microfuge tubes. The final plasmid concentrations were determined by 
UV spectrophotometer at an OD of 260 nm using a quartz cuvette (Shimadzu, Milton 
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Keynes, UK). An Absorbance at 260 nm of 1.0 corresponds to a concentration of 
50µg/ml for double-stranded DNA. The readings were taken at 260nm and 280 nm and 
the ratio for the absorbance at 260 nm and 280 nm gives an estimate of purity of the 
DNA, which is 1.8, with values below this suggestive of protein contamination. 
 
2.2.2 Restriction endonuclease digestion of DNA  
 
                  For mapping and analysis of DNA with restriction endonucleases, 0.5-3µg 
of DNA was typically digested for 2-4 hours in a total volume of 30-50µl, with a 5-10-
fold excess of enzyme. Digests were carried out in the buffers recommended by the 
manufacturer. The total volume of enzyme did not exceed 10% of the total digest 
volume.  
2.2.3 Agarose gel electrophoresis of DNA  
 
                  Nucleic acids were separated by gel electrophoresis using agarose gels. 
DNA samples were mixed with 0.1 volumes of DNA loading buffer (40% sucrose, 
10mM Tris-HCl pH 8.0, 1mM Na EDTA pH 8.0, 2% w/v SDS, 0.5% w/v bromophenol 
blue, 0.5% w/v xylene cyanol) prior to electrophoresis in EM100 gel tanks (Cambridge 
Electrophoresis, Cambs, UK).  Restriction digests of plasmids and genomic DNA 
fragments between 1-50kb in size were resolved in 0.8-1.5% agarose-TBE gels 
containing 0.25µg/ml ethidium bromide, run at 75mA for 30-45 minutes.  Small PCR 
products and small digestion fragments were resolved on 1-2% agarose-TBE gels.   
 
2.2.4 Preparation of electrocompetent cells  
 
                 10 ml of 2X YT media was inoculated with E.Coli (XL Blue reporter strain. 
Strategene) and grown overnight in a 50ml tube at 37°C with shaking. The cells were 
diluted 1:1000 in 2, 200ml 2X YT media and grown until the optical density (OD) 
reached ~ 0.8.The cultures were incubated on ice for an hour. The cells were harvested 
by centrifugation at 3000 rpm at 4°C for ten minutes, in a Sorval High speed centrifuge. 
The cell pellet was resuspened in ice cold wash buffer (10% ultra-pure glycerol in ultra-
pure deiodinised water).The cells were centrifuged at 3000 rpm at 40 C for thirty 
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minutes. The cell pellet was resuspended again in wash buffer and harvested by 
centrifugation at 3000 rpm at 4°C for thirty minutes. The cell pellet was resuspended in 
10 ml ice-cold wash buffer and harvested by centrifugation at 300 rpm at 4°C for 10 
minutes. The cell pellet was resuspended in 0.5 ml of ice cold wash buffer and was 
aliquoted in 50µl volumes in sterile screw- cap microfuge tubes. The aliquots were 
frozen in liquid nitrogen and stored at – 80°C. 
 
2.2.5 Bacterial Transformation by Electroporation method         
 
                 All transformations in the BacterioMatch II Two-Hybrid assays were carried 
out by electroporation method using the Bio-Rad electroporator (Bio-Rad, UK). Fifty 
ng each of the bait and target plasmid DNA was added to 40 ul of electrocompetent 
cells in a pre-chilled 0.1 cm cuvette and mixed gently by inverting the cuvette. Control 
transformations were carried out with 50 ng each of the positive control plasmids, pBT-
LGF2 and pTRG-Gal11P and negative control plasmids pBT and pTRG and the target 
plasmid with the empty bait. The cuvette was placed in the electroporation chamber and 
electroporated with the electroporator set to voltage of 1.5kv, resistance to 400 Ohms 
and the capacitance to 25 µF. The cells were resuspended in 1 ml of pre-warmed (37°C) 
SOC medium and incubated with shaking at 225 at 37°C rpm for 90 minutes. The cells 
were centrifuged at 2000 & g for 10 minutes. The supernatant was discarded and the 
rich media was removed by washing the cells in 1ml of M9+ His-dropout broth and 
centrifugation at 2000 & g for 10 minutes. The cells were resuspended in 1 ml of M9+ 
His-dropout broth and incubated at 37°C with shaking at 225 rpm for 2 hours. The 
cotransformation mixture was plated on to the 150mm plates containing non selective 
medium and selective medium (5mM 3-Amino-124Triazole). The plates were 
incubated at 37°C for 24 hours. The colonies were picked and patched on to 100mm 
plates with selective medium and incubated at room temperature for 16 hours for 
enrichment of the cotransformants. The cells were picked and repatched on to dual 
selective medium plates containing the 3-AT and streptomycin and LB agar plates 
containing tetracycline and chloramphenicol. The colonies grown on the dual selective 
medium plates indicate the true interactors and were analysed further as described 
under the library screening. 
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2.2.6 Chemical Transformation of bacterial competent cells with Recombinant 
DNA 
 
                 For transformation of DNA, DH5! cells were generally used. 100 #l of 
competent cells were aliquoted into pre-chilled 1.5 ml Eppendorf tube and 1-10 ng of 
the DNA was added to the cells. The cells were then incubated on ice for 30 minutes 
after which they were heat-shocked at 42°C for 45 seconds and then placed back on ice 
for 2 minutes. 1 ml of LB medium was added to each transformation and incubated at 
37°C with shaking at 150 rpm for 1 hour to allow cells to recover and start expressing 
the corresponding antibiotic resistance gene. Cells were centrifuged briefly and the 
medium was removed, leaving 100-200 #l of LB medium. The cells were re-suspended 
in the remaining medium, which was spread on an LB agar plate made up with the 
appropriate antibiotic and incubated overnight at 37°C. 
 
2.2.7 Spectrophotometry 
 
                   Concentrations of nucleic acids were determined photometrically at a 
wavelength of 260 nm using quartz cuvettes (Shimadzu, Milton Keynes, UK). An 
optical density (OD) of 1 corresponds to a concentration of 50 µg/ml for double-
stranded DNA and 40 µg/ml for RNA (Sambrook et al. 1989). The ratio between the 
readings at 260 nm and 280 nm (A260/OD280) provides an estimation of the purity of the 
nucleic acid preparation. Highly pure DNA or RNA is characterized by ratios between 
1.8 and 2.0 respectively.  
    The bacterial culture growth was assessed in disposable polystyrene cuvettes 
at a wavelength of 600nm using the same spectrophotometer. 
 
2.2.8 Ethanol Precipitation of Nucleic acid 
 
                 DNA was precipitated from aqueous solution by the addition of 0.1 volume 
of 3M sodium acetate, pH 5.2 and 2.5 volumes of absolute ethanol. After mixing, the 
tube was placed at -70° C for 30 minutes. Precipitated DNA was pelleted by 
centrifugation at 13,000 rpm for 10 minutes. The supernatant was removed and the 
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nucleic acid pellet washed carefully with ice-cold 70% ethanol. After washing, all 
ethanol was removed and the DNA pellets vacuum-dried and resuspended in the 
appropriate volume of 1 X TE buffer or autoclaved ddH2O. 
 
2.2.9 Automated sequencing of double-stranded plasmid DNA 
 
                 All the plasmids used in the experiments were sequenced to verify the inserts 
by automated DNA sequencing using an ABI3700 DNA sequencer and ABI BigDye 
chemistry version3 terminator mix (Applied Bio systems, Cheshire, UK) at the DNA 
Sequencing Service, Genetics Core Facility, ICSM, Hammersmith Campus, London. 
Sequencing reactions were set up in 10 #l, containing the DNA to be sequenced (200–
500ng per 3kb) and the primers (3.2 pmol) and was submitted to the sequencing lab. 
The sequencing technique is based on the dideoxynucleotide chain termination method 
(Sanger et al., 1977). Chain termination sequencing involves the synthesis of new 
strands of DNA complementary to a single-stranded template. The template DNA is 
supplied with a mixture of all four deoxynucleotides, four dideoxynucleotides, each 
tagged with a different fluorescent dye. As all four deoxynucleotides are present, chain 
elongation proceeds until, by chance, DNA polymerase inserts a dideoxynucleotide. 
The result is a new set of DNA chains all of different lengths. The fragments are then 
separated by size using gel electrophoresis. As each labelled DNA fragment passes a 
detector at the bottom of the gel, the colour is recorded. The DNA sequence is then 
reconstructed from the pattern of colours representing each nucleotide sequence. The 
sequence was analyzed using Vector NTI programme (Invitrogen, UK). 
 
2.2.10 Bacteriomatch II cDNA Expression Library Screening 
 
                  The bait construct, pBT encoding AF1 of human ER!, in which serine 
residues at positions 104, 106 and 118 have been substituted by glutamic acid (AF1-
EEE) was used as a bait in two-hybrid screening of the human breast cDNA library 
(BacterioMatch Two-Hybrid System XR Plasmid cDNA Library) (Stratagene, UK), 
according to manufacturer’s instructions using the electroporation method. The bait and 
target plasmid  were co transformed in an E.coli reporter strain that carries a reporter 
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cassette consisting HIS 3 and aadA gene conferring streptomycin resistance. Putative 
positive clones were isolated by growth medium containing 5mM, 3-amino triazole (3-
AT) which is competitive inhibitor of His3 enzyme. These clones were retested for 
interaction by their ability to grow in the presence of streptomycin and are considered 
as true positives. DNA from these clones was isolated based on tetracycline and 
chloramphenicol selection. The target DNA was then separated from the bait, based on 
the tetracycline resistance gene encoded by target plasmid but not the bait plasmid. The 
isolated target DNA was then retransformed with the bait plasmid in the reporter cell 
along with empty bait as a control. Inserts of target plasmids of positive clones were 
sequenced.  The sequences of the target plasmids were compared to the Gene bank 
database using the BLASTn search (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
2.2.11   Site directed mutagenesis 
 
                 Site directed mutagenesis is technique to introduce a mutation at a desired 
position site within the target DNA. The mutant strand synthesis reaction was set up in 
thin-walled 0.5 ml tubes as listed below 
 2.5 #l of 10X reaction buffer 
 100ng of the DNA template 
 100 ng of the primer 
 1 #l of the dNTP mix 
 1 #l of the Quick change multi enzyme blend 
 ddH2O to final volume of 25 #l 
 
The following cycling parameters were used for the reaction: 
Segment 1         95°C for 1 min. 
Segment 2                95°C for 1 min. 
                                  55°C for 1min. 
                                  65°C for 10 min. for 16 cycles 
            Following the completion of the reaction 1 #l of DpnI restriction endonuclease 
was added to the reaction mixture and incubated at room temperature for one hour. 
DpnI digests methylated and hemimethylated DNA, but not in vitro synthesised 
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unmethylated DNA. DNA isolated from almost all E. coli strains is dam methylated 
and therefore gets digested. 1.5 #l of the mutagenesis reaction was used to transform 
XL-10 Gold ultracompetent cells and plated on LB agar plates with appropriate 
antibiotic selection. Miniprep DNAs were screened for successful mutagenesis by 
automated DNA sequencing. The primers used for the mutant p68LSYAA are shown 
below. 
 
 
 
2.2.12 Cell Culture 
 
                  Frozen cells were thawed in a 37oC water bath, resuspended in 20ml 
DMEM, supplemented with 10% FCS and PSG and pelleted by centrifugation at 1200 
rpm for 5 minutes in a bench top centrifuge. The pelleted cells were washed with 
DMEM and resuspended in 10ml DMEM containing 10% FCS in a T25 tissue culture 
flask and incubated at 37oC in a humidified, 5% (v/v) CO2: air atmosphere incubator. 
     Cultures grown to 70-80% confluency were trypsinised (10% trypsin in 
0.02% Na EDTA) for 3-5 minutes to detach the cells from the plastic. The trypsin 
reaction was terminated by adding DMEM supplemented with 10% FCS and the cells 
were passaged into new flasks. All mammalian cell lines were routinely maintained in 
DMEM with either 5% or 10% FCS and PSG. 
      Aliquots of cells were frozen at regular intervals to have a supply of stocks. 
For this, cells from healthy confluent culture were trypsinised and pelleted by 
centrifugation at 1200 rpm for 5 minutes. The cell pellet was resuspended in 1 ml 
freezing medium (40% DMEM, 10% DMSO, and 50% FCS). Cells were aliquoted into 
2 ml cryovials, placed at -80oC overnight and then transferred to a liquid nitrogen 
container for long-term storage. 
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2.2.13 Mammalian Cell Transfections 
2.2.13.1 Transient transfection of COS-1 cells for reporter gene assay 
 
                 COS-1 cells were maintained in DMEM supplemented with 5% FCS. For 
transient transfections, COS-1 cell were cultured for three days in DMEM lacking 
phenol red and supplemented with 5% DSS. Cells were seeded at 5 X 104 cells per well 
in 24 well plates. The following day the cells were transiently transfected using Fugene 
6 (Roche diagnostics, UK), a lipid based multicomponent transfection reagent, which 
complexes with the DNA and transports the complex into cells. Per transfection, 3 #l of 
Fugene 6 was diluted in 50 #l of DMEM without serum and mixed with the 50 #l of 
DMEM containing the DNAs. The mixture was incubated for 20 min. at room 
temperature. The Fugene-DNA mixture was added drop-wise to the cells. The DNA 
mix comprised 100 ng of the estrogen-responsive luciferase reporter gene, 100 ng of 
renilla control reporter gene (RLTK), 110 ng of the carrier DNA (BSM), together with 
the expression plasmids (up to a total of 250 ng), to give a total amount of DNA of 1 
#g. Four hours post-transfection, the medium was replaced with fresh medium 
(DMEM-PR, 5% DSS) containing 17ß-estradiol (E2; 10 nM) or 4-hydroxytamoxifen 
(OHT; 100 nM), as appropriate. Since E2 and OHT were prepared in ethanol, an equal 
volume of ethanol was added to the no ligand controls. The cells were harvested after a 
further 24 hours using the passive lysis buffer (Promega, UK) and assayed for firefly 
and renilla luciferase activities.  
      For the mammalian 2-hybrid assay, COS-1 cells were transfected as above, 
using 100 ng of 5Gal-tk-luc, 100 ng of RLTK, 100 ng of the Gal4-p68 fusion constructs 
and 50 ng of the ER! expression plasmid HEG0 or VP16-fused to the DBD and LBD 
of ER! (VP16-HEG19). The cells were harvested and processed for determination of 
luciferase activities 48 hours following the addition of E2. 
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2.2.13.2 Transient transfection of COS-1 cells for preparation of whole cell 
extracts 
 
                 For whole cell extract preparation following transient transfection of COS-1 
cells, 3 X 105 cells were plated in each well of 6-well plates, and transfected with 0.5 
#g of each expression plasmid, up to a total of 1 #g of DNA, using 4 #l of Fugene 6, 
essentially as described in section 2.2.11.1. Four hours following transfection the 
medium was replaced with fresh medium and a further 48 hours later the cells were 
washed twice with PBS and lysed by the addition of 100 #l of 2xLaemmli buffer (0.12 
M Tris HCl, pH 6.8, 4% w/v SDS, 20% glycerol, 0.2 M DTT, 0.008% bromophenol 
blue), heated to 100oC. The cells were scraped using a rubber policeman and the lysates 
collected in 1.5 ml microfuge tubes. The samples were heated to 100oC for 10 minutes, 
cooled on ice and stored at -80oC. 
 
2.2.13.3 Transfection of MCF-7 cells for over expression of p68 and p72 
 
                 For over-expression studies, MCF-7 cells were transfected in 6 well plates 
using the transfection reagent, Fugene 6 (Roche, UK) as per the manufacturer’s 
instructions. Prior to transfection MCF-7 cells were grown in DMEM containing 
5%DSS for three days. The cells were seeded in 6 well plates at a density of 3 X105 and 
transfected 16-24 hours later with 0.5 #g of expression plasmid and 4 #l of Fugene 6.  
The cells were harvested into hot lysis buffer as described for COS-1 cells (Section 
2.2.13.2).  
 
2.2.13.4 RNA Interference 
 
                 RNA interference was carried out using double-stranded RNA 
oligonucleotides (Table 2.9) purchased from Dharmacon (USA). MCF-7 cell were 
transfected using lipofectamine siRNAMAX (Invitrogen, UK), as per the 
manufacturer’s “reverse transfection” protocol for transfecting MCF-7 cells. MCF-7 
cells were routinely cultured in DMEM, supplemented with 10% FCS. Three days prior 
to transfection the medium was changed to DMEM-PR containing 5% DSS. MCF-7, 
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MELN or MVLN cells were trypsinised and resuspended in DMEM-PR containing 5% 
DSS (no antibiotics), at a cell number per ml, as listed in Table 2.10. Double-stranded 
RNAi oligonucleotides diluted in optiMEM-I medium (Invitrogen) were added to the 
plates, followed by the addition of the appropriate volume of Lipofectamine 
RNAiMAX, as listed in Table 2.10. Transfection complexes were allowed to form in 
the well by incubating at room temperature for 20 minutes. MCF-7 cells were added to 
the wells containing the transfection complexes and returned to the CO2 incubator. 
Cells were harvested 48 hours post-transfection, with E2 (10n M) being added 4 or 8 
hours prior to harvesting for preparation of total RNA, protein lysates, or in the case of 
MELN and MVLN cells, to perform the firefly luciferase reporter gene assay. RNA 
interference was carried out in 10 cm plates for RNA preparation, in 6-well plates for 
protein lysates and in 24-well plates for luciferase assays. 
      In order to determine the effect of RNA interference on MCF-7 cell growth, 
the transfections were carried out in 96-well plates. 16-24 hours after transfection the 
medium was replaced with fresh medium containing estrogen (10nM), or an equal 
volume of ethanol (vehicle). Cell numbers were estimated using the SRB growth assay. 
 
               Table 2.9 p68 and p72 siRNA oligos  
 
 
 
 
 
 
 
 
 
 
 
 
 
p68 and p72 siRNA Sequences   
        p68                                                   
AACUCUAAUGUGGAGUGCGAC  
        p72                                                   
AACAAGGGUACCGCCUAUACC 
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Table 2.10   Quantities of siRNAs and transfection reagents used for transfections 
of MCF-7 cells 
  
 
2.2.14 Luciferase reporter assay 
 
                 The Firefly and renilla luciferase activities were determined using Dual-Glo 
Luciferase Assay system (Promega LTD, UK).  Media was removed from the wells and 
the cells were washed twice with PBS. Then 50µl of passive lysis buffer (PLB, 
Promega LTD, UK) was added to each well and the plates left on a rocking tray for 30 
minutes at room temperature. Lysates were then transferred to reading plates, to which 
50µl of the Firefly reagent was added to initiate Firefly bioluminescence. The plates 
were read by TopCount NXT Microplate Scintillation and Luminescence Counter 
(Parkard Bioscience).  Then 50µl of Stop-Glo buffer was added, to detect the Renilla 
luciferase activity, the plate was read again and Firefly luciferase readings were then 
normalised against the Renilla luciferase. 
 
2.2.15 Determination of protein concentration in whole cell lysates 
 
                 The amount of protein in bacterial and cellular lysates was determined using 
Bio-Rad protein assay kit (Herts, UK). The Bio-Rad Protein Assay is a dye-binding 
assay in which a differential colour change of a dye occurs in response to various 
concentrations of protein. The absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 dye shifts from 465 nm to 595 nm when binding to 
protein occurs. A standard curve was generated using serial dilutions (100-5000 µg/ml) 
of bovine serum albumin (BSA). The Bio-Rad reagent was diluted 1:5 in ddH2O and 
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990 #l of the diluted reagent was mixed with 10 #l of each sample and BSA standards 
in 1 ml plastic cuvettes (Sigma, Dorset, UK). The samples were mixed and incubated at 
room temperature for 10 minutes. The optical density was measured at a wavelength of 
595 nm. The OD of the standards was plotted as a line graph and the protein 
concentration of the samples was determined from the standard curve. 
 
2.2.16 SDS- Polyacrylamide gel electrophoresis and Immunoblotting 
 
                  SDS-PAGE and western blotting was carried out using a Bio-Rad mini gel 
system (Herts, UK).  Protein samples were mixed with an equal volume of 2X Laemmli 
buffer (50 mM Tris.HCl pH 6.8, 15% Glycerol, 2% SDS, 10 mg bromophenol blue dye, 
1 mM DTT).  All lysates in Laemmli buffer were heated to 100°C on a heat block for 5 
minutes prior to loading on a gel.  Lysates were fractionated on 10%-15% SDS-
polyacrylamide gels. The molecular weights of the protein bands were identified by 
comparison with the Full Range Rainbow markers (Amersham Life Science, Bucks, 
UK).  Gels were electrophoresed in 1x SDS-PAGE running buffer (25mM Tris base; 
192mM glycine; 0.1% SDS) at 80 - 100V for 1 – 11/2 hours until the dye front reached 
the bottom of the gel.  The gel was blotted onto Hybond ECL nitrocellulose membrane 
(Amersham Biosciences, Bucks, UK) at 90V for 11/2 hours in 1 x transfer buffer (5mM 
Tris base; 38mM glycine; 20% methanol).  Successful transfer was indicated by the 
presence of the coloured molecular weight markers on the membrane.  In order to 
prevent non-specific binding of antibody, the membrane was placed into blocking 
solution (3% Marvel/PBS-0.05%Tween20) for 30–60 minutes at room temperature, 
prior to incubation with the appropriate primary antibody (diluted in 0.3% Marvel/PBS-
0.05%Tween20) for 1 hour at room temperature. The blot was then washed 3 x in PBS-
0.05%Tween20 (wash buffer) for 15 minutes per wash, blocked in blocking solution for 
a further 30 minutes, then incubated with the appropriate horseradish peroxidase (HRP) 
conjugated secondary antibody in 0.3% Marvel/PBS-0.05%Tween20 for 1 hour.  The 
membrane was then washed 4 times in wash buffer, again for 15 minutes per wash.  
Bands were visualised using SuperSignal West Pico Chemiluminscent Substrate kit 
(Pierce, Perbio Sciences UK LTD). Signals were detected by exposing X-ray film 
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(BioMax 10 X-ray film, Kodak UK Ltd, Cambridge, UK) to the membrane and films 
were developed with a Konica SRX-101A X-ray developer. 
 
2.2.17 In vitro transcription and translation  
 
                   In vitro transcription and translation was performed using the TNT T7 
Quick Coupled Transcription/Translation System kit from Promega (# L1170).  40 #l 
of TNT master mix, 1 #g of plasmid DNA, 2 #l of 35S-labelled methionine 
(1,000Ci/mmol) and nuclease-free ddH2O to a final volume of 50 #l were assembled in 
a 1.5 ml tube and incubated for 90 minutes at 30oC in a water bath. Two #l of the 
reaction was used to analyse the translation product by SDS-PAGE. 
 
2.2.18 In vitro Phosphorylation of ER! by MAPK 
 
                  Purified GST proteins GST-ER!, GST-AF1 were incubated with 20µM 
ATP with or without 50 ng of MAPK, 10 ul of 7 X protease inhibitor cocktail and 50µl 
of MAPK buffer for 30 minutes. The reaction was stopped by adding 40µl of 2 X SDS 
buffer. 
 
2.2.19 GST pull-down assay 
 
                   E. coli BL21 (DE3) cells were transformed with pGEX constructs for 
expression of GST-fusion proteins. A single colony was picked into 5 ml LB broth 
containing ampicillin and chloramphenicol and incubated overnight in a shaker at 37oC. 
The cultures were diluted 1:10 in LB medium and grown for 1 hour and protein 
expression was induced by adding IPTG to a final concentration of 0.1 mM and grown 
for a further three hours. Cells were pelleted by centrifugation at 4000 x g for 10 
minutes at 4oC, the pellets were resuspended in 10 volumes of NETN buffer and 
sonicated four times for 30 seconds. The samples were centrifuged at 15000 rpm for 15 
minutes at 4oC. The supernatants were collected and protein concentration estimated 
using the Bio-Rad assay. Fifty µg of crude bacterial GST-fusion protein was added to 
100 #l of glutathione-sepharose beads (Amersham biosciences) as 50% slurry in NETN 
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buffer. NETN buffer was added to a total volume of 1 ml and the samples were 
incubated, with shaking, at 4oC for 1 hour. The samples were centrifuged and unbound 
protein was cleared by washing 4 times with 1 ml NETN buffer. Twenty µl of 35S 
labelled in vitro translated protein was added, the volume made up to 1 ml with NETN 
buffer and the samples incubated at 4oC with shaking, for an hour. The samples were 
centrifuged and washed 4 times with 1 ml NETN buffer, followed by the addition of 40 
#l of 2 X Laemmli buffer to the beads and eluted proteins analysed by SDS- PAGE. 
The gels were fixed, dried and exposed on Kodak BioMax Light 1 film for visualisation 
of 35S-labelled proteins. 
 
2.2.20 Immunoprecipitations 
 
                 COS-1 cells cultured in DMEM-PR supplemented with 5% DSS for three 
days were seeded in 10 cm dishes at a density of  7.5 X 104. Sixteen to 24 hour later, 
the cells were transfected with 10 #g each of expression plasmid (ER!, p68, p72, as 
appropriate), using Fugene 6 (Roche, UK). 48 hours following transfection the cells 
were lysed in 0.5 ml of High salt lysis buffer (330mM NaCl, 0.1% NP-40 and 10 mM 
Tris–HCl (pH7.5) containing protease inhibitors. Lysates (1 mg) were 
immunoprecipitated using an anti-ER! mouse monoclonal antibody (6F11). Control 
immunoprecipitations were carried out using mouse immunoglobulins (Sigma-Aldrich, 
UK). Immunoprecipitates were resolved by SDS–PAGE and immunoblotted using 
rabbit polyclonal antibody to ER! (HC20, Santa Cruz) and rabbit polyclonal antibody 
to p68 RNA helicase (pAb 2906) or a rabbit polyclonal antibody for p72 (Gift from Dr 
FV Fuller Pace). 
                For the co immunoprecipitation of endogenous p68/72 and ER proteins in 
MCF cells, nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Pierce Biotechnology, # 78833) as per the manufacturer’s 
instructions. MCF-7 cells were grown in 5%DSS medium for 3 days and were seeded 
in 10 cm dishes at a concentration of 2.4 X106. Cells were grown in the absence or 
presence of 10nM of estrogen for 24 hours. After washing the cells with 1% PBS cells 
from 4 plates were pooled and harvested by centrifugation at 5000 rpm for 2-3 minutes. 
The cell pellet was mixed with 1ml of ice cold CER I (composition withheld by the 
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manufacturer). The sample was vortexed vigorously for 15 seconds to fully resuspend 
the pellet and was incubated on ice for 10 minutes. 500ul of CER II was added, 
vortexed for 5 seconds and incubated on ice for 1 minute. The sample was vortexed 
again for 5 seconds and centrifuged in a micro centrifuge    at 13000 rpm for 5 minutes. 
The supernatant containing the cytoplasmic extract was discarded and pellet containing 
the nuclear extract was resuspended in 250 ul of ice cold NER (composition with held 
by the manufacturer). The tube was vortexed every 15 seconds for a total of 40 minutes 
keeping the sample on ice in between the vortex. The sample was centrifuged at 
maximum speed of 13000 rpm for 10 minutes. The supernatant was transferred to a 
pre-chilled eppendorf tube and placed on ice. The samples were stored at -80°C. 
Immunoprecipitations were carried out as described for COS-1 cells. 
 
2.2.21 RNA Extraction 
 
                  Total RNA was extracted from MCF-7 cells using the RNeasy mini-kit 
(Qiagen) as per the manufacturers’ instructions. The cells were washed with PBS and 
harvested by adding 600 #l of RLT buffer containing " mercaptoethanol (composition 
withheld by the manufacture). The lysate was loaded on to “QIA shredder” column 
placed in a 2 ml collection tube. The lysate was centrifuged at 13000 rpm for 2 minutes. 
To this, one volume of 70% ethanol was added and mixed well by pipetting. The 
sample was transferred to RNeasy mini column placed in a 2 ml collection tube and 
centrifuged at 10000 rpm for 15 seconds and the flow-through was discarded. To 
remove genomic DNA contaminating the lysate DNase digestion was performed by 
washing first with 350 #l of Buffer RW1 (composition withheld by the manufacturer) 
followed by addition of DNase incubation mix (10ul of DNase stock solution plus 70 #l 
of Buffer RDD (composition withheld by the manufacturer) and incubation for 15 
minutes on a bench top. A further wash was performed by adding 350 #l of Buffer 
RW1 and centrifuging for 15 seconds. The flow-through was discarded and the column 
washed twice with 500 #l buffer RPE (composition withheld by the manufacturer), 
centrifuging for 15 seconds for first wash and for 2 minutes for the second wash. The 
RNA binds to the RNeasy column membrane and the washes remove the contaminants. 
The column was transferred to a new collection tube and centrifuged for 1 minute, 
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placed in a new 1.5 ml collection tube and RNA eluted by adding 40 #l of RNase free 
water to the column and centrifuging for 1 minute at 10000 rpm. The RNA 
concentration was determined using a spectrophotometer. 
 
2.2.22 cDNA preparation by Reverse Transcription (RT) 
 
                  RNA was converted to cDNA using reverse transcriptase. The reaction was 
set up in a thin-walled PCR tube with the following components. 
 4 µl  5x RT buffer (containing DTT - Mbi Fermentas) 
 2 µl dNTPs (10nM stock) 
 1 µl random hexamers Pd (N) 6 (200ng) 
 2 µg total RNA 
            1 µl Reverse transcriptase stock (Revert Aid M-MuLV - Mbi Fermentas) 
 Sterile water to a total volume of 20µl 
 The reaction was incubated at 37°C for 1 hour and then heat inactivated at 65°C 
for 10 minutes. The product was diluted in 80 #l of water and 2 µl of cDNA was 
subsequently used for each PCR reaction. 
 
2.2.23 Polymerase chain reaction (PCR) 
 
      The PCR reactions were set up in thin-walled PCR tubes containing 2 #l of 
cDNA, 12.5 #l of PCR master mix (Reddy Mix, ABgene, Epsom, UK), 2.5 #l each of 
forward and reverse primers, and 5.5 µl of water in a 25 #l reaction volume. The 
samples were centrifuged briefly and loaded onto a Gene Amp 9700 PCR machine 
(Applied Bio systems, Cheshire, UK). The PCR primers used are listed in Table 2 .8 
and the cycling parameters are as given below. 
            Hot start 94°C  5 minutes 1 cycle 
 Denaturation 95°C   1 minute   
 Annealing X°C   1 minute (where X is the optimal annealing temperature) 
            Extension 72°C   1.5 minutes, 22-28 cycles 
            Extension 72°C   5 minutes 1 cycle 
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The optimal primer annealing temperature (X°C) was typically calculated using the 
following equation: 
  Tm = (4 x G + C) + (2 x A + T) 
PCR products were visualised using an UV transilluminator following electrophoresis 
on 0.25µg/ml ethidium bromide-agarose gels. The concentration of the gel was 
dependent on the expected size of the PCR product to be resolved. 
 
2.2.24 Real-time RT-PCR 
 
                  Real-time RT-PCR, also known as kinetic PCR, qRT-PCR or RT-qPCR, is a 
quantitative PCR method for the determination of copy number of PCR templates such 
as cDNA in a PCR reaction. Real-Time PCR was performed using the ABI-Prism 7700 
sequence analyser system (Applied Bio systems). A special thermo cycler equipped 
with a sensitive laser that monitors the fluorescence in each well of the 96-well plate at 
frequent intervals during the PCR Reaction. It requires a pair of PCR primers as in 
standard PCR with an additional fluorogenic probe which is an oligonucleotide with 
both a reporter fluorescent dye and a quencher dye attached. The primers and the 
probes used are shown in Table 2.8. The reactions were set up in 20 #l volume 
containing 2 #l of cDNA, 1#l of primers (Custom TaqMan Gene Expression Assays, 
Applied Bio systems)  10 #l of  2 x Taqman Fast universal PCR mix (Applied Bio 
systems)  and 7 #l of RNase free water, in Optical 96-Well Fast Thermal Cycling Plate( 
Applied Bio systems),  in triplicates. The level of expression of a gene was quantitated 
using the comparative CT (threshold cycle) method. The level of expression of a target 
gene was expressed as fold difference relative to the reference gene, GAPDH.  
 
2.2.25 SRB Growth assay     
   
                  Sulphorhoadmine B (SRB; Sigma, UK) is a pink aminoxanthene dye which 
binds to protein basic amino acid residues in TCA-fixed cells and provides a sensitive 
index of cellular protein content which reflects cell growth. Cells were fixed by adding 
ice-cold 40% trichloroacetic acid (TCA) and incubating for 1 h at room temperature. 
The plates were washed with distilled water, air-dried and stained with SRB solution 
 104 
(0.4%, w/v, in 1% acetic acid) for 30 min at room temperature. Unbound SRB was 
removed by washing with 1% acetic acid and the plates were air-dried. The bound SRB 
stain was solubilised with 10mM Tris buffer, and the optical density was read on a 
spectrophotometric plate reader at a wavelength of 492 nm. 
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3. RESULTS 
 
3.1. Bacterial 2-hybrid approach for the identification of AF1-interacting proteins 
 
                  The functional reconstitution of a transcription factor through protein-
protein interactions between two proteins of interest allows functional studies on the 
nature of the interaction. Such an approach has been exploited in the generation of 
screening strategies, particularly in yeast, whereby a protein of interest is expressed as a 
fusion protein with a DNA binding domain, allowing for screening for interacting 
partners using cDNA expression libraries in which the proteins are expressed as fusions 
with a transcriptional activation domain (Fields and Song, 1989). Although this method 
has allowed the identification of numerous interacting proteins it is difficult to use if the 
protein of interest is a transcription factor capable of activating the reporter gene. In 
this context ER! and the AF1 region of ER! are both transcriptionally active in yeast 
cells (Metzger et al., 1988; Metzger et al., 1992). A technique that is based on the same 
principle as yeast two-hybrid system but uses a bacterial host, was developed by Dove 
et al (Dove et al., 1997). This bacterial two-hybrid approach is more amenable for the 
study of mammalian transcription factors, as mammalian transcription activation 
domains are unlikely to activate gene expression in bacterial cells. Further, the system 
offers a number of advantages over the yeast 2-hybrid system, which include higher 
transformation efficiency and faster growth of E. coli, allowing a reduction in the time 
required for screening cDNA expression libraries for interacting partners. I used the 
BacterioMatch II Two-Hybrid system (Stratagene, UK) based on the above 
methodology to screen for ER! interacting proteins. In the Bacteriomatch II system the 
bacterial hisB gene is mutated, but the strain has stable integration of the yeast His3 
gene, which can complement for the bacterial hisB gene. The $ operator sequence has 
been engineered in the yeast His3 gene promoter, so that growth of this strain on 
medium lacking histidine requires the $cI repressor-mediated recruitment of bacterial 
RNA polymerase. This is achieved by fusion of the $cI repressor to the protein of  
interest. The interacting partner is fused to the ! subunit of bacterial RNA polymerase, 
such that a productive interaction between the proteins of interest results in the  
 
 106 
 
 
 
 
 
 
 
 
 
 
             
 
Figure 3.1 Schematic diagram of the bacterial two hybrid system. Bait (X) protein 
fused to full length bacteriophage  repressor protein,!%cI and the Target (Y) protein 
fused to  subunit (!N) of  E.coli RNA  polymerase (RNAP), are expressed in a reporter 
strain. When the hybrid bait and target proteins interact, the RNA polymerase is 
recruited to the promoter activating the transcription of HIS3. The system has a second 
reporter that confers streptomycin resistance (Strepr), useful in verifying the bait and 
target protein interactions. 
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recruitment of RNA polymerase to the His3 gene promoter, enabling gene expression 
and consequent growth on medium lacking histidine (Figure 3.1). 
                 To assess the efficacy of this system for screening a cDNA expression 
library for ER! interacting proteins, a panel of known ER!  interacting proteins was 
tested for interaction using the system. The AF1 and LBD/AF2 domains of ER! were 
cloned into the bait vector, pBT, in fusion with $cI coding sequences. Previous work in 
our laboratory has shown that substitution of the key AF1 phosphorylation sites, serines 
104, 106 and 118 to glutamic acid stimulates ER!  activity in a ligand-independent 
manner, potentially by “mimicking” phosphorylation at these sites, whereas 
substitution by alanines reduces AF1 activity. The ER!  AF1 region in which the serine 
residues at these positions were substituted by glutamic acid (AF1-EEE) or by alanines 
(AF1-AAA) were also generated, in order to identify ER!%interacting proteins that are 
preferentially recruited to the phosphorylated AF1 region. Finally, an AF2 mutant that 
does not interact with coactivators and is transcriptionally inactive, AF2-L539A/L540A 
(AF2-LLAA) was also constructed, as a negative control for interaction with AF2. The 
known ER! coactivators SRC1 and TIF2, which interact with AF2 in a ligand-
dependent manner, were cloned into the target vector, pTRG, in frame with ! unit of 
RNA polymerase. Additionally, p68 RNA helicase, which preferentially interacts with 
AF1 phosphorylated at serine 118, as well as with AF1 in which serine 118 has been 
replaced by glutamic acid, but not with AF1 in which serine 118 has been substituted 
by alanine, was cloned into pTRG. pBT-LGF2 and pTRG-Gal11p are the bait and 
target plasmids encoding yeast transcriptional activator Gal4 and a domain derived 
from a mutant form of Gal11 protein, called Gal11p, respectively. These have been 
shown to interact in E. coli cells and are used as positive controls for interaction in the 
Bacteriomatch system. The respective bait and target plasmids were cotransformed into 
the reporter strain and were plated into selective and non-selective medium. Growth 
was observed in nonselective medium lacking histidine under all conditions (Figure 
3.2). This growth is likely to be due to leaky expression of the His3 gene, as has been 
described (Stratagene manual). 3-amino-1, 2, 4-triazole (3-AT), is a competitive 
inhibitor of the yeast His3 enzyme and is added to reduce background growth due to 
leaky expression of the His3 gene. In the presence of 10 mM 3-AT in the medium, no 
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Figure 3.2 Bacterial growth spot assay showing interaction between ER! and ER! 
coactivators. Bait plasmids encoding the ER! LBD/AF2 (AF2WT), AF2 with alanine 
substitution of residues 539 and 540 (AF2LLAA), the ER! AF1 region (AF1WT), AF1 
in which serines 104, 106 and 118 have been substituted by glutamic acid (AF1-EEE) 
or alanines (AF1-AAA) or control bait plasmid LGF2, were cotransformed with the 
target plasmids encoding the steroid receptor interacting domain of SRC1, p68 RNA 
helicase (p68), the region of TIF2 shown to interact with the AF1 region of ER ! or the 
control target plasmid Gal11.The co-transformants were plated on minimal media with 
or without 3-AT(5-10mM).                             
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growth was observed for pBT-AF2 co-transformed with pTRG-Gall11p, in the absence 
or presence of 17ß-estradiol (Figure 3.2). As expected, growth was also not observed 
for pBT-AF2 co-transformed with pTRG-p68, since p68 interacts with AF1. pBT-AF2 
and pTRG-SRC1 did, however, interact, as evidenced by growth in the absence of 
histidine and in the presence of 10 mM 3-AT. This growth was not observed for AF2-
LLAA, indicative of a productive interaction between AF2 and SRC1. Some growth 
was also observed for AF1, when cotransformed with SRC1 or TIF2, but not with p68. 
Similar growth was observed for AF1-AAA, although not for AF1-EEE. Whilst 
interaction of AF1 with SRC1 and TIF2 has been described, but the lack of interaction 
between p68 and AF1-EEE was unexpected, since interaction of p68 RNA helicase 
with AF1 in which S118 has been substituted by glutamic acid has been described 
(Endoh et al., 1999), and may be a reflection of incorrect folding of AF1. 
                The ligand-dependence of the interaction between AF2 of ER! and SRC1 
was further demonstrated by cotransforming target vector encoding SRC1 with pBT or 
pBT-AF2 and assaying for growth in the presence or absence of ligands (Figure 3.3). 
When AF2 and SRC1 were cotransformed and plated on minimal medium lacking 
histidine and containing 5 mM 3-AT, 300 colonies were obtained in the presence of 
estrogen, whereas only 50 colonies were observed in the presence of no ligand. In the 
presence of the pure estrogen antagonist ICI182, 780 (ICI) no colonies were observed, 
indicating that ICI blocks AF2 interaction with SRC1 in bacterial cells, as it does in 
mammalian cells.  When SRC1 was cotransformed with the empty bait plasmid there 
was no growth in the presence or absence of ligands. These data indicate that SRC1 and 
the ER! LBD interact in bacterial cells in a ligand-dependent manner.  
 
3.2 cDNA Expression Library Screening for proteins that interact with the human 
ERAF1 domain 
 
                  Numerous transcriptional coactivators that are recruited through interaction 
with the LBD/AF2 region of ER!, as well as other nuclear receptors, have been 
described in the literature. To date, however, very few AF1-interacting transcriptional 
coregulator proteins have been described. I therefore, wished to determine if the 
bacterial 2-hybrid system could be used to identify AF1-interacting proteins. 
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Figure 3.3 Ligand–dependent interaction of the ER!  AF2 domain with the steroid 
receptor interacting domain of SRC1 in bacterial cells. The reporter strain co-
transformed with pTRG-SRC1 and pBT or pBT-AF2 was plated on minimal media 
containing 5mM 3-AT. Cells were also plated in the absence of 3-AT to determine total 
colony number, as a measure of transformation efficiency (control). 100 nM E2 or ICI 
were added, as shown. Plates were incubated for 24 hours and growth was assayed by 
colony count. The table shows the colony count for each transformation. 
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Furthermore, as AF1 phosphorylation stimulates ER!  activity, I wished to see whether 
the bacteriomatch system could be used to identify proteins that interact preferentially 
with ER! phosphorylated at serines 104, 106 and 118, by using the glutamic acid 
substitutions at these positions. I therefore screened a human breast cDNA expression 
library using AF1-EEE as bait. The human breast cDNA expression library from 
Stratagene was reported as being prepared from an oligo d(T)-primed normal human 
mammary gland RNA derived from 10 pooled samples of women, aged 33-80 years 
and containing 2.5x106 independent clones. Prior to screening the cDNA library, the 
expression of the bait was verified by Western blotting. Lysates were prepared from 
Bacteriomatch II reporter strain transformed with the pBT-AF1-EEE and 
immunoblotted and probed with antibodies specific for AF1 and $cI. Immunoblotting 
demonstrated IPTG-induced expression of the bait protein, with the detected 
polypeptide having the expected molecular weight (Fig. 3.4). 
                     An overview of library screening using the BacterioMatch II Two-Hybrid 
system is shown in the in Fig. 3.4. The BacterioMatch Two-Hybrid system reporter 
strain, a derivative of Stratagene’s XL1-Blue MR, was transformed with the bait AF-
1EEE and electrocompetent cells were prepared, as described in the Materials and 
Methods chapter. These cells were transformed with the pTRG-cDNA expression 
library using the electroporation method. The transformed cells were plated on medium 
containing 5 mM 3-AT, together with the antibiotic streptomycin. Control plating was 
carried out in the absence of 3-AT and/or streptomycin. The transformation yielded 7.5 
X 105 clones, with 644 colonies being obtained on plates containing 3-AT. The 
BacterioMatch Two- Hybrid system reporter strain has a second $cI-regulated reporter 
gene, aadA, which confers streptomycin resistance. Of the 644, 3-AT-resistant clones, 
104 were able to grow in the presence of streptomycin. The pTRG plasmids were 
recovered from the 104 colonies by growth of the 3-AT and streptomycin-resistant 
colonies on tetracycline, as the pTRG plasmid, but not the pBT plasmid, encodes the 
tetracycline-resistance gene. All pTRG plasmids were sequenced and the sequences 
were compared to the Genbank database using BLASTn search 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
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Figure 3.4 A) Overview of cDNA breast library screening with the bait AF1-EEE 
using the Bacteriomatch two-hybrid system.  B) Immunoblotting for expression of   the 
bait fusion protein. Total cell lysates were prepared from the reporter strain transformed 
with pBT-AF1-EEE following the addition of IPTG (lanes 2 and 4). Immunoblotting 
was performed using antibodies to ER!  (6F11; Novocastra, UK) and $cI (Stratagene, 
UK), as shown.  
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A significant proportion (44%) of the positives encoded mitochondrial genes, various 
immunoglobulin gene sequences and sequences mapping to several chromosomes, at 
regions which did not correspond to any predicted genes. The remaining sequences 
corresponded to genes encoding proteins involved in signal transduction, cytoskeleton 
and membrane proteins. Multiple independent clones for some genes, Surf4 (13 
clones), hARF5 (8 clones), ATP binding cassette (6 clones) and cyclophilinB (4 clones) 
were obtained. However, for all but two cases, the protein-coding sequences were in the 
wrong reading frame relative to the ! subunit of RNA polymerase, which would 
prevent correct translation. Regardless of whether they were in frame, the positive 
clones were analysed further to confirm the interaction, although the clones encoding 
mitochondrial genes, immunoglobulins, as well as the chromosomal sequences with no 
clear open reading frame were not included in the further analysis. The remaining 
positive clones were re-transformed to reconfirm the interaction by testing the positive 
clone for its dependence on the bait plasmid in activating the reporter genes. Each 
positive cDNA target plasmid was cotransformed with either the empty bait or the bait 
encoding AF1-EEE and plated on to non-selective and selective medium containing 3-
AT. However, none of the positive clones showed interaction with AF1-EEE, following 
re-transformation, indicating that these clones do not encode genuine AF1-interacting 
proteins. 
                The bacterial two-hybrid has been reported to give fewer false positives 
compared to the yeast two- hybrid system. Our screen yielded 104 potential interacting 
proteins out of the 7.5X 105 primary transformants, all of which proved on further 
analysis to be false positives. Such a high number of false positives indicated that it was 
unlikely that further screening would successfully lead to the identification of AF1- 
interacting proteins. Given the disappointing nature of these results I decided not to 
persevere with the Bacteriomatch methodology. 
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Table 3.1 -List of genes identified by screening the human breast cDNA library with 
AF1-EEE as the bait using the bacterial two-hybrid system. The gene accession 
numbers for all genes is also shown. 
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4. RESULTS:  
Characterisation p68 RNA helicase as a coactivator of ER! 
4.1 Reporter gene assays show that p68 and p72 RNA helicases are coactivators 
for ER!   
                  As discussed in the Introduction, p68 RNA helicase was previously shown 
to interact with ER! (Endoh et al., 1999). In the absence of significant findings from 
the Bacteriomatch II hybrid screening and because of in vitro studies showing that p68 
binds preferentially to the ER! AF1, when it is phosphorylated at serine 118 by MAPK 
or to the ER! AF1 when S118 was substituted by glutamic acid, I decided to further 
characterise p68 as an ER! coactivator, and to investigate its importance for ER! 
function using over expression and RNA interference in breast cancer cell lines. 
Reporter gene assays were carried out using ER!  and deletion and substitution mutants 
of ER! (Figure 4.1). Firstly, I confirmed the previously published findings showing 
that p68 acts as a coactivator for ER!, using reporter gene assays. COS1 cells were co 
transfected with increasing amounts of ER!, p68 and/or the well-characterised 
ER! coactivator, SRC1, along with an estrogen responsive luciferase reporter gene 
encoding three copies of estrogen responsive elements upstream of the thymidine 
kinase promoter and were assayed for luciferase activity (ERE-luc). Stimulation of 
ER! activity by SRC1 and p68 was observed when low amounts (0.5-2.5 ng) of ER! 
were used, coactivation not being evident if higher amounts of ER! were transfected 
(Figure 4.2). Synergy between p68 and SRC1 was also evident in the presence of low 
levels of ER!. The lack of coactivation by known ER! coactivators unless low 
amounts of ER! are co-transfected, is in agreement with a previous study by Lee et al., 
who showed that synergy between coactivators is best seen when small amounts of  
ER! are transfected (Lee et al., 2002).  
      Having established that p68 stimulates ER! activity and that p68 synergises 
with SRC1, ER! was co-transfected with increasing amounts of p68, in order to 
determine the amount of p68 required for optimal coactivation. Increasing the amount 
of p68 transfected did not significantly increase the coactivator activity of p68, and 
indeed, at the highest concentration, coactivation by p68 was slightly inhibited 
(Figure4.3). Hence, optimal coactivation by p68 and synergism with SRC1 was  
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obtained following transfection with 1 ng of ER!, 20 ng of SRC1 and 250 ng of p68. 
These data are in agreement with a recent report showing that 250-500 ng of p68 
provide the highest level of coactivation of p53 in reporter gene assays (Bates et al., 
2005). The need for such high amounts of the p68 expression plasmid may be due to 
the high levels of p68 present in most cell types, together with the difficulty in 
achieving good expression of exogenous p68 (F.V. Fuller-Pace, personal 
communication). Therefore 1 ng of ER expression vector and 250 ng of p68 were used 
in reporter gene assays for further experiments. 
 
4.2 p68 RNA helicase is a coactivator of ER!  and shows synergism with SRC1 
 
                 As shown in figure 4.4, p68 stimulated ER! activity by about 1.5-fold, and 
synergised with SRC1, stimulating ER! activity by about 7-fold. These findings are 
similar to those previously reported for p68 stimulation of ER! activity (Endoh et al., 
1999). Another DEAD box protein, named p72 RNA helicase, is very closely related to 
p68 (Lamm et al., 1996), and in reporter gene assays, p72 stimulated ER! activity at a 
level similar to that observed for p68 (Watanabe et al., 2001). Further, p72 also showed 
synergy with SRC1 (Figure 4.4). Similar results have been reported for p53, although 
p68 was found to be a more potent coactivator of p53 than p72 (Bates et al., 2005).  
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Figure 4.1 Schematic diagram depicting the domains of ER! and the constructs used in 
the transient transfection experiments. ER!, LBD-deleted ER! (ER!-'LBD) and AF1-
deleted ER! (ER!-'AF1) are shown. The location of serines 104, 106 and 118 is 
shown, as is the position of amino acids in the ligand binding domain (LBD), whose 
mutation either stimulates ER! in a ligand-independent manner, or the mutation of 
which prevents coactivator recruitment by the LBD.  
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Figure 4.2 p68 RNA helicase (p68) is a coactivator for ER!  in reporter gene 
assays. COS-1 cells, grown in medium lacking estrogen, were transfected with 
increasing amounts of expression vectors of ER! (as shown), 20ng of SRC1, 250ng of 
p68, 100ng of ERE-luc. A thymidine kinase (tk)-regulated renilla luciferase reporter 
(RLTK; 100 ng) was cotransfected, as a control for transfection efficiency. 17ß-
estradiol (E2; 10 nM) was added, as shown, with an equal volume of vehicle (ethanol), 
being added to the no ligand (NL) controls, Shown are the ERE-luc activities, with the 
luciferase activity obtained for pSG5 (lane 1) being taken as 1. All other activities are 
shown relative to this. The results show the means of three independent experiments, 
with the error bars depicting the standard errors of the mean (SEM).   
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Figure 4.3 Stimulation of ER!  activity by p68. COS-1 cells were transiently 
transfected with expression vectors encoding ER! (1ng), 20ng of SRC1 and varying 
amounts of p68 as indicated, together with 100ng of ERE-luc and RLTK. As shown for 
Figure 4.2, 17ß-estradiol (E2; 10 nM) was added, with an equal volume of vehicle 
(ethanol), being added to the no ligand (NL) controls, The reporter gene activity 
obtained with 1ng of ER ! in the presence of E2 and absence of coactivator was set at 1 
and other data is expressed relative to this. The results show the means of three 
independent experiments, with the error bars depicting the standard errors of the mean 
(SEM).  
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Figure 4.4 p72 RNA helicase is an ER! coactivator. COS-1 cells were transiently 
transfected with expression vectors encoding ER! (1ng), 20ng of SRC1 250 ng p68 and 
250 ng p72, as indicated, together with 100ng of ERE-luc and RLTK. As shown for 
Figure 4.2, 17ß-estradiol (E2; 10 nM) was added, as shown, with an equal volume of 
vehicle (ethanol), being added to the no ligand (NL) controls, The reporter gene activity 
obtained with 1ng of ER! in the presence of E2 and absence of coactivator was set at 1 
and other data is expressed relative to this. The results show the means of three 
independent experiments, with the error bars depicting the standard errors of the mean 
(SEM). 
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4.3 p68 modulates the activity of both AF1 and AF2 of ER!  
                p68 has been reported to be an AF1 specific coactivator of ER!  (Endoh et 
al., 1999). In order to investigate this further, reporter assays were carried out using 
deletion mutants of ER! (Figure 4.1) in COS-1 cells. As expected and in agreement 
with the published data, p68 stimulated the activity of ER!-(LBD, which lacks the 
LBD and contains the AF1 and DBD domains (Figure 4.5). In this context p68 and 
SRC1 also demonstrated some cooperativity in stimulating the activity of AF1. 
Interestingly, p68 also stimulated the activity of ER!-(AF1, which encodes the DBD 
and LBD/AF2 but lacks AF1 (Figure 4.6). 
                The above data suggest that p68 potentiates the activity of the ER! LBD. As 
this has not previously been described, further reporter gene assays were carried out so 
as to confirm a role for p68 as a coactivator for the LBD/AF2. In order to do this, p68 
was co-transfected with ER! in which key residues in the ! helices 3, 5 and12 had 
been substituted. These residues in !-helices 3, 5 and 12 form the AF-2 surface that is 
important in the ER! LBD interaction with coactivators (Feng et al 1998; Mak et al 
1999). COS-1 cells were transiently transfected with expression plasmids encoding 
ER! containing amino acid substitutions, together with p68 and SRC1. Substitution of 
D351 affects ligand binding by ER!, particularly anti-estrogen binding (Wolf and 
Jordan, 1994). D351Y mutant has reduced basal activity that is stimulated to 40-fold by 
the addition of tamoxifen, in the presence of the SRC1 homologue, TIF2 (Anghel et al., 
2000). In agreement with this report, high reporter activity of D351Y mutant was seen 
with SRC1 in the presence of tamoxifen. p68 also stimulated the activity of this mutant 
and increased activity was also seen in the presence of tamoxifen (Figure 4.7). 
     Amino acids in !-helix 12 in the ER! LBD form the interaction surface with 
the coactivators and the positioning of helix 12 is key to discriminating the agonist and 
antagonist nature of ligands (Norris et al., 1998). Estrogen binding results in 
conformational change in the LBD, which allows co-activator recruitment to the LBD. 
In the tamoxifen-bound LBD, helix 12 takes up position in the co-activator binding 
groove, thereby blocking coactivator recruitment by ER! (Shiau et al, 1998). Mutations  
in helix 12 prevent coactivator binding, presumably by altering the structure of helix 
12. 
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Figure 4.5 p68 enhances ER!  AF1 activity. COS-1 cells, grown in medium lacking 
estrogen, were transfected with increasing amounts of expression vectors of ER! (LBD 
(as shown), 20ng of SRC1, 250ng each of p68 and p72, together with 100ng of ERE-
luc and RLTK. Shown are relative ratios of firefly to renilla control luciferase 
activities. The results show the means of three independent experiments, with the error 
bars depicting the standard errors of the mean (SEM).   
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Figure 4.6 p68 modulates ER! AF2 activity. COS-1 cells, grown in medium lacking 
estrogen, were transfected with increasing amounts of expression vectors of ER! (AF1 
(as shown), 20ng of SRC1, 250ng each  of p68 and p72, together with 100ng of ERE-
luc and RLTK. 17ß-estradiol (E2; 10 nM) was added, as shown, with an equal volume 
of vehicle (ethanol), being added to the no ligand (NL) controls. Shown are relative 
ratios of firefly to renilla control luciferase activities. The results show the means of 
three independent experiments, with the error bars depicting the standard errors of the 
mean (SEM).   
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This is particularly seen for leucine 539, leucine 540, methinine 543 and leucine 544, 
whose substitution by alanine, blocks coactivator recruitment and prevents ER! 
activation (Danielian et al., 1992; Danielian et al., 1993; White et al., 1997). Neither 
SRC-1 nor p68 stimulated the activities of these mutants (Figure 4.7). The mutants 
E542A or M543A transactivate less efficiently than wild-type ER! and this was 
reflected in the lower reporter gene activities, although the extent of coactivation by 
SRC1 and p68 was similar to that for wild-type ER!, again in agreement with the 
published reports (Hong et al., 1997; Valentine et al., 2000). Conversely, substitution of 
leucine 536 and tyrosine 537 can lead to ligand-independent coactivator recruitment 
and ER! activation (Eng et al., 1997; White et al., 1997; Zhao et al., 2003; Zhong and 
Skafar, 2002). p68 was able to stimulate the activities of these ER! mutants in a ligand-
independent manner, as also observed for SRC-1.  
Together, these results indicate that coactivation of ER! by p68 is similar to 
coactivation by SRC1, further supporting the idea that p68 modulates the activity of 
LBD/AF2, as well as that of AF1 of ER!. 
 
4.4 Synergism between p68 and SRC1 in coactivation of ER!  
"
                p68 has shown to interact with other coactivators such as the p160 
coactivators SRC1 and AIB1, the histone acetyltransferase CBP and with the RNA 
coactivator, SRA (Watanabe et al., 2001; Rossow & Janknecht, 2003). The interaction 
of p68 with SRC1 requires activation domain 2 (AD2) of SRC1 (Watanabe et al., 
2001). In order to determine whether the cooperativity of p68 and SRC1 in regulating 
ER! activity is mediated by p68 recruitment by AF1 and SRC1 recruitment by AF2, the 
ability of p68 and SRC1 to cooperate, was assessed using mutants of SRC1 in which 
the LBD-interacting motifs and a mutant in which AD2 was deleted. SRC-M123 is a 
mutant in which the key leucine residues in the three NR boxes (LXXLL) of SRC1have 
been substituted by alanine (LXXAA). This mutation impairs the ability of SRC1 to 
interact with AF2 of ER! and therefore is functionally inactive in coactivator assays 
(Kalkhoven et al., 1998). As expected, SRC-M123 failed to stimulate ER! activity  
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Figure 4.8 Synergistic coactivation of ER!  by SRC1 and p68. COS-1 cells were 
transfected with 1 ng of ER! (&), or ER! (AF1 (B), 250ng each of p68 and p72, 
together with 100ng of ERE-luc and RLTK and 20ng each of SRC1 and the indicated 
SRC1 mutants. 17ß-estradiol (E2; 10 nM) was added, as shown, with an equal volume 
of vehicle (ethanol), being added to the no ligand (NL) controls. The reporter gene 
activity obtained with 1ng of ER! (&), or ER! (AF1 (B) in the presence of E2 and 
absence of coactivator was set at 1 and other data is expressed relative to this. The 
results show the means of three independent experiments, with the error bars depicting 
the standard errors of the mean (SEM).  
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(Figure 4.8A). On cotransfection with p68, however, the reporter activity observed was 
higher than that associated with p68 alone, which may result from SRC-M123 
recruitment to ER! through interaction with p68. This synergism was not observed, 
however, for ER!%'AF1, (Figure 4.8B), suggesting that the synergistic coactivation of 
SRC1 and p68 requires an intact AF1. Cooperativity between p68 and SRC1 was  
maintained when the AD2 domain of SRC1 was deleted (SRC-'AD2), although the 
stimulation of ER! activity was additive, rather than synergistic, suggesting that both  
p68 and SRC1 were recruited to ER!, but did not interact with each other. Clearly it 
would be interesting to determine whether the cooperativity would be observed for 
ER!%'AF1. 
 
4.5 Phosphorylation of Serine 118 is not required for p68 interaction with ER!  
          
                 Phosphorylation of ER! enhances its activity and the key phosphorylation 
sites are mapped within AF1 of ER! at serines 104, 106 and 118. The mechanisms by 
which phosphorylation enhances its activity remain unclear and it has been postulated 
that the increase in ER! activity as a result of AF1 phosphorylation is due to 
recruitment of specific coactivators (Lannigan, 2003). p68 RNA helicase was originally 
identified in an in vitro screen for proteins that interact with AF1 phosphorylated at 
S118 (Endoh et al., 1999). However the reported stimulation of ER! activity by p68 
was rather weak and has not been confirmed by other groups. The data shown above 
provide the first confirmation of the original description of p68 as a coactivator for 
ER!. The results described above also show, however, that p68 appears to be a 
coactivator for the ER!LBD, in addition to stimulating AF1 activity. In order to 
examine the importance of S118 phosphorylation for interaction with p68, COS-1 cells 
were transiently transfected with p68, ER! and ER! in which S118 has been 
substituted by alanine, or by glutamic acid. A glutamic acid substitution at this position 
has been shown to stimulate p68 interaction with ER! (Endoh et al., 1999). As shown 
in figure 4.9, p68 enhanced the activity of ER! by 1.5 fold. There was an increase in 
the reporter gene activity when S118 was substituted by glutamic acid (S118E), 
whereas substitution by alanine (S118A) reduced ER! activity, as has previously been 
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described (Ali et al., 1993). As expected, p68 stimulated the activities of S118E (Figure 
4.9), although the stimulation was no greater than that observed for the wild-type ER!. 
Further, S118A activity was stimulated to a similar extent, indicating that S118 is not 
important for ER! interaction with p68. Other work from our laboratory has shown that 
ERK1/2 MAPK can phosphorylate S104 and S106, in addition to S118 (Thomas et al. 
2008). It is possible, therefore, that p68 interaction involves these residues, in addition 
to S118. Substitution of S104 and S106, singly, doubly, or in combination with S118, 
however, gave the same result, namely a similar level of activation by p68. These 
results suggest that the serine residues at 104, 106 and 118 are not important for 
coactivation of ER! by p68. 
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4.6 The interaction of p68 with ER! does not require the LXXLL-type sequence in 
p68 
                 Ligand-dependent transactivation by nuclear receptors involves the 
sequential recruitment and dissociation of a number of coactivators. Many of these 
proteins are recruited to nuclear receptor LBDs through !-helical motifs containing the 
sequence, LXXLL where L is Leucine and X is any amino acid (Heery et al, 1997). 
Scanning the amino acid sequence of p68 RNA helicase shows the presence of the 
sequence 145-TLSYLL-150 (Figure 4.10). As the previous experiments suggested that 
the p68 RNA helicase modulates the activity of AF2 and hence may bind to the ER! 
LBD, we speculated that p68 might interact with ER! through this potential LXXLL 
motif. Therefore we generated a LXXLL motif mutant, p68 LSYAA, in which the 
leucine residues were replaced by alanine by site directed mutagenesis and examined 
the effect of this mutant on transactivation of ER!. However, stimulation of ER! 
activity by this mutant was similar to that seen with wild-type p68 (Figure 4.11B), 
suggesting that any interaction between p68 and ER! is independent of this LXXLL 
motif. The expression of the mutant and the wild type proteins in COS1 cells were 
confirmed by immnobloting with p68 antibody (Pab 204) (Figure 4.11C). 
4.7 The helicase activity of p68 is not required for the ER! coactivator activity of 
p68  
                 DEAD box proteins are characterized by the presence of a central conserved 
helicase motif. These proteins have multiple functions, not of all which require the 
helicase activity (Fuller-Pace, 2006). The requirement for the helicase activity for its 
coactivator functions is variable, being dispensable for coactivator function of p53. The 
role of helicase activity of p68 for coactivator function of ER! was assessed using a 
DEAD box mutant in which the first aspartate (amino acid 240) of the DEAD box in 
p68 was substituted by aspargine to generate p68-NEAD. p68-NEAD and p72-NEAD 
stimulated ER! activity as well as wild-type p68 and p72. Nor did the NEAD mutants 
affect synergism of p68 and p72 with SRC-1 (Figure 4.11A). The expression of he 
helicase mutants were confirmed by immunobloting using a p68 antibody (Figure 
4.11C).  
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Figure 4.10 Amino acid sequence of human p68 RNA helicase. Position of the 
LXXLL sequence and the DEAD box are underlined. 
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Figure 4.11(A) The LXXLL sequence in p68 not required for coactivation of ER!. 
COS-1 cells were transfected with of expression vectors of ER! (1ng), 20ng of SRC1, 
250 ng each of p68, and LXXLL mutant of p68, p68LSYAA, together with 100ng of 
ERE-luc and RLTK. 17ß-estradiol (E2; 10 nM) was added, as shown, with an equal 
volume of vehicle (ethanol), being added to the no ligand (NL) controls. Shown are the 
ERE-luc activities, with the luciferase activity obtained for ER! in the presence of E2 
and absence of coactivator being taken as 1. All other activities are shown relative to 
this. The results show the means of three independent experiments, with the error bars 
depicting the standard errors of the mean (SEM). (B) Helicase activity is not required 
for the stimulation of ER! activity by p68 and p72.COS-1 cells were transfected 
with of expression vectors of ER! (1ng), 20ng of SRC1, 250 ng each of p68, p72, 
helicase mutants of p68/72, p68NEAD and p72NEAD, together with 100ng of ERE-luc 
and RLTK. 17ß-estradiol (E2; 10 nM) and 100nM of tamoxifen (OHT) was added, as 
shown, with an equal volume of vehicle (ethanol), being added to the no ligand (NL) 
controls. Shown are the ERE-luc activities, with the luciferase activity obtained for 
ER! in the presence of E2 and absence of coactivator being taken as 1. All other 
activities are shown relative to this. The results show the means of three independent 
experiments, with the error bars depicting the standard errors of the mean (SEM). (C) 
Immunoblotting showing the expression of p68/72 and the mutants. Cells were 
transfected with 500ng each of expression vectors for myc taggedp68, p68NEAD, p68 
LSYAA, p72 and p72NEAD.Lysates were immunoblotted with anti-cmyc and anti-p68 
antibody.  
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These findings are in accordance with the findings of Endoh et al who showed that a 
mutation in the ATP binding domain (p68 K144R), which abolishes p68 helicase 
activity stimulated ER! activity as well as wild-type p68 (Endoh et al., 1999). 
 
4.8 Interaction of p68 and ER! in vitro  
 
                 The reported studies of p68 and ER! have demonstrated a direct interaction 
between p68 and the AF1 region of ER!, with the interaction being regulated by 
phosphorylation at S118. As the reporter gene studies described above provide clear 
evidence that p68 influences AF2 activity in addition to its action on AF1, GST pull 
down assays were performed in order to determine whether regions of ER! other than 
AF1 interact with p68. GST fusion proteins encoding full-length ER!, or small regions 
of ER! (Figure 4.12A) were expressed in E.coli and the expression was confirmed by 
immunoblotting using GST antibody (4.12B). Purified GST fusion proteins were 
incubated with in vitro translated 35S-methionine-labelled p68. p68 interacted with 
ER!, ER!-'LBD and ER!-'AF1, but there was little interaction of p68 with AF1 or 
LBD, suggesting that the interaction of p68 may involve the ER! DNA binding 
domain. The interaction was similar in the absence or presence of E2, and the 
antagonists OHT and ICI, demonstrating that the interaction of p68 with ER! is ligand-
independent (Figure 4.13A). Similar results were obtained when the pull downs were 
carried out using GST-p68 (Figure 4.13B), whereas the interaction of the ER! LBD 
with SRC1 showed estrogen regulation, indicating that the lack of ligand regulation for 
the interaction of p68 and ER! is not due to an artefact of the in vitro binding assay. As 
these results suggest an interaction of p68 with the ER! DBD, we tested whether p68 
interacts with ERß, since ER! and ERß show considerable divergence in AF1, whereas  
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Figure 4.12 (A) Schematic representation of ER! and the deletion mutants used in the 
GST pull down assays (B) Purified GST-ER! fusion proteins were immunoblotted 
using an antibody for GST. The positions of the molecular weight markers are depicted 
on the right. 
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Figure 4.13 p68 interacts with ER!  in vitro. (A) GST-ER! proteins were expressed 
in E.Coli and purified on glutathione beads. Purified proteins were incubated with in 
vitro translated, 35S-methionine-labelled p68 in the presence or absence of 17ß-estradiol 
(E2; 100 nM), 4-hydroxytamoxifen (OHT; 100 nM) or ICI 182, 780 (ICI; 100 nM). An 
equal volume of the vehicle (ethanol) was added to the no ligand controls. (B-C) In 
vitro translated 35S-labelled ER! or ER! deletion mutants, (B) or in vitro translated 
human ERß (C) were used in GST pulldown assays using GST-p68, in the presence or 
absence of 100 nM E2. Input refers to 10% of the in vitro translation reaction used in 
the pull down. 
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the DBD is 97% identical between ER! and ER" (Mosselman et al., 1996). Indeed, 
ER" also bound p68, both in the presence and absence of estrogen (Figure 4.13C). 
These finding show that p68 interacts with ER! in vitro and suggest that the interaction 
is mediated by the ER! DBD, although there was evidence for weak interaction of p68 
with the AF1 region.  
 
4.9 Mapping the region(S) of p68 that mediate interaction with ER! in vitro 
 
                 To determine the sequences in p68 required for interaction with ER!, a 
series of GST fusion proteins containing different regions of p68 (Figure 4.14 A) were 
expressed in E.coli and the expression was confirmed by immunoblotting the purified 
extracts with a GST antibody (Figure 4.14 B). Purified proteins were assayed for 
interaction with in vitro translated 35S-methionine-labelled ER!. As shown above, ER! 
interacted with full-length p68 (Figure 4.14A, construct 1). Substitution of the DEAD 
box motif by the sequence NEAD did not prevent interaction with ER!. Deletion of 
amino acids 1-59 appeared to reduce interaction of ER! with p68, suggesting that this 
region plays a role in the interaction. However, p68 amino acids 386-501 were 
sufficient for interaction with ER!, whereas amino acids 386-460 did not interact 
strongly with ER!, suggesting that amino acids 460-501 are important for interaction 
of ER! with p68. This was confirmed by the finding that amino acids 432-501 bind 
ER! strongly, as do amino acids 471-501. Further deletions did not allow finer 
mapping of the region of interaction, suggesting that amino acids 471-501 may 
represent the smallest region of p68 required for interaction with ER!.  
                 The results shown here are contradictory to the results reported by Endoh et 
al who mapped the p68 interacting region in AF1 of ER!, to amino acids 56-127 and 
the interaction domain in p68, to amino acids 300 to 400. In their interaction assays 
deletion of amino acids 200-400, 200-614 and 1-400 resulted in loss of binding while in 
our assays the binding was seen with these deletions. Further our assays show that p68 
binds to the ER! AF1 region and to the ER! DBD. The reasons for the disparity in the 
findings presented here and those of Endoh et al. may be due to the fact that the GST  
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Figure 4.14 Detailed mapping of the regions of p68 required for interaction with 
ER in vitro (A) Schematic representation of GST-p68 fusion proteins p used in the 
GST pull down assays. The right hand panel shows the results of the pull down assay, 
using in vitro translated 35S-labelled ER!. 10% of the in vitro translated ER! used in 
the pull downs is shown as input. (B) Immunoblotting showing the expression of GST 
fusion proteins with p68 and the deletion constructs. Positions of the molecular size 
markers are shown on the right.  
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pull down assays they described were carried out with the AF1 region of ER!, and not 
with full-length ER! or ER! containing the DBD, although as suggested by the fact  
that deletion of amino acids 1-59 reduce interaction between ER! and p68, support the 
possibility that multiple regions of p68 can interact with ER!. 
 
4.10 The in vitro interaction of p68 and ER!  does not require phosphorylation at 
Serine 118 
  
      ER! is phosphorylated at S118 by MAP kinase in vitro and in vivo (Chen et 
al., 2002; Kato et al., 1995; Arnold et al., 1995; Bunone et al., 1996), as are S104 and 
S106 (Thomas et al., 2008). The results of the reporter gene assays indicate that S104, 
S106 and S118 are not required for co-activation by p68, suggesting that 
phosphorylation of these residues is not involved in recruitment of p68 by ER!. In 
agreement with these findings, in GST pull down assays, mutation of S118 to alanine 
did not affect interaction of the AF1 or the AF1-DBD regions of ER!, with p68 (Figure 
4.15A). In the reciprocal pull down assay, mutation of S118, or all three MAPK 
phosphorylation sites in AF1 (S104, S106, S118) did not influence interaction of full-
length ER! with p68 (Figure 4.15 B). It is possible that the lack of requirement for 
these residues is due to their mutation in these studies, so recombinant ER! was 
phosphorylated by ERK2 MAPK in vitro and subjected to pull down assays with p68, 
in order to investigate whether direct phosphorylation at these sites influences p68 
recruitment in vitro. Purified GST-ER! and GST-ER!-AF1 were phosphorylated in 
vitro by incubation with purified ERK2 MAPK, followed by incubation of the GST 
proteins with in vitro translated p68. Immunoblotting with an antibody specific for ER! 
phosphorylated at S118 showed ER! phosphorylation occurred following incubation 
with ERK2 MAPK (Figure 4.16). However, there was no difference in p68 interaction 
with ER! or with the AF1 region following phosphorylation, compared with the 
unphosphorylated ER!.  
      Taken together, the GST pull down assays confirm the reporter gene assay 
findings, showing that phosphorylation of ER! does not influence the interaction of 
p68 with ER! in vitro.  
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Figure 4.15 Mutation of phosphorylation sites of ER ! at serine 104, 106 and 118 
does not affect the interaction of ER! with p68. (A) GST fusion proteins with the 
ER! lacking the LBD (ER!%(LBD), ER!%(LBD in which S118 was substituted by 
alanine (ER!%(LBD-118A), the ER! AF1 region (ER!-AF1) and ER!-AF1-118A 
were used to pull down in vitro translated p68. (B) GST-p68 was used in pull down 
assays using ER!, or mutants of ER! in which the indicated serine residues were 
substituted by alanine or glutamic acid. 
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Figure 4.16 Phosphorylation of ER!  by MAPK does not influence p68 binding in 
vitro. GST-ER! and GST-AF1 purified following expression in E.coli were 
phosphorylated by incubating with purified MAPK. The phosphorylated proteins were 
incubated with in vitro translated 35S-methionine-labelled p68. The autoradiograph of 
p68 interaction with ER! (top panel) is shown. Immunoblotting using antibodies to 
GST (bottom panel) show the amounts of GST-ER! and GST-AF1 present in the pull 
downs, whilst immunoblotting using an antibody specific for ER! phosphorylated at 
S118 is also shown (middle panel).   
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4.11 Co-immunoprecipitations show that p68, p72 and ER!  interact in vivo 
                 Co-immunoprecipitations were carried out in order to show direct interaction 
between ER! and p68 in vivo. Whole cell extracts prepared from COS-1 cells 
transiently transfected with ER! and p68 were immunoprecipitated using antibodies for 
ER!. Immunoprecipitated proteins were analysed by Western blotting with antibodies 
for p68 and ER! (Figure 4.17A). Control immunoprecipitations were carried out using 
mouse immunoglobulins (IgG). As shown in figure 4.17A, p68 co-immunoprecipitated 
with ER!, indicating that p68 interacts with ER! in vivo. The interaction of p68 with 
ER! was not influenced by estrogen, in agreement with the GST pull down results, 
indicating that the interaction of p68 and ER! is ligand-independent. Similar results 
were obtained for p72 when whole cell lysates of COS-1 cells transfected with ER! 
and p72 were immunoprecipitated using the ER! antibody (Figure 4.17B). As for p68, 
the interaction with ER! was independent of ligand. 
 
                 The above immunoprecipitation was carried out following over-expression 
of ER! and p68 in COS-1 cells. In order to examine whether endogenous ER! and p68 
interact, nuclear extracts prepared from MCF-7 cells treated with E2 for 24 hours were 
immunoprecipitated using an ER! antibody. As observed in the over-expression, p68 
co-immunoprecipitated with ER!, and as seen for the over-expression, the interaction 
was not stimulated by ligand (Figure 4.17C). Together, these results indicate that ER! 
interacts with p68 and p72 in vivo, confirming the in vitro findings presented earlier in 
this chapter. 
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Figure 4.17 ER!  interacts with p68 and p72 in vivo. (A) Whole cell extracts 
prepared from COS-1 cells transiently transfected with ER! and p68 were 
immunoprecipitated using an ER! antibody or using mouse immunoglobulins (IgG) as 
a negative control. Shown are immunoblots for ER! and p68. E2 (10 nM) was added 30 
mins before cell harvesting. An equal volume of ethanol was added to the vehicle 
control. (B) Immunoprecipitations were performed as in (A), following transfection of 
ER! and p72. (C) Nuclear extracts prepared from MCF-7 cells treated with 10 nM E2 
for 24 hours were immunoprecipitated with an ER! antibody, followed by 
immunoblotting for p68 and ER!, as in (A). The input lane represents 10% of the 
lysate used for the immunoprecipitation.  
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4.12 Effect of over-expression of p68 and 72 in MCF7 cells 
 
                 The results described above show that p68 and p72 can both act as co-
activators for ER! in reporter gene assays. In order to address whether p68 and p72 
also stimulate ER! activity in breast cancer cells, MCF-7-derived cells were transiently 
transfected with c-myc-tagged p68 and/or p72, in order to determine if their over-
expression can affect the expression of endogenous estrogen-regulated genes. 
Transfection of p68 resulted in increased levels of the estrogen-responsive pS2 and 
cathepsin D (CTD) proteins (Figure 4.18), in agreement with the reporter gene data. 
Interestingly, however, p72 transfection did not increase pS2 or CTD levels, nor was an 
increase observed when p68 and p72 were co-transfected. Both p68 and p72 
transfections worked, as seen with immunoblotting with antibodies to the c-myc tag.  
"
4.13 p72 knock down inhibits the transactivation of ER !  while p68 knock down 
has no effect. 
 
                 In the over expression studies, in COS-1 cells both p68 and p72 enhanced 
the transcriptional activity of ER!. We wished to examine the effects of endogenous 
p68 and p72 on the transcriptional activity of endogenous ER! in MCF -7 cells by 
RNA interference. For this we chose two MCF-7 derived cell lines, MELN and MVLN, 
stably transfected with estrogen responsive luciferase reporter genes (Demirpence et al., 
1993; Balaguer et al., 2001). The advantage of these cell lines is that the estrogen 
induced transcriptional activity can be measured directly without the need for 
transfection of exogenous estrogen responsive reporter gene. The cells were transfected 
with the siRNA for p68, p72 and control siRNA, treated with estrogen for 4 and 8 hours 
and assayed for luciferase activity. The efficiency of knock down of both p68 and p72 
was confirmed by immunoblotting of lysates from cells transfected with siRNA (Figure 
4.19B). p68 knock down had no effect on transcriptional activity of ER! while p72 
knock-down inhibited the transcriptional activity by nearly 40% compared to the 
untransfected control (figure 4.19 A and B).  
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Figure 4.18 Transfection of MCF-7 cells with p68 increases the levels of pS2 and 
cathepsin D. MCF-7 cells were grown in double stripped serum for 3 days and 
transfected in 6-well plates with vector, c-myc-tagged p68 and c-myc-p72, singly or in 
combination. Following transfection the cells were treated with 10nM E2 for 8hrs, prior 
to preparation of whole cell lysates. Immunoblotting for c-myc, cathepsin D and pS2 
are shown. Immunoblotting for ß-actin served as a control for protein loading.  
 
 
 
 
 
 
 
 
 
 
B
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Figure 4.19 (A) p72 knock down inhibits the transactivation of ER! .  MELN and 
MVLN cells were grown in double stripped serum for 3 days and transfected in 24 well 
plates with indicated siRNA. The cells were, treated with 10nM of E2 for 4/8hrs and 
harvested 48 hrs post transfection and assayed for luciferase activity. The results show 
the means of three independent experiments, with the error bars depicting the standard 
errors of the mean (SEM). The bottom panel shows immunoblotting of extracts used in 
the experiment for p68 and p72 and "-actin as control for protein loading.  
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Figure 4.19 (B)  p72 knock down inhibits the transactivation of ER! . MCF-7 cells 
were grown in double stripped serum for 3 days and transfected in 24 well plates with 
indicated siRNA. The following day they were transfected with 100ng each of the 
estrogen responsive reporter gene and renilla reporter gene used as control for 
transfection efficiency. The cells were, treated with 10nM of E2 for 24 hrs, harvested 48 
hrs post transfection and assayed for luciferase activity. The results show the means of 
three independent experiments, with the error bars depicting the standard errors of the 
mean (SEM). 
 
 
 
 
 
.  
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The lack of any effect on the ER transactivation with knock down, might be due to 
compensation by the over expression of p72 which is also a coactivator of ER!, in p68 
depleted cells. Surprisingly, the double knock down marginally affected the 
transcriptional activity. Perhaps this was a result of rescue by another yet unknown 
helicase or another unknown factor. The control scrambled siRNA consistently gave 
higher reporter activity.  
 
4.14 RNA interference-mediated knock-down of p68 and p72 RNA helicases in 
MCF-7 cells suggests that p72 is important for ER! function in breast cancer cells 
 
                 The above findings show that p68 and p72 RNA helicases can function as 
co-activators for ER!, although in MCF-7 cells, overexpression of p68, but not of p72 
stimulated the expression of estrogen-responsive genes. RNA interference mediated 
gene knockdown was carried out in order to more fully determine the importance of 
p68 and p72 for the regulation of gene expression by ER!. MCF-7 cells were 
transfected with double-stranded RNA (dsRNA) oligonucleotides for p68 and p72 that 
have previously been described (Bates et al., 2005; Jalal et al., 2007). Transfection with 
dsRNA for Lamin A/C was used, together with a scrambled dsRNA, as positive and 
negative controls for the RNA interference, respectively. Transfection with the lamin 
A/C siRNA resulted in down regulation of Lamin A/C protein. Knockdown of p68 was 
also successful, with little p68 protein being detectable (Figure 4.20). P68 knockdown 
did not, however, result in reduction in the expression of CTD or pS2, and there was an 
increase in p72 levels. The increase in p72 levels following siRNA for p68 has 
previously been observed, with no effect on p68 levels following p72 knockdown 
(Bates et al., 2005; Jalal et al., 2007). However, p72 knockdown resulted in reduced 
levels of CTD and pS2, with a similar down regulation being observed when both p68 
and p72 were simultaneously knocked down. Another interesting finding was that in 
the double knock down, the down regulation of pS2 and CTD was not as severe as 
observed for p72 alone, despite the marked depletion of both p68 and p72 in these cells. 
This suggests that there may be a compensatory mechanism involved that rescues the 
cells from the effects of depleting the cells of both p68 and p72.  
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      To confirm these findings at the mRNA level, RNAi was performed in MCF-7 cells 
and total RNA was prepared from cells treated with estrogen for 4 hours. The levels of 
mRNA of pS2 and CTD were determined by quantitative real time RT-PCR and were 
expressed relative to the levels of reference gene GAPDH. As observed above, p72 
knockdown inhibited pS2 and CTD expression (Figure 4.20), as did the double 
knockdown. There was again significant reduction in the induction of pS2 with p72 
knock down while p68 knock down had no effect. However, similar degree of 
inhibition was not seen with p72 knock down in the induction of cathepsin D (Figure 
4.20). 
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Figure 4.20 RNAi-mediated knockdown of p72 RNA helicase inhibits the 
expression of estrogen-regulated genes. MCF-7 cells were grown in double stripped 
serum for 3 days and transfected in 6 well plates with 100nM of the indicated siRNA. 
Treated with 10nM of E2 for 8hours (A) and 16hours (B) and harvested 48 hours post 
transfection and lysates were immunoblotted(top panel).Cells were treated for 4 hours 
and RNA was extracted 48 hours post transfection. The mRNA levels of pS2 and 
cathepsin D were determined by RT-PCR and expressed as fold difference relative to 
GAPDH (bottom panel). The results show the means of three independent experiments, 
with the error bars depicting the standard errors of the mean (SEM). 
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4.15 p72 knock down affects the growth of MCF-7 cells 
 
                The ER! is a key player in estrogen-dependant growth and progression of 
breast cancer. The knock down experiments consistently showed that p72 plays an 
important role in modulating ER transcriptional activity and on the expression of 
estrogen regulated genes. We investigated the effect of depleting p68 and p72 on the 
estrogen dependent growth of the breast cancer cells.  
                The MCF-7 cells were transfected with siRNA for p68 and p72, singly and in 
combination and treated with or without estrogen. Growth was assayed by SRB 
colorimetric assay over 6 days.   p68 knock down had no effect on the growth but p72 
depletion resulted in inhibition of growth compared to the untransfected cells (Figure 
4.21). The lack of effect on growth in p68 depleted cells could be due to the over 
expression of the p72 in these cells which might compensate for p68.  Depletion of both 
p68 and p72 resulted in inhibition of growth but not more than that seen with p72 
depletion (Figure 4.21). This might be due to perhaps another unknown helicase or 
unknown factor rescuing the cells from the effects of double knock-down. 
                Overall the results of the p68 and p72 knock down on growth mirrors the 
pattern shown with the siRNA experiments on estrogen regulated genes and ER 
transactivation.  
                Our data somewhat contradict the results reported by Jalal et al who reported 
that the growth inhibition was seen only with the double knock down (Jalal et al., 
2007). This is probably due to the fact that in the double knock down they titrated the 
siRNA oligos to prevent the over expression of p72 with p68 knock down.  
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Figure 4.21 Effect of p68 and p72 knock down on the growth of MCF 7 cells. MCF 
7 cells were transfected with the indicated siRNAs and treated with or without estrogen 
(NL) and growth was assayed over 5 days following transfection by SRB colorimetric 
assay. The results show the means of three independent experiments, with the error bars 
depicting the standard errors of the mean (SEM) 
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5. DISCUSSION 
 
5.1 Identification and characterisation of AF1 interacting proteins 
 
                 Transcriptional activation by ER! is mediated by two activation domains, 
AF1, whose activity is potentiated by phosphorylation at specific residues, and AF-2 
whose activity requires ligand binding. Although the mechanisms by which the 
LBD/AF2 recruits transcriptional coactivator protein complexes to regulate gene 
expression are well-defined, the mechanisms by which phosphorylation of AF1 
stimulate ER! activity are unclear. Phosphorylation of ER! can result in its activation 
in both ligand dependant and ligand-independent manner and the key phosphorylation 
sites have been mapped to transactivation function AF1. Determination of the 
mechanisms by which AF1 phosphorylation stimulates ER! activity may be 
particularly pertinent  as the phosphorylation mediated cross talk between ER! and 
growth factor  induced signalling pathways has been implicated in endocrine resistance 
(Masserweh and Schiff, 2006; Clarke et al, 2003; Nicholson et al ., 2004; Ring and 
Dowsett, 2004; Shou et al., 2004). Though the exact mechanism by which 
phosphorylation stimulates AF1 activity is unclear, it is likely that phosphorylation of 
AF1 facilitates the recruitment of transcriptional coactivators that mediate the 
transcriptional activity of AF1. Among the known coactivators, CBP/p300 and SRC1 
are known to interact with AF1 but phosphorylation of ER! is not a requirement for 
these interactions. Therefore it was thought that there must be ‘unknown’ coactivators 
that mediate stimulatory AF1 activity of ER! upon phosphorylation (Kato, 1999). 
Three potential co-regulator proteins recruited preferentially by ER! phosphorylated at 
serine 118 (S118) have been described to date. The first, p68 RNA helicase has been 
shown to preferentially interact with AF1 phosphorylated at serine 118 (Endoh et al., 
1999), but the stimulation of ER! activity by p68 is relatively weak and cell specific 
and it is not strictly S118 dependent. The second, stromelysin-1 platelet-derived growth 
factor responsive element-binding protein (SPBP) acts not as a coactivator, but as a 
corepressor for ER! (Gburcik et al., 2005). Finally, another protein that interacts 
preferentially with ER! phosphorylated at S118 is the spliceosome component splicing 
factor (SF)3a p120, which stimulates alternative splicing by ER! (Masuhiro et al., 
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2005). Collectively, these data argue for additional coactivator proteins that facilitate 
transcription activation by ER! phosphorylated at S118. The aim of this work was to 
identify and characterise AF1 interacting proteins in order to understand the role of 
phosphorylation in ER transactivation, through recruitment of activators. Two 
approaches were used to identify and characterise coactivators recruited preferentially 
by ER! phosphorylated at sites in AF1. In the first approach, I screened a breast cDNA 
expression library using the bacterial two-hybrid system and in the second, p68 and p72 
RNA helicases, two known coregulators, previously reported to interact with AF1 of 
ER !, were characterised as coactivaotrs of ER!. 
 
5.2 Bacterial two-hybrid for identification of AF1 interacting proteins 
 
                The functional reconstitution of a transcription factor through protein-protein 
interactions between two proteins of interest allows functional studies on the nature of 
the interaction. Yeast two hybrid based on transcriptional activation of a reporter gene 
has been a powerful tool for studying protein-protein interactions and mapping the 
protein interaction network. Bacterial two hybrid system which is analogous in 
principle to the yeast two hybrid system was used to screen a human breast cDNA 
expression library (Dove et al., 1997). The bacterial two hybrid was used in preference 
to the yeast two hybrid because of a number of reported advantages with this system 
including faster screening of cDNA libraries and lower false positive results. 
Additionally, ER! and ER!-AF1 are transcriptionally active in yeast which would 
cause reporter gene activation and therefore it will be problematic to use a yeast two 
hybrid approach. The bacterial two hybrid system has been compared to the yeast two 
hybrid in screening the cDNA libraries and the results are comparable (Saito et al., 
2004; Serebriiskii et al., 2005). The efficacy of this system was initially established to 
detect the interaction between ER! and the known coactivators. The system was able to 
readily show the ligand dependant positive interaction between ER LBD and SRC1. No 
interaction was demonstrated when SRC1 was cotransfected with an ER LBD mutant 
with alanine substitution at residues 539 and 540 which abolish coactivator interaction. 
There was also no interaction when pure estrogen antagonist ICI 182, 780 was added to 
the system. An AF1 construct encoding glutamic acid in place of serine 104,106 and 
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118 was used as bait since these substitutions may mimic phosphorylation (Ali et al., 
1993). The library screen was fraught with problems. All positives obtained from 
screening of a breast cDNA expression library turned out, upon careful characterisation 
to be false positives. The reasons for the large number of false positives are unclear, but 
are presumably due to leaky expression of the selective marker genes, perhaps due to 
the considerable mutability potential of bacterial cells. Indeed, this problem has been 
recognised by the manufacturers, Stratagene Ltd., who attempted to improve the 
Bacteriomatch system resulting in the generation of Bacteriomatch II, which was used 
here. Another problem appears to be the high percentage of mitochondrial sequences 
and immunoglobulin gene sequences represented in this library, suggestive of 
contamination with genomic DNA. One possible approach for the latter problem would 
be to construct a cDNA expression library. However, given the problems with 
selection, I decided that whilst improving the cDNA expression library, this may not 
resolve problems with selection. The likelihood of high false positive results still 
remains and the screening process would still require considerable time.  I have 
therefore decided not to pursue this. 
 
5.3 p6 modulates the activity of both AF1 and AF2 of ER ! 
 
                 In the original report by Endoh et al, p68 was shown to be an AF1 specific 
coactivator of ER!. p72 has similar properties as a co activator of ER! and both 
proteins potentiate ER activity in a synergistic manner with SRC1, in reporter gene 
assays. Furthermore, helicase activity was dispensable for the coactivator function of 
both proteins (Endoh et al., 1999; Watanabe et al., 2001). In agreement with these 
reports, we confirmed that the p68/72 stimulate the activity of ER! and shows 
synergistic enhancement of ER! activity with SRC1. We also confirmed that the 
helicase activity is required, neither for the transactivation of ER! nor for the 
synergism with SRC1. However, in contradiction with the published results, we have 
shown that p68 also, stimulates the activity of ER! ( AF1 encoding DBD and LBD, in  
the reporter gene assays. To further establish the effect of p68 on AF2 activity, we have 
examined the p68 coactivation of a number of mutants of key residues in !-helices 3, 5 
and 12 which form the AF-2 surface, important in the ER! LBD interaction with 
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coactivators. In these reporter gene assays, the coactivation of p68 paralleled that of 
SRC1. Taken together, these results supports that the p68 modulate the activity of AF2 
which is consistent with the recruitment of p68 to promoter of estrogen regulated gene, 
pS2, in response to estrogen. p68 has a nuclear receptor interacting signature motif, 
LXXLL in the coding sequence. We probed whether p68 influence the AF2 activity by 
interaction with ER through the LXXLL motif.  Replacement of leucine residues by 
alanine in the LXXLL motif in p68 had no effect on the coactivation of ER! in the 
reporter gene assays which suggest that the p68 influences the AF2 activity 
independent of LXXLL motif. 
 
5.4 Interaction domain of p68 in ER!  is mapped to the AF1 and DBD and the 
interaction domain of ER!  in p68 is outside the helicase domain  
 
                We have shown that p68/72 interact with ER! in vitro and confirmed these 
results in vivo by over expression of these proteins in COS-cells. We also confirmed the 
interactions with endogenous p68/72 and ER! in MCF-7 cells. Endoh et al mapped the 
p68 interacting region in AF1 of ER!, to amino acids 56-127 and the interaction 
domain in p68, to amino acids 300 to 400. In their interaction assays deletion of amino 
acids 200-400, 200-614 and 1-400 resulted in loss of binding while in our assays the 
binding was seen with these deletions. We have mapped the interaction domain in p68 
to the C-terminal region, outside the helicase domain. The helicase domain itself, as 
shown by the reporter gene assays and the in vitro binding assays, is not essential for 
the interaction which suggests hat the C-terminal extension is important for coactivator 
function of p68 
                Our findings were also different to those reported by Endoh et al with respect 
to the p68 interaction domain in ER. Our assays show that p68 binds to the ER! AF1 
region and to the ER! DBD. In fact, in our binding assays the DBD containing 
constructs showed stronger interaction compared to AF1 alone. Furthermore, p68 also 
bound ER ", which shares 97% homology in the DBD with ER!, which further 
supports that the p68 interacting domain in ER spans the DBD.  
                 The results shown here are contradictory to the results reported by Endoh et 
al and the reason for this disparity may be due to the fact that the GST pulldown assays 
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Endoh et al described were carried out with the AF1 region of ER!, and not with full-
length ER! or ER! containing the DBD. The mapping of different regions of 
interaction between p68 and ER! by Endoh et al and us and the fact that p68 modulates 
the AF2 activity, argue for the possibility of multiple points of contact between p68 and 
ER!. Furthermore, p68/72 have also been shown to harbour activation and repression 
domains (Wilson et al., 2004) and collectively these findings indicate that p68/72 may 
cooperate or operate separately but in different contexts, such as with ER! bound by 
different ligands or promoter context. A recent report suggest a role for p68 as a 
coactivator of Androgen receptor which adds to the growing number of transcription 
factors and repertoire of interactions that p68/72 are involved with and their role as 
multifunctional proteins. 
 
5.5 Phosphorylation of AF1 is not required for p68 interaction with ER ! 
 
                 The interaction of p68 was previously reported be potentiated by the 
phosphorylation of ER at serine 118 (Endoh et al., 1999). We have shown in the 
reporter gene assays that the substitution of serine 118 by alanine or glutamic acid in 
ER had no effect on the p68 coactivation. Our group has shown ERK1/2 MAPK also 
phosphorylate S104 and S106, in addition to S118 (Thomas et al. 2008). It was 
possible, therefore, that the p68 interaction might involve these residues. However, 
substitution of these serine residues, singly, doubly, or in combination with S118 by 
glutamic acid or alanine showed that it had no effect on the p68 coactivation. These 
results were further confirmed by in vitro binding assays where in vitro 
phosphorylation of ER by MAPK did not affect the p68 interaction with ER. 
Collectively these studies show that the phosphorylation is not important for the 
recruitment of p68 RNA helicase. It might be that the phosphorylation of p68 itself is 
important in its interaction with ER. Yang et al have shown that the p68 is 
phosphorylated at multiple amino acid residues and phosphorylated p68 activates the 
transcription of cyclin D1 and c-Myc genes, promoting cell proliferation. Furthermore, 
phosphorylated p68 was shown to be associated with promoters of cyclin D1 and c-
Myc suggestive of direct involvement in transcriptional regulation (Yang et al., 2007). 
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They have also reported that p68 was phosphorylated at tyrosine residue(s) in different 
cancer cell lines but not in the corresponding normal tissues (Yang et al., 2006). 
 
5.6 Complex role of p68 and p72 in regulation of ER activity: p72 more important 
than p68? 
 
                 p68 and p72 have high degree of homology in the central helicase domain 
with divergence in the N and C terminal domains. p68 and p72 share several functions 
showing some functional redundancy. These proteins exist as heterodimers in cells and 
present in complexes of varying sizes with the potential of interaction with other 
cellular factors (Ogilvie et al., 2003). As a coactivator of ER, p53 and MyoD, p72 is 
analogous to p68 with some subtle differences (Fuller-Pace, 2006; Shin and Janknecht, 
2007). The expression of these proteins is developmentally regulated with the 
differences in the expression of these genes. Interestingly, p68 may auto regulate its 
own expression which has been shown with its yeast homologue Dbp2p (Barta and 
Iggo, 1995). Furthermore, we and others have observed negative regulation of 
expression of 72 by p68 (Bates et al., 2005; Jalal et al., 2007).The over expression of 
p72 on depletion of p68 by siRNA but not vice versa   might be a compensatory 
phenomenon and this has been seen with the SRC family of coactivators, reflecting the 
functional redundancy of these proteins. In SRC1 knock out mice, there was up 
regulation of TIF2 with relatively subtle defects in the development of estrogen-
dependent tissues, including the uterus and breast (Xu and Li, 2003). This complex 
regulatory mechanism on the expression of p68/72 might have consequences in their 
overall function in the cells. 
                 We have examined the functional consequences of the coactivator function 
in MCF-7 cells by siRNA mediated knock down of these proteins. In our initial 
experiments, we found that p68 depletion in MCF-7 cells had no effect on ER function  
which was surprising, given the findings from over-expression in reporter gene assays. 
However, in subsequent experiments siRNA mediated knockdown of p68 and p72, 
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          Table 5.1 Effect of p68/p72 knock down on ER function in MCF-7 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
singly and in combination, showed striking differences in ER transactivation and the 
regulation of estrogen dependant genes, pS2 and Cathepsin D (CTD). p72 but not p68 
depletion resulted in marked reduction of ER transactivation. Interestingly, the 
combined knock down did not reduce the ER activity more than the p72 knock down. 
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Similar effects were seen on the expression of estrogen target genes, at both the protein 
and mRNA level. p68 knock down had little effect on the expression of these genes 
while p72 depletion resulted in a marked down regulation of both baseline and estrogen 
stimulated-expression of these genes. The consequences of these on the growth of 
MCF-7 cells were examined by siRNA mediated depletion of p68 and p72. The results 
again mirrored   the pattern shown with the siRNA experiments on estrogen regulated 
genes and ER transactivation (Table 4.1).  In the above experiments the lack of any 
effect on ER responses with the p68 knock down may be due to the compensatory over 
expression of p72 in the p68 depleted cells. The effects of double knockdown were also 
less pronounced than those seen with the p72 knock down. This suggests that there may 
be a compensatory mechanism involved that rescues the cells from the effects of 
depleting the cells of both p68 and p72. Our findings on the growth are some what 
contradictory to the results reported by Jalal et al. who reported that the growth 
inhibition was seen only with the double knock down (Jalal et al., 2007). This is 
probably due to the fact that in the double knock down they titrated the siRNA oligos to 
prevent the over expression of p72 with p68 knock down. Similar results were also 
reported by Shin et al. who showed that p68 and p72 double knock down in colon 
cancer cell lines, inhibited the cell proliferation and diminished their ability to from 
tumours in vivo. However, the data on the effect of individual p68 or 72 depletion on 
growth has not been reported by them given that they showed up regulation of p68 on 
p72 knock down and vice versa. We and others have not observed this in our 
experiments. 
                 Over-expression of p68/72 in MCF cells interestingly had different effects 
on the expression of estrogen target genes. p68 over-expression resulted in increased 
levels of pS2 and cathepsin D proteins, in agreement with the reporter gene data. 
However, p72 over-expression or over-expression of both p68 and p72 did not increase 
pS2 or cathepsin D levels. 
 
                 These results show that p72 is more important in modulating transcriptional 
responses of ER ! and it may be that the balance and interplay between p68 and p72, 
fine tune these responses. However, these findings should be understood in their proper 
context and the differences we have seen might be relevant to the role of these proteins 
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in the physiological and pathological contexts. Both proteins are important in the 
physiological context, as shown by the knock out studies in the mice embryos.  In p68 
disrupted embryos, the embryos did not survive beyond 11.5 days while the p72 knock 
out mice survived only for 2 days after birth. Embryos with double knock out led to 
earlier death of embryos than the p68 knock out alone (Fukuda et al., 2007). The 
transcription factor/ promoter context might also be important and relevant to their 
function. For example, p68 was shown to be more important than p72 in modulating 
p53 regulated genes as the depletion of p72 had no effect on the p53 regulated genes 
(Bates et al., 2005).The lack of any effect on ER transactivation on p68 knock down 
while its over expression   stimulated the ER activity suggests that in the physiological 
context p68 may be less important than p72. However it might be different in cancer 
where it may play dominant role in driving ER responses.  
 
5.7 Role of p68/p72 helicases in regulating ER mediated gene expression 
 
                The regulation of gene expression by nuclear receptors involves complex but 
coordinated, sequential recruitment of cofactor complexes involved in chromatin 
modelling along with transcription complexes at the promoters of the target genes 
(McKenna and O’Malley, 2002; Shang et al., 2000; Métivier et al., 2003, Reid et al., 
2003). p68 is recruited to the promoter of the estrogen target gene, pS2 in response to 
estrogen, indicating direct involvement of p68 in transcriptional regulation of ER. In 
the cyclical recruitment of various cofactor complexes at the promoter of pS2, p68 is 
the first to be recruited in the transcriptionally productive cycle. p68 precedes the 
recruitment of HATs and HMTs promoting acetylation and demethylation, leading to 
active chromatin state. This suggests that the p68 may be required for the binding of 
chromatin modifying proteins in transcriptional initiation (Caretti et al., 2007). p68/p72 
may be also involved in attenuating the gene responses after initial activation. p68/p72 
interacts with SRA which in turn associates with a corepressor, SMRT and 
HDAC1-associated repressor protein (SHARP) (Shi et al., 2001). SHARP is a repressor 
of SRA stimulated ER transcriptional activity and the interaction between SRA and 
SHARP is thought be responsible for attenuating the ER responses (Shi et al., 2001). 
Furthermore, Drosophila p68 RNA helicase has been shown to be involved in clearance 
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of transcripts from the promoters attenuating the gene response. p68/p72 can also 
repress   transcription by association with HDACs which   is dependant on the promoter 
context. These reports suggest that   apart from regulating transcription initiation 
p68/72 may also be involved in attenuating the transcription. 
                 Our reporter gene assays data suggest that the p68 influences both AF1 and 
AF2 activation domains of ER! and, by their known interaction with the other 
coactivators like SRC1, CBP and SRA, might work to synergise the function of AF1 
and AF2 .Our in vitro data show that the p68 interacts with AF1 and DBD of ER! and 
the mapping of p68 interaction domain suggest multiple contacts between p68 and 
ER!. 
                The functional consequences of these findings in vivo are complex, with p72 
having a more profound effect on the ER transactivation and growth of MCF-7 cells.  
From our in vitro and in vivo data it appears that the interplay between p68 and p72 
might regulate and fine tune the ER responses.  This adds another layer   to the 
complexity of the transcriptional regulation by ER!. 
 
5.8 Potential role of p68/p72 in breast cancer 
 
                  p68 and p72 helicases have been considered as multifunctional proteins, 
involved in diverse biological functions (Fuller-Pace, 2006). Several reports show that 
these proteins act as cofactors for transcription factors such ER, p53 and MyoD. Both 
have been involved in regulation of p53 which is a tumour suppressor gene, mutated in 
more than 50 % human cancers (Greenblatt et al., 1994; Bates et al., 2005).  p68 is also 
involved in the regulation of proto-oncogenes such as, c-Myc, cyclin D1, c-jun, and fra-
1, through "-catenin (Yang et al., 2007; Shin et al., 2007). p68/p72 has been found to 
be over expressed in colon cancer cell lines and the expression of these proteins was 
found to be progressively increased in the specimens of colonic polyp, adenoma and 
carcinoma, which is the sequence of events in colon carcinogenesis. Down regulation 
of p68/p72 lead to inhibition of the colon cancer cell proliferation and inability of these 
to form tumours in vivo (Shin et al., 2007). p68 has been shown to be over expressed in 
colon cancer and is poly-ubiquitylated, suggestive of defect in protesomal degradation 
of p68 in tumour cells (Causevic et al., 2001). p68 was found to be phosphorylated in 
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different cancer cell lines including breast cancer cell line but not in the corresponding 
normal tissues. Phosphorylated p68 was shown to be involved in the regulation of 
cyclin D and c-Myc promoting abnormal cell proliferation. Phosphorylation of p68 
therefore might be involved in carcinogenesis (Yang et al., 2005; Yang et al., 2007). 
                 The role of p68/72 in breast cancer is unclear. We have shown that in breast 
cancer cell line, MCF-7, depletion of p72 results in significant inhibition of ER 
transcriptional activity and down regulation of key estrogen target genes such as pS2 
and cathepsin D. Furthermore, depletion of p72 inhibited the growth of MCF-7 cells. In 
these experiments the p72 depletion had more profound effect than the p68 or 
combined depletion of p68 and p72. Interestingly, p68 depletion had no significant 
effect either on the ER transactivation or on the expression of estrogen regulated genes, 
pS2 and cathepsin D. In order o further exmine the role of these proteins in ER function 
in vivo, we plan to establish stably transfected breast cancer cell lines with short hairpin 
(sh) RNA targeting p68 and p72. Expression profiling of genes regulated by p62 and 
p72 in these cell lines, will be carried out to identify and characterise novel estrogen 
regulated genes modulated by p68/p72. 
                  To study the relevance of these findings  clinically, we are currently 
examining the expression of these proteins in patients with ER positive breast cancer 
.These  tumours had been previously analysed for ER! phosphorylated at S118 and 
other  proteins  including Her2, PR and AIB-1. The simultaneous analysis of expression 
of   the oncoproteins such as HER 2 in breast cancer and the correlation of these will 
help clarify he role of these proteins in breast cancer pathogenesis. We will use tissue 
microarray studies which will help to simultaneously look at the expression of ER, p68, 
and p72 in large number of samples utilizing very small amounts of tissue as well as 
saving time. The expression of p68 and p72 in the primary samples and at the time of 
relapse on tamoxifen will help to clarify the role of these proteins in tamoxifen 
resistance. 
Collectively these data will enable to define the role of these proteins in breast cancer 
pathogenesis and potentially identify ways of targeting these in treatment of breast 
cancer. 
 
5.9 Future directions 
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                 p68 and p72 seem to regulate the ER! activity in a complex manner. While 
they have been shown to have functional redundancy, our findings demonstrate their 
opposing roles. It would be interesting to clarify and refine further, the role of each 
protein in ER responses and to differentiate their role in the physiological and 
pathological context. P68 has been shown to coactivate androgen receptor and to 
regulate androgen dependant gene expression through its splicing function for p68/p72. 
It is not known whether its splicing function has any effect on its role in transcriptional 
regulation of ER! and whether it is coupled to transcription.  
                 The role of these proteins in breast cancer is yet to be established though the 
data presented here show that p72 affect the growth of estrogen dependant breast 
cancer cells by modulating estrogen-dependent transcription. Further studies enlisted 
above will help clarify the role and the mechanism(s) by which p68/p72 contribute to 
development and progression of breast cancer. Hopefully, this will identify ways to 
target p68/p72 network in the treatment of breast cancer or preventing resistance to 
endocrine therapy. As RNA helicases are essential for survival of bacteria and viruses, 
they have been targeted for development of antibacterial and antiviral drugs. The over 
expression of p68 and the posttranslational modifications in colon cancer and cancer 
cell lines indicate their potential for use as diagnostic/prognostic markers in cancer. 
More studies are needed to validate these observations and for application in clinical 
practice.  
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